https://biospectrumindia.com/rssfeed/states/telangana telangana https://biospectrumindia.com/views/109/28550/if-youre-looking-to-build-the-next-generation-of-life-sciences-innovation-wed-be-delighted-to-partner-with-you.html https://biospectrumindia.com/views/109/28550/if-youre-looking-to-build-the-next-generation-of-life-sciences-innovation-wed-be-delighted-to-partner-with-you.html Thu, 01 Oct 2026 11:20:30 +0530 Congratulations on your appointment as CEO of Telangana Life Sciences. What are your top three priorities during your first year in office? Thank you. Telangana is entering a defining phase in its life sciences journey, and I am excited to be part of that transformation. The state already has a strong foundation built on progressive policies, world-class infrastructure, and a collaborative ecosystem. My team and I will be working across several areas including investments, innovation, talent, startups, infrastructure, and global partnerships. However, if I had to identify the three priorities that will shape our efforts during the first year, these would stand out. The first is execution. Telangana has a clear vision for the sector, and our immediate focus is on translating that vision into measurable outcomes. Whether it is facilitating investments, enabling strategic projects, or creating a business-friendly environment, our emphasis will be on delivering tangible impact. The second is preparing the ecosystem for the future. Life sciences is evolving rapidly with advances in biologics, AI, digital health, precision medicine, and advanced manufacturing. We want Telangana to be among the first places where these technologies are developed, adopted, and scaled. The third is strengthening the ecosystem for long-term growth. This includes building a future-ready talent pipeline, encouraging stronger industry-academia collaboration, supporting startups and entrepreneurs, and expanding global partnerships that bring knowledge, technology, and investment into Telangana. Ultimately, our goal is not just to sustain Telangana's leadership in India, but to position it among the world's leading life sciences ecosystems where innovation, research, manufacturing, and entrepreneurship can thrive together. Telangana has established itself as India's life sciences capital. What is your vision for the ecosystem over the next five years, and how do you plan to build on the state's existing strengths? Over the next five years, I believe our biggest opportunity is to move beyond being known primarily as a manufacturing hub and establish Telangana as a complete life sciences ecosystem where research, innovation, manufacturing, startups, talent, and global companies grow together. To achieve this, our role is not to build everything ourselves but to bring the ecosystem together and accelerate areas that will define the future of life sciences. One area of focus will be strengthening innovation and biomanufacturing capabilities by supporting initiatives around biologics, cell and gene therapy, precision fermentation, and advanced therapeutics. At the same time, we want to create stronger pathways for startups to access research infrastructure, funding, mentors, industry partners, and global markets. Another important area is building ecosystem capabilities. This means working closely with industry to identify infrastructure gaps, strengthening academia-industry collaboration, developing future-ready talent through initiatives such as the Telangana School of Life Sciences, and supporting companies with the ecosystem they need to scale. We also see significant value in global collaboration. Over the next few years, we will continue building partnerships with leading international clusters, research institutions, and companies to facilitate technology transfer, collaborative research, investment, and market access. Ultimately, success will not be measured only by the number of companies we attract, but by the strength of the ecosystem we create. If Telangana becomes the place where companies can innovate, manufacture, collaborate, and scale throughout their entire journey, I believe we will naturally emerge as one of the world's leading life sciences hubs. Since assuming office on April 1, what have been your key observations after interacting with industry, startups, academia, and research institutions? Where do you see the biggest opportunities and gaps? Over the last few months, I've had the opportunity to interact with industry leaders, startups, academia, researchers, and investors across the ecosystem. One thing that has become very clear is that Telangana has all the ingredients needed to become one of the world's leading life sciences ecosystems. What impressed me most is the depth and diversity of the ecosystem. We have the presence of leading global life sciences companies across pharmaceuticals, biotechnology, medtech, and Life Sciences Global Capability Centres (GCCs). We have one of the country's strongest talent pipelines with a large concentration of pharmaceutical colleges, top engineering institutions, and management schools. Alongside this, Hyderabad has a mature supporting ecosystem of IT companies, consulting firms, digital capability centres, Contract Research Organisations (CROs) and other professional services that today's life sciences industry increasingly depends on. The research and innovation ecosystem is equally impressive. Institutions such as Dr. Reddy's Institute of Life Sciences (DRILS), research centres, and more than 20 life sciences incubators and innovation platforms, including BioNESTs, Biotechnology Incubation Centre (BTIC), Antimicrobial Resistance Centre of Excellence (AMR CoE), T-Hub, and other startup enablers, provide a strong foundation for innovation and entrepreneurship. Combined with an industry-friendly government and progressive policies, Telangana offers an ecosystem that is difficult to replicate. At the same time, I believe the next opportunity lies in bringing these strengths together more effectively. The ecosystem already has all the right building blocks. Our focus now is to create stronger collaboration between industry, academia, startups, research institutions, and government so that talent development, innovation, infrastructure, and policy evolve together. Initiatives like the Life Sciences & Healthcare GCC Consortium are a step in that direction, creating structured platforms where the ecosystem can collectively identify challenges and work towards practical solutions. How do you plan to strengthen collaboration between the government, industry, research institutions, and investors to create a more integrated innovation ecosystem? One of our priorities is to create platforms where different stakeholders can regularly work together to identify challenges, develop solutions, and drive implementation. A good example is the Life Sciences & Healthcare GCC Consortium, where industry leaders, government, academia, and ecosystem partners are working together on four priority areas: capability building, innovation & technology, infrastructure enablement, and policy & regulatory engagement. Rather than being a networking forum, it is designed as an execution platform led by industry. We want to adopt a similar approach across other areas of the life sciences sector. Whether it is startups working with global companies, researchers collaborating with industry on translational research, or investors connecting with high-potential innovators, our role is to create the right platforms and remove barriers that slow collaboration. I also believe research should not remain confined to laboratories. Hyderabad has outstanding universities, research institutions, incubators, hospitals, and global companies. The opportunity is to create stronger pathways for ideas to move from research to commercialisation through industry partnerships, startup engagement, access to shared infrastructure, and global market connections. When collaboration becomes structured and purpose-driven, innovation accelerates naturally. That is the approach we want to strengthen across Telangana's life sciences sector. Global life sciences companies are increasingly looking at India for R&D and manufacturing. What strategies will Telangana adopt to attract the next wave of investments in areas such as biologics, cell and gene therapy, precision medicine, and AI-driven drug discovery? The next wave of investments will be very different from the last. Companies investing in biologics, cell and gene therapy, precision medicine, and AI-driven drug discovery are looking beyond manufacturing. They want locations that offer strong research capabilities, advanced infrastructure, scientific talent, and opportunities to collaborate across the entire innovation value chain. Our focus is on strengthening these capabilities by expanding advanced biomanufacturing, research infrastructure, translational research, and creating stronger linkages between industry, startups, research institutions, and healthcare providers. We're also seeing a shift in how global companies are investing in Telangana. Many are expanding across the entire value chain. For example, companies like Novartis have both manufacturing operations and a Global Capability Centre in Hyderabad, while several others are establishing high-value R&D, AI, digital, clinical, and regulatory capabilities alongside their core operations. Our objective is to build on this momentum and ensure Telangana continues to be the destination where global companies choose not only to manufacture, but also to innovate, collaborate, and scale their global operations. Startups have been a major driver of innovation in Telangana. What new initiatives are being planned to improve access to funding, incubation, mentoring, and global market opportunities? You're absolutely right. Startups have been one of the biggest drivers of innovation in Telangana, and we want to build on that momentum. Our focus now is to help more startups move beyond the proof-of-concept stage and successfully commercialise their innovations. We're strengthening platforms such as the State Biotechnology Incubation Centre (SBTIC) and 1Bio, while also operationalising the Rs 100 crore Life Sciences Innovation Fund, which will provide equity and grant support to promising startups working in areas such as biotherapeutics, molecule discovery, and biomanufacturing. Alongside this, platforms like BioAsia and our partnerships with global companies and investors will help startups build collaborations, attract investment, and access international markets. Our ambition is simple: if you're building the next breakthrough in life sciences, Telangana should be the best place to start, grow, and scale. Talent continues to be a critical challenge for the sector. How will Telangana strengthen its skilled workforce pipeline through academia-industry partnerships and specialised training programmes? One of Telangana's biggest strengths is its talent base. Hyderabad has one of the highest concentrations of pharmacy colleges in the country, along with leading engineering and management institutions. This gives us a unique advantage in building multidisciplinary talent for the future of life sciences. Our focus now is to build on this strength by working more closely with industry and academia. We're encouraging industry-led curriculum development, internships, apprenticeships, live industry projects, and specialised training in emerging areas such as biologics, AI, digital health, and advanced manufacturing. We have launched a unique PhD programme in collaboration with BITS Pilani and RMIT University to build globally competitive research talent for Telangana’s life sciences ecosystem. The programme goes beyond academic research by connecting PhD scholars with industry-led challenges, real-world use cases and translational opportunities. Our objective is to create a talent pipeline that can drive the next generation of innovation—from advanced therapeutics and biomanufacturing to AI-enabled life sciences. We have launched the 1M1B–Microsoft Centre of Excellence to build a future-ready workforce with a strong focus on green skills and sustainability. Our aim is to equip young talent with the skills needed for emerging green technologies and sustainable industries, while creating stronger linkages between education and industry. For Telangana, this is about building not just a skilled workforce, but a workforce that can power our transition towards a greener and more sustainable life sciences ecosystem. Innovation today increasingly cuts across biotechnology, medtech, digital health, AI, and data science. How do you see Telangana creating stronger convergence across these sectors? The future of life sciences is no longer about individual sectors. Companies like Medtronic, Johnson & Johnson, and Thermo Fisher Scientific are bringing together biotechnology, medical devices, AI, digital health, engineering, and data science to develop integrated healthcare solutions. That's the direction the global industry is moving. Telangana is uniquely positioned to lead this convergence because we already have one of the world's strongest life sciences clusters alongside one of India's largest technology ecosystems. Hyderabad is home to global technology leaders such as Microsoft, Amazon, Google, and many others, while also hosting leading pharmaceutical, biotech, and medtech companies. This unique combination allows innovations in AI, cloud computing, data science, engineering, and automation to be rapidly adopted across the life sciences value chain. I believe this convergence will define the next phase of healthcare innovation, and Telangana is well positioned to lead it. How will Telangana Life Sciences measure success over the next three to five years? Are there specific investment, employment, startup, or innovation milestones that you have set for the organisation? Over the next three to five years, we will measure success not just by the amount of investment attracted, but by the quality and depth of the ecosystem we build. We want to see more companies choosing Telangana for R&D, innovation, advanced manufacturing and global capability centres; more high-value jobs being created; and a stronger pipeline of startups moving from research and ideas to commercial scale. Ultimately, our measure of success will be whether Telangana becomes a place where the world’s leading life sciences companies come not only to manufacture, but to innovate, collaborate and build the future. Looking ahead, what message would you like to convey to global investors, multinational companies, and emerging biotech entrepreneurs considering Telangana as their destination for innovation and growth? At the end of the day, investors and innovators look for confidence. Confidence in policy, confidence in talent, confidence in infrastructure, and confidence that the government will be a long-term partner. That's what we're committed to building in Telangana. If you're looking to build the next generation of life sciences innovation, we'd be delighted to partner with you.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/109/28573/biomanufacturing-firm-preferco-names-shakthi-m-nagappan-as-chairman-managing-director.html https://biospectrumindia.com/news/109/28573/biomanufacturing-firm-preferco-names-shakthi-m-nagappan-as-chairman-managing-director.html Wed, 30 Sep 2026 15:14:41 +0530 PreferCo, a precision fermentation company headquartered in Hyderabad, has announced that Shakthi Nagappan will lead the company as Chairman & Managing Director, as it builds an integrated platform spanning strain engineering, process development and bioprocess scale-up being built in partnership with German process technology major Glatt. Nagappan brings close to two decades of experience at the intersection of life sciences, industry and government. As the former CEO of the Telangana Life Sciences Foundation, he played a key role in the development of Hyderabad and Telangana into one of Asia’s leading life sciences hubs. During his tenure, Telangana’s life sciences ecosystem expanded significantly in scale and global stature witnessing investments to the $15 billion and today hosts nine of the world’s top lifesciences companies, alongside more than 2,000 life sciences companies. Nagappan continues to be associated with the Government of Telangana in an advisory capacity on life sciences. PreferCo is building an integrated precision fermentation platform in Hyderabad focused on one of the industry’s most critical challenges — translating promising biology from the laboratory into robust and commercially viable manufacturing at scale. ]]> https://biospectrumindia.com/news/109/28578/asms-and-huwel-lifesciences-join-hands-to-expand-access-to-compact-rt-pcr-testing-across-india.html https://biospectrumindia.com/news/109/28578/asms-and-huwel-lifesciences-join-hands-to-expand-access-to-compact-rt-pcr-testing-across-india.html Wed, 30 Sep 2026 16:37:58 +0530 Hyderabad-based Avio Smart Market Stack Limited (ASMS), formerly Bartronics India Limited, and Huwel Lifesciences are strengthening their collaboration to build a nationwide commercialisation platform for Cubo, Huwel’s ultra-compact RT-PCR system. The initiative aims to expand access to molecular diagnostics across India’s private healthcare sector, including hospitals, diagnostic centres, research institutions and smaller healthcare facilities. As part of the collaboration, the two companies plan to establish a dedicated sales and distribution infrastructure, including the recruitment of senior sales leadership, formation of specialised sales teams and development of strategic channel partnerships. The initiative will initially focus on Cubo while creating opportunities to commercialise Huwel’s broader molecular diagnostics portfolio. Cubo is designed to enable RT-PCR testing beyond conventional centralised laboratory environments. Its ultra-compact design allows molecular diagnostic capabilities to be considered for smaller and more decentralised healthcare settings, potentially reducing dependence on large centralised facilities. This is particularly relevant to India’s healthcare landscape, which spans metropolitan centres as well as a large and geographically distributed network of Tier-II and Tier-III cities, hospitals and diagnostic facilities. The commercialisation strategy will focus on private hospitals, diagnostic chains, independent laboratories, medical colleges, research institutions and other healthcare establishments. The proposed sales organisation will work across direct sales and channel partnerships, supported by product demonstrations, installation support and ongoing customer engagement. Beyond instrument deployment, ASMS and Huwel intend to develop an ecosystem around the platform, comprising compatible molecular assays and consumables that can support recurring testing requirements. Huwel’s capabilities across molecular diagnostic applications could enable Cubo installations to serve multiple testing needs rather than being limited to a single application.   ]]> https://biospectrumindia.com/news/109/28540/researchers-in-hyderabad-explore-microwave-based-technology-for-early-detection-of-breast-cancer.html https://biospectrumindia.com/news/109/28540/researchers-in-hyderabad-explore-microwave-based-technology-for-early-detection-of-breast-cancer.html Fri, 25 Sep 2026 17:10:58 +0530 NR Vignana Jyothi Institute of Engineering and Technology (VNR VJIET), Hyderabad, has published a patent for a novel microstrip patch antenna-based design aimed at enabling the non-invasive detection of skin and breast cancer at an early stage. The research focuses on a specially designed microstrip patch antenna that uses electromagnetic waves to study differences in the properties of healthy and potentially malignant tissue. The research patent has been published and is currently at the simulation stage, with the research team working towards further validation and eventual prototype development. The approach is being explored in response to the continuing need for simpler, accessible and cost-effective methods of detecting cancer at an early stage. Unlike conventional diagnostic approaches that may involve imaging, tissue sampling or invasive procedures, the proposed technology is designed to sense variations in tissue characteristics without cutting, inserting or penetrating an instrument into the body. The technology uses a specially designed microstrip patch antenna to transmit electromagnetic energy towards biological tissue. Healthy and abnormal tissues can differ in their dielectric properties and conductivity. When electromagnetic energy interacts with these tissues, a portion of the energy is absorbed or scattered, while the remaining energy is reflected towards the antenna. These variations can influence the reflected electromagnetic signal. By analysing these changes, the researchers are studying how the technology can help distinguish normal tissue from abnormal or potentially malignant tissue.  The research is currently in its early stage with simulation effort; further fabrication, testing and clinical validation would be necessary to establish its effectiveness as a diagnostic technology. ]]> https://biospectrumindia.com/news/109/28542/healthark-sets-agenda-for-next-generation-of-life-sciences-and-healthtech-gccs-at-rise-2026.html https://biospectrumindia.com/news/109/28542/healthark-sets-agenda-for-next-generation-of-life-sciences-and-healthtech-gccs-at-rise-2026.html Sat, 26 Sep 2026 14:19:30 +0530 Healthark, a healthcare and life sciences strategy and capability-building firm specialising in building niche and specialised global capability centres (GCCs), brought together senior leaders from global pharmaceutical, medtech, healthcare and technology companies at RISE Health Innovation Summit 2026 in Hyderabad, with a strong focus on how India can become a global hub for high-value healthcare and life sciences capabilities. A key highlight of the RISE summit was the launch of Healthark's new publication, Unlocking India as the Strategic Hub for Life Sciences & Healthcare GCCs, by D. Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana. The publication examines the evolution of India's life sciences and healthcare GCC landscape and the opportunity for global companies to build increasingly sophisticated capabilities in India across regulatory affairs, clinical development, medical affairs, quality, analytics, digital, AI and other specialised functions. It also brings together perspectives and experiences from industry leaders associated with Novo Nordisk, Roche, Opella and other global organisations, alongside Healthark's own experience working with healthcare and life sciences companies. Key statements by these leaders are annexed. The summit comprised a two-day virtual programme on September 22 - 23, followed by a live summit in Hyderabad on September 24. Across the three days, RISE 2026 brought together speakers from Novo Nordisk, Carelon Global Solutions, Opella, Thermo Fisher Scientific, Roche, Deloitte, Bosch, Medtronic, Sandoz, 4baseCare, Biostate, CRISPR Bits and MedGenome, among others who shared insights on how India's role in global healthcare and life sciences is changing from the growth of specialised capabilities and R&D to the increasing use of AI, analytics, engineering, genomics and biotechnology to solve complex global problems. Addressing the audience, Minister D. Sridhar Babu said “RISE 2026 brings together an important cross-section of leaders from healthcare, life sciences, technology, GCCs, research and innovation at a time when India’s role in the global economy is evolving significantly. Hyderabad is particularly well positioned for this next phase, with a strong life sciences ecosystem, deep technology and engineering talent, and an increasingly connected innovation landscape. Our opportunity in Telangana is to bring these strengths together and create an ecosystem where science, technology, talent and industry work together to solve real problems.” Commenting on the event, Dr Purav Gandhi, Founder & CEO, HealthArk, said, “The conversation around GCCs is changing. For healthcare and life sciences companies, the opportunity is no longer simply about moving more work to India. It is about deciding which capabilities can be built here, creating the right operating model and developing teams that can take global ownership. We believe India can become one of the most important global centres for specialised healthcare and life sciences capabilities.” Sudeep Krishna, Co-Founder & President, HealthArk, added: “Building a successful GCC requires much more than access to talent. Companies need the right domain capabilities, leadership, operating model and integration with their global organisation. Healthark's focus is to help companies navigate that journey - from strategy and capability design through to building and scaling teams on the ground.”     ]]> https://biospectrumindia.com/news/109/28526/syneos-health-launches-largest-asia-centre-in-hyderabad.html https://biospectrumindia.com/news/109/28526/syneos-health-launches-largest-asia-centre-in-hyderabad.html Wed, 23 Sep 2026 15:23:31 +0530 Syneos Health®, a leading fully integrated biopharmaceutical solutions organisation, has opened its new Global Life Sciences and Technology Centre in Hyderabad, adding to the city’s growing concentration of global life sciences and technology capabilities. The 137,000-sq-ft centre is the company’s largest in Asia and third-largest globally, with an initial workforce of more than 700 professionals, expected to grow over the coming years. The centre was inaugurated by D. Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana, in the presence of senior Syneos Health leaders. The new centre brings together capabilities in clinical development, commercialisation, medical affairs, technology, AI and corporate functions. Syneos Health is also positioning India as a strategic growth hub beyond the traditional delivery-centre model, with global leaders and teams working from the city to support drug development and commercialisation for customers worldwide.  Hyderabad has emerged as India’s healthcare-biotech GCC leader, accounting for 20–23% of the country’s overall healthcare-biotech GCC market. This builds on Telangana’s end-to-end life sciences ecosystem, spanning APIs, bulk drugs, generics, CDMO, vaccines, research and discovery. Global companies including MSD, Sanofi, Bristol Myers Squibb, Eli Lilly Amgen, among others, are building capabilities across this value chain, from R&D and clinical development to data, technology and AI.  The opening of the new centre marks another step in Syneos Health’s long-term commitment to India and reflects Telangana’s growing strength as a global destination for life sciences, technology and innovation. ]]> https://biospectrumindia.com/news/109/28499/hyderabad-based-health-tech-startup-litemed-india-introduces-curapod-m.html https://biospectrumindia.com/news/109/28499/hyderabad-based-health-tech-startup-litemed-india-introduces-curapod-m.html Thu, 17 Sep 2026 16:18:19 +0530 Litemed India, a Hyderabad-based health-tech startup, has introduced Curapod M, a science-led solution developed specifically for menstrual pain and cramps. Fully engineered and manufactured in India, Curapod M brings together medical-grade photobiomodulation (PBM), adaptive personalisation and digital intelligence to address an experience that women have been expected to plan their lives around for generations. Curapod M is licensed by CDSCO and registered with the US FDA. At the centre of Curapod M is a clinically validated photobiomodulation platform designed to work on biological processes associated with menstrual pain, including prostaglandin-linked pathways involved in cramping. In clinical evaluation, 80% of women experienced zero pain after using Curapod M. Curapod M uses specific red and near-infrared wavelengths through photobiomodulation, supported by a proprietary adaptive engine that personalises therapy. Its companion app learns from the user’s cycle, pain patterns, and therapy history and is designed to anticipate the likely intensity of an upcoming cycle. Together, the device and app shift the experience from reacting to pain to anticipating and managing it more intelligently. Curapod M is expected to roll out across India through Curapod’s website, Amazon, and Flipkart, with an indicative launch price of around Rs 11,999. Availability will extend across metros and Tier 2 markets. ]]> https://biospectrumindia.com/news/109/28484/dr-reddys-marks-entry-into-biosimilar-immuno-oncology-in-india-with-launch-of-nivorz.html https://biospectrumindia.com/news/109/28484/dr-reddys-marks-entry-into-biosimilar-immuno-oncology-in-india-with-launch-of-nivorz.html Tue, 15 Sep 2026 16:30:26 +0530 Hyderabad-based Dr. Reddy’s Laboratories has announced the launch of NIVORZ® (Nivolumab Biosimilar) in India. NIVORZ® is a biosimilar to Opdivo® (nivolumab),  a fully human monoclonal antibody that targets the PD-1 (Programmed Death-1) immune checkpoint, helping restore the immune system's ability to identify and fight cancer cells.  The launch represents a significant milestone for Dr. Reddy’s, with NIVORZ® marking its entry into biosimilar immuno-oncology in India. Developed and manufactured entirely in-house at Dr. Reddy's biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation. Oncology remains an important focus area for Dr. Reddy's. The launch of NIVORZ® further strengthens the company's oncology portfolio and expands its presence in immuno-oncology. The Immuno-Oncology market in India is estimated at approximately Rs 3,900 crore in 2025 and is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab. Access to immuno-oncology therapies remains a challenge for many patients due to the cost and duration of treatment. Through NIVORZ®, Dr. Reddy's aims to broaden access to high-quality nivolumab therapy with an affordable biosimilar option for eligible patients. Based on the clinical development programme, NIVORZ® has been approved in India by the Drugs Controller General of India (DCGI). ]]> https://biospectrumindia.com/news/109/28485/neuland-accelerates-peptide-manufacturing-expansion-to-meet-rising-customer-demand.html https://biospectrumindia.com/news/109/28485/neuland-accelerates-peptide-manufacturing-expansion-to-meet-rising-customer-demand.html Tue, 15 Sep 2026 16:38:03 +0530 Hyderabad-based Neuland Laboratories is accelerating its peptide manufacturing expansion, as the first of four scheduled modules has commenced operations at its commercial peptide manufacturing site.  Significantly, with foundational infrastructure for the second module already in place, Neuland expects to begin work ahead of the original timeline once customer requirements are finalised — configuration, instrumentation and capacity are currently being defined in close collaboration with the customer whose projects will anchor the expanded capability. The newly operational module one provides 7000L total reactor capacity, 750L of solid-phase peptide synthesis (SPPS) and 6250L liquid-phase peptide synthesis (LPPS). This enables flexible customer programmes from small‑scale to multikilogram quantities for complete peptide APIs – including complex and long‑chain peptides – as well as commercial scale production of crude peptides. Additionally, the SPPS and LPPS reactors are housed in different suites enabling parallel operation and are supported by three Dynamic Axial Compression (DAC) columns [one 45 cm and two 60 cm] and two lyophilisers with 100 L and 200 L capacities.   Following the $30 million investment in module one, Neuland is aligning further investment for subsequent modules with new customer requirements. Module two is planned to provide an overall reactor capacity of up to 18,000 L, comprising three 5,000 L LPPS reactors, as well as either a 1,000 L or 2,000 L SPPS reactor, and smaller reactors of up to the 1,000 L scale. This flexible configuration will allow Neuland to support a broad range of peptide programmes and production scales. The range of partner indications is also broadening beyond obesity and metabolic disease, with oncology emerging as a particularly active area of early-stage development. As peptide pipelines expand, a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity. Module one is supported by a team of nearly 212 peptide experts and this latest news follows on from an impressive few years for the CDMO. Revenues rose by a massive 116.3% in its most recent quarterly results, driven chiefly by increased commercial contracts, as well as a growing number of clinical projects.  ]]> https://biospectrumindia.com/news/109/28451/msd-inaugurates-expanded-hyderabad-tech-centre.html https://biospectrumindia.com/news/109/28451/msd-inaugurates-expanded-hyderabad-tech-centre.html Thu, 10 Sep 2026 13:18:47 +0530 MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) has announced the opening of its expanded Hyderabad Tech Centre, a new facility supporting enterprise digital technology capabilities across artificial intelligence, data, digital platforms, cybersecurity, cloud, automation and software engineering and more. The Centre was inaugurated by D. Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs, joined by Abhishek Narayan Singh, senior vice president, Digital Human Health, MSD. Building on MSD’s long-standing presence in India, the expanded office enhances the company’s global technology network and brings together technology talent focused on developing scalable digital solutions that help advance MSD’s purpose of saving and improving lives. Since its launch in 2025, the Hyderabad Tech Centre has grown in scale and scope as an important part of MSD’s global technology network. The expanded facility adds capacity for Hyderabad-based teams to contribute to enterprise technology solutions, collaborate with colleagues globally and help advance the digital capabilities that support MSD’s work to deliver innovative solutions for human and animal health around the world. Together with strategic partnerships that support manufacturing excellence and reliable access to medicines, the inauguration reflects the breadth of capabilities being developed across India to support MSD's efforts to improve health outcomes for patients. D. Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana, said, “Telangana has built a truly end-to-end life sciences ecosystem of more than 2,000 companies. Hyderabad has emerged as a global life sciences capital and is home to one of the largest concentrations of USFDA-approved facilities outside the United States. Over the last two years, we have built on this strong foundation to accelerate discovery, innovation, advanced R&D and global capability creation. Through our Next-Gen Life Sciences Policy 2026–30, we are bringing discovery, manufacturing, clinical research and technology together, giving Hyderabad a unique global advantage. We will soon reach 100 GCCs this year, building on the 75+ established last year and creating 4 lakh direct and indirect high-value opportunities across Telangana.” Abhishek Narayan Singh, Senior Vice President, MSD said, “Hyderabad's vibrant technology ecosystem, deep digital expertise and strong talent pool make it an ideal location for MSD, and we are grateful for the support and engagement of the Telangana government." ]]> https://biospectrumindia.com/news/109/28438/hrv-pharma-invests-rs-150-cr-to-expand-peptide-and-high-potent-api-capabilities.html https://biospectrumindia.com/news/109/28438/hrv-pharma-invests-rs-150-cr-to-expand-peptide-and-high-potent-api-capabilities.html Mon, 07 Sep 2026 18:25:56 +0530 Hyderabad-based HRV Pharma, a global asset-light pharmaceutical platform, has announced strategic investments to expand its capabilities across two high-value and supply-constrained pharmaceutical segments, synthetic peptides and high-potency oncology APIs. These initiatives are designed to strengthen HRV’s portfolio of complex molecules, accelerate access to regulated markets, and create dedicated supply capabilities while continuing to operate through its asset-light business model. HRV Pharma is investing as part of a combined Rs 40 to Rs 50 crore programme to establish dedicated cGMP peptide manufacturing capacity through a strategic capacity underwriting arrangement. The initiative will focus on commercial-stage and new-to-generic synthetic peptides across multiple therapeutic areas, with HRV retaining ownership of regulatory assets, product IP, and global commercialisation rights. The capacities are currently scaling rapidly and are expected to be ready in the next 6-8 months, giving HRV Pharma the opportunity to address a totally addressable market of more than $2 billion. The company is establishing a strategic joint venture with a focus on high-potency oncology APIs and specialised molecules, with an investment commitment of approximately Rs 100 crore. The platform will create specialised capabilities for developing and commercialising high-potent APIs, initially focusing on oncology and niche therapeutic segments where supply capabilities remain highly specialised. The peptide capacity initiative will support the development and commercialisation of commercial-stage and new-to-generic synthetic peptides across regulated markets including the US, Europe, and other global regions. The platform is expected to develop 20–30 oncology and high-potent APIs in phases, beginning with R&D capabilities and regulatory filings, followed by dedicated commercial-scale capabilities. ]]> https://biospectrumindia.com/news/109/28424/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-for-rs-135-cr.html https://biospectrumindia.com/news/109/28424/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-for-rs-135-cr.html Thu, 03 Sep 2026 19:35:00 +0530 Mumbai-based RPG Life Sciences has announced that its wholly owned subsidiary, RPG Active Pharma (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences on a going-concern basis through a slump sale. Acquisition of the API and intermediates business undertaking for consideration up to Rs 135 crore, subject to customary adjustments and closing conditions, adds approximately 300 KL of installed capacity in a state-of-the-art EU-GMP approved plant and a portfolio of 22 commercialised APIs plus 7 under development, with strong regulatory approvals.  The acquisition is the next step in RPGAP's consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organization. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP's manufacturing base, product portfolio, regulatory capabilities and customer access across geographies. Raghava operates a modern API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated R&D set-up. ]]> https://biospectrumindia.com/news/109/28425/cohance-lifesciences-commits-18-m-across-nj-bio-and-aruka-bio-to-expand-adc-capabilities.html https://biospectrumindia.com/news/109/28425/cohance-lifesciences-commits-18-m-across-nj-bio-and-aruka-bio-to-expand-adc-capabilities.html Thu, 03 Sep 2026 22:12:56 +0530 Hyderabad-based Cohance Lifesciences has announced a strategic investment of $18 million- in NJ Bio ($13 million) and Aruka Bio ($5 million) to strengthen its Antibody-drug Conjugate (ADC) platform and expand its global CRDMO capabilities. Both the transactions will be funded through internal accruals.The re-organisation establishes distinct priorities: deeper integration of NJ Bio’s customer-facing services with Cohance, and focused development of Aruka’s proprietary pipeline through potential partnerships. Cohance will increase its common-equity ownership in NJ Bio from 56% to 67.3%, acquiring the entire holdings of Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr Naresh Jain will retain 32.7%.    On the other hand, Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead programme is currently at the preclinical stage. Cohance’s $5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital. Following completion and Dr Jain’s upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr Jain.  Aruka will become Cohance’s direct subsidiary. The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.   ]]> https://biospectrumindia.com/news/109/28412/healthcare-and-life-sciences-leaders-to-convene-in-hyderabad-for-rise-health-innovation-summit-2026-.html https://biospectrumindia.com/news/109/28412/healthcare-and-life-sciences-leaders-to-convene-in-hyderabad-for-rise-health-innovation-summit-2026-.html Wed, 02 Sep 2026 16:56:31 +0530 Healthark's RISE Health Innovation Summit 2026 will hold its live event on September 24 at Trident, Hyderabad, beginning at 10:00 AM. This marks the culminating day of the summit, bringing together industry leaders for a day of direct engagement and dialogue. The event brings together leaders from across the life sciences and healthcare (LSHC) industry for a day of dialogue on the sector's evolving global priorities. Discussions throughout the day are expected to span leadership perspectives on the healthcare industry's future, the changing role of Global Capability Centers (GCCs), and emerging developments in genomics and biotechnology, reflecting the breadth of conversations shaping the industry today. Esteemed leaders across pharmaceutical, healthcare, and technology organisations are set to take the stage, including John Dawber, VP & MD, Global Business Services, Novo Nordisk; Vignesh Krishnakumar, Senior Manager - Analytics, GATE, Roche; and Mahesh Natrajan, Senior Director - R&D, Thermo Fisher Scientific, alongside other senior voices from the sector. RISE Health Innovation Summit 2026 continues to bring the global LSHC ecosystem onto a single platform, creating space for cross-industry dialogue on the challenges and opportunities ahead. In doing so, the summit reinforces its standing as a leading global forum for healthcare innovation, research, and talent. Registration for the live event is now open, with limited paid access available for delegates.   ]]> https://biospectrumindia.com/news/109/28380/aurigene-announces-manufacturing-and-supply-partnership-with-global-pharma-company.html https://biospectrumindia.com/news/109/28380/aurigene-announces-manufacturing-and-supply-partnership-with-global-pharma-company.html Wed, 26 Aug 2026 14:56:15 +0530 Hyderabad-based Aurigene Pharmaceutical Services, a wholly owned subsidiary of Dr. Reddy's Laboratories, has announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets. The agreement establishes a full-service framework for technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. The collaboration highlights Aurigene’s expanding drug product CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) capabilities, particularly in sterile injectables and biologics, complementing its established development and manufacturing expertise across the pharmaceutical value chain. The initial portfolio comprises 20+ products spanning sterile injectables, biologics and topicals, to be manufactured across facilities in India. The partnership is expected to progress through a phased technology transfer programme over the next two to three years, paving the way for commercial manufacturing and supply. At full commercialisation, the portfolio is expected to represent an estimated annual volume of approx.18 million units, largely being injectables, with revenues expected to commence from the calendar year 2028. ]]> https://biospectrumindia.com/news/109/28331/telangana-aims-to-emerge-as-indias-life-sciences-innovation-capital-with-25b-investment-target-by-2030.html https://biospectrumindia.com/news/109/28331/telangana-aims-to-emerge-as-indias-life-sciences-innovation-capital-with-25b-investment-target-by-2030.html Tue, 18 Aug 2026 13:54:11 +0530 As India sets an ambitious roadmap to reach a $130 billion pharmaceutical market valuation by 2030, industry leaders converged in Hyderabad to outline the country’s shift from volume-driven manufacturing to high-value innovation, research, and global regulatory excellence. Ahead of the 19th edition of CPHI & PMEC India 2026, scheduled for November across two venues, senior stakeholders emphasized that the next phase of Indian pharma requires a synchronised effort across CDMO services, digital transformation, and stringent quality compliance. The official launch and precursor event of CPHI & PMEC India 2026, held under the banner of the Pharma Leadership Exchange at the Novotel Hyderabad Convention Centre, brought together an exceptional gathering of pharma leaders, CXOs, industry stalwarts, and key voices from across India’s pharmaceutical and life sciences ecosystem, including Sarvesh Singh, Director & CEO,  LifeSciences & Pharma, Government of Telangana; Pushpa Vijayaraghavan, Director, Healthcare & Lifesciences Advisory, Sathguru Management Consultants; M. Roja Rani, Executive Director, Bulk Drug Manufacturers Association of India (BDMAI) and Chakravarthi AVPS, Chairman-Federation of Pharma Entrepreneurs, Telangana & Andhra Pradesh, and Rahul Deshpande, Sr. Group Director, Informa Markets in India. With Telangana contributing nearly 40% of India’s pharmaceutical production and approximately one-third of global vaccine output, the state is positioning itself as the nation’s life sciences innovation capital. Sarvesh Singh, CEO, Lifesciences & Pharma, Government of Telangana, said, “Our focus is on moving up the value chain, from generics and APIs to biologics, biosimilars, cell and gene therapies, and other cutting-edge areas where biology, chemistry and technology converge. With a strong research ecosystem, global capability centres, a deep talent pool, world-class manufacturing infrastructure and more than 20 dedicated life sciences incubators supporting over 1,000 startups, Telangana has all the ingredients to drive the next phase of life sciences innovation. Through our Next-Gen Life Sciences Policy 2026–2030, we aim to attract $25 billion in investments and create more than 5 lakhs jobs over the next five years. We are also positioning Telangana at the intersection of biology and deep technology, leveraging AI, data science and advanced technologies to accelerate research, innovation and sustainable manufacturing. We are strengthening global partnerships across the US, Europe, Japan, South Korea and China, while creating an environment that enables global companies, research institutions and startups to collaborate and scale. Our Green Skills Centre of Excellence, established in collaboration with Microsoft and 1M1B, is another important step, using AI and deep tech to address real-world sustainability and ESG challenges while building future-ready skills." Industry experts noted that while India maintains a robust generic medicine base, the future lies in "backward integration"—reducing dependency on imported key starting materials—and embracing the CRDMO (Contract Research and Development Manufacturing Organization) boom. With the global CRDMO industry projected to reach up to $22 billion by 2030, integration between technology providers and manufacturers is becoming a strategic necessity. The 19th edition of CPHI & PMEC India 2026 will be hosted across two venues, with CPHI India at IICC, Yashobhoomi, Dwarka from 23–25 November 2026, and PMEC India at IEML, Greater Noida from 24–26 November 2026. CPHI India will focus on finished dosage, excipients, natural extracts, fine chemicals and intermediates, and APIs, while PMEC India will focus on cleanroom technology, machinery and equipment, packaging, and laboratory and analytical equipment. The shows will also be supported by key industry bodies including the Pharmaceuticals Export Promotion Council of India (Pharmexcil), Indian Pharmaceutical Alliance (IPA), Organisation of Pharmaceutical Producers of India (OPPI), Indian Drug Manufacturers’ Association (IDMA) and Federation of Pharma Entrepreneurs (FOPE). ]]> https://biospectrumindia.com/news/109/28321/thermo-fisher-launches-vanquish-amplify-uhplc-system-and-orbitrap-excedion-mass-spectrometer-in-india.html https://biospectrumindia.com/news/109/28321/thermo-fisher-launches-vanquish-amplify-uhplc-system-and-orbitrap-excedion-mass-spectrometer-in-india.html Sat, 15 Aug 2026 14:02:49 +0530 At the recently held Biopharma Summit 2026 in Hyderabad, Thermo Fisher unveiled innovative products for the Indian researchers and scientific community. A highlight of the day was the launch of the Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometer, marking an exciting step forward in next-generation biotherapeutic characterisation. Powered by industry-leading high-resolution accurate-mass (HRAM) technology, the Orbitrap Excedion is designed to help scientists tackle increasingly complex modalities and generate deeper insights, supporting confident decisions across the biopharma development journey. Another highlight was the launch of the Thermo Scientific™ Vanquish™ Amplify UHPLC system, alongside the new Thermo Scientific™ SurePac™ Oligo RP MDi™ and SurePac™ Protein RP MDi™ columns, designed to bring greater confidence and performance to complex biopharma workflows. During an exclusive interaction with selected media, Srinath Venkatesh, Managing Director, India and South Asia, Thermo Fisher Scientific said, “These products have already been launched globally, and now we are bringing them to India in response to customer needs. As the industry moves towards large molecules, there is a great deal of work happening on complex therapeutics, especially oligonucleotides, peptides, proteins, and other complex biologics. The Excedion is specifically designed for those applications.” “Our focus is not just on launching the product, but also on ensuring customers receive the training they need, including data interpretation and data analysis. This summit is about demonstrating how data generated by these instruments is analysed, and we will continue doing that through smaller training sessions with scientists so that we can provide access to all of them”, he further said. Sharing his thoughts on the objective behind organising the Biopharma Summit, Venkatesh said, “This is the second in the series. Last year, we organised what we called the Orbitrap Summit. This year, we have expanded it into the BioPharma Summit. Last year it was held in Bengaluru. This year it is in Hyderabad. Based on how we see it today, this is going to become an annual feature. Tony Acciarito, President, APMEA, Thermo Fisher Scientific said “The feedback from customers last year was very positive. That's why the team believes this is a great forum to continue building on. As we learn more about what works and what doesn't, we will continue to refine and expand it.” The Biopharma Summit 2026 also included a detailed tour of the company’s Customer Experience Centre (CEC), at the Genome Valley in Hyderabad. With a combined investment of Rs 85-90 crore in CEC and the Bioprocess Design Centre (BDC), in Hyderabad’s Genome Valley, Thermo Fisher is building on its investments and growing presence in India. “The Customer Experience Centre and the Bioprocess Design Centre were established in response to what our customers asked for. Our customers and stakeholders clearly told us they wanted access to world-class technology here in India so that researchers could experience it firsthand. They also wanted a partner they could co-create with. Customers also asked us to help solve challenges around productivity and time to market. I think our differentiation lies in responding directly to what our customers are asking us to do. From a talent perspective, we have built partnerships with many of the country's leading academic institutions. Our objective is to integrate all of these into an ecosystem where we can help develop the new talent the industry requires and ensure they acquire these skills”, said Venkatesh. Tony Acciarito further mentioned, “The day we stop listening to our customers and start focusing on being better than our competition is the day we will fail. If our competitors are building similar capabilities, then congratulations to them. More capability on the ground is a positive outcome, regardless of who provides it. For us, the priority is staying very close to our customers.”   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/news/109/28295/aig-hospitals-collaborates-with-johnson-johnson-to-implement-polyphonic-surgery.html https://biospectrumindia.com/news/109/28295/aig-hospitals-collaborates-with-johnson-johnson-to-implement-polyphonic-surgery.html Wed, 12 Aug 2026 16:02:36 +0530 Hyderabad-based AIG Hospitals has announced a collaboration with Johnson & Johnson to implement Polyphonic™ Surgery, the flagship solution within the Polyphonic digital ecosystem for surgery, designed to support secure surgical video recording, review, collaboration, learning, and knowledge-sharing across surgical teams. AIG Hospitals will be among the early centres in not just in India but entire Asia-Pacific to implement such a digital ecosystem for surgical procedures, marking an important step towards the future of surgical intelligence. The platform is designed to bring surgical video, case-based review, team collaboration, learning resources, and structured feedback into one centralized environment. Through hands-on use and ongoing collaboration with surgeons, operating room teams, residents, information technology professionals and hospital leadership, AIG Hospitals will help evaluate how connected digital technologies can support clinical excellence and operational effectiveness. The collaboration also aligns with AIG Hospitals’ larger vision of integrating clinical excellence with academics, research, digital innovation and AI-enabled healthcare solutions. As part of the programme, participating users at AIG Hospitals will provide feedback on usability, workflow integration and clinical connectivity, helping inform future applications across surgical specialties and hospital systems. ]]> https://biospectrumindia.com/news/109/28300/ikp-knowledge-park-inks-mou-with-centre-for-healthcare-entrepreneurship.html https://biospectrumindia.com/news/109/28300/ikp-knowledge-park-inks-mou-with-centre-for-healthcare-entrepreneurship.html Wed, 12 Aug 2026 18:19:40 +0530 A Memorandum of Understanding (MoU) has been signed between IKP Knowledge Park and Centre for Healthcare Entrepreneurship (CfHE), Indian Institute of Technology (IIT) Hyderabad, marking the beginning of a collaborative effort to nurture the next generation of healthcare innovators through the IKP-CfHE Biodesign Fellowship 2026-27. The fellowship is designed to strengthen India's healthcare innovation ecosystem by bringing together medicine, engineering, and entrepreneurship to identify unmet clinical needs, develop innovative medical technologies, and translate ideas into scalable healthcare ventures. The IKP-CfHE Biodesign Fellowship will officially commence on 15 August 2026, welcoming a new cohort of fellows committed to solving real-world healthcare challenges. This partnership reflects a shared commitment to fostering innovation that addresses pressing healthcare needs and creates lasting societal impact. Both organisations are aiming to support a new generation of fellows as they transform ideas into technologies that improve lives across India and beyond. ]]> https://biospectrumindia.com/news/109/28291/amgen-to-open-new-science-innovation-centre-in-genome-valley-hyderabad.html https://biospectrumindia.com/news/109/28291/amgen-to-open-new-science-innovation-centre-in-genome-valley-hyderabad.html Tue, 11 Aug 2026 19:25:36 +0530 US-based Amgen has announced plans to open a new Science and Innovation Centre at Genome Valley in Hyderabad. The centre will join Amgen’s global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities.   The new site reflects Amgen’s continued focus on fighting the world’s toughest diseases by harnessing the best of biology and technology. By integrating advanced scientific capabilities with data and digital innovation, the company aims to accelerate the discovery and development of innovative medicines for patients worldwide.   “The new centre in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities and complements our strong US-based Research and Development footprint,” said Jay Bradner, M.D., executive vice president of Research and Development, Artificial Intelligence and Data at Amgen.   The centre is expected to be operational in 2027, and will bring together scientists and technologists across discovery chemistry, drug metabolism & pharmacokinetics and precision medicine, working closely with Amgen’s research sites around the world. This approach is designed to enhance how medicines are discovered and developed, improving speed, precision, and efficiency.   ]]> https://biospectrumindia.com/news/109/28302/indian-regulators-revamped-approval-route-looks-to-clear-biosimilar-bottleneck.html https://biospectrumindia.com/news/109/28302/indian-regulators-revamped-approval-route-looks-to-clear-biosimilar-bottleneck.html Mon, 10 Aug 2026 00:00:00 +0530 Arvind Kukrety, Deputy Drugs Controller at the Central Drugs Standard Control Organisation (CDSCO), set out the agency's position at Sartorius's Process Intensification (PI) Forum in Hyderabad, India, on 3 June 2026. Kukrety placed India's biosimilar market at $800 million to $1 billion in 2024, projected to reach around $10 billion by 2030, against a global biosimilar market heading toward $75 billion to $80 billion. CDSCO rewrote its post-approval change rules in 2024, the first revision since 2008. The guidance splits the dossier and post-approval routes, adds a fourth reporting tier for the lowest-risk changes on top of the existing three, and raises documentation to match WHO and Health Canada requirements. Where the agency has no guidance of its own it accepts ICH standards. Thus, the continuous-manufacturing framework ICH Q13, adopted internationally in 2022, already applies. That framework covers the conversion of an approved batch product to continuous production, extends to biosimilars and other therapeutic proteins, and runs a defined path. A change to the drug substance process is treated as a notifiable change, carrying a set data package of a process flow diagram, in-process controls, a process performance qualification, certificates of analysis for three batches, and stability data at room temperature and accelerated conditions. Adding a new manufacturing site is a higher-tier supplement needing prior approval. Comparability against the approved product runs through the whole process, with the manufacturer having to show the critical quality attributes are unchanged or justify any that are. The route is not theoretical, as the Indian drugmaker Enzene – also present at the Sartorius PI Forum – has taken four biosimilars made on a fully connected continuous line onto the Indian market, among them an adalimumab it launched as the first product it commercialized using continuous manufacturing, all cleared by CDSCO. Kukrety said CDSCO now clears an investigational new drug application in 30 days and a biologics market authorization within 120, though the guidance stops short of committing to fixed timelines. Working with the Kaizen Institute, the agency has stripped redundant steps from its own review and cut turnaround over the past year.. Filing has moved almost entirely online through a set of central and state e-governance portals covering market authorizations, manufacturing and sales licenses, and test licenses, and Kukrety said the agency wants to issue market authorization, registration, and import licenses together rather than in sequence, closing a lag that applicants have long complained about. The constraint, however, is people. CDSCO runs on about 800 staff at headquarters, with a further 2,000 in central laboratories and up to 3,000 across the states, and Kukrety was blunt that 800 is not enough for a review load running into the thousands a year. The fix rides on Biopharma SHAKTI, the ₹10,000 crore (about $1.2 billion) program announced in the February 2026 union budget to build out India's biologics and biosimilars base over five years. It funds a dedicated scientific review cadre at CDSCO, and Kukrety put the agency's own reinforcement at 1,500 additional reviewers. Kukrety framed the overhaul as an open door. “From CDSCO's point of view, we are committed, we are open, and we encourage you to come up with whatever you feel for improvement in our organization or our systems,” he said. ]]> https://biospectrumindia.com/news/109/28238/bits-pilani-develops-sustainable-tech-to-convert-biopharma-wastewater-into-reusable-water-clean-energy.html https://biospectrumindia.com/news/109/28238/bits-pilani-develops-sustainable-tech-to-convert-biopharma-wastewater-into-reusable-water-clean-energy.html Thu, 30 Jul 2026 21:00:25 +0530 Scientists at BITS Pilani, Hyderabad have developed an integrated and low-energy technology for wastewater treatment. It can provide a sustainable solution to the management of one of the most problematic wastewater streams in the biopharmaceutical industry. Researchers have successfully demonstrated the technology at the laboratory scale, the research team is now working with Biological E. Limited, one of India's leading vaccine manufacturers based in Genome Valley, Hyderabad, to scaling the system for industrial deployment. The innovative system replaces conventional chemical- and steam-based sterilisation with Pulsed Electric Field (PEF) technology. It enables biopharmaceutical fermentation wastewater to be safely disinfected while recovering reusable water and methane-rich biogas.  The technology could be applied to other pharmaceutical and vaccine production facilities and high-strength industrial wastewaters, to benefit industries with water-saving, energy-recovery and environmentally friendly integrated solutions. The project is supported by the Department of Science and Technology (DST), Government of India, through its ‘Water Technology Initiative’ of the Optimum Water Use in Industrial Sectors programme. The core disinfection technology has been filed for an Indian patent. Biopharmaceutical fermentation wastewater is among the most difficult industrial effluents to treat because it contains millions of live production microorganisms, residual antibiotics, and antibiotic resistance genes. Owing to the associated biosafety risks, industries currently rely on chemical treatment followed by steam-based autoclaving before disposal—a process that is both energy-intensive and expensive. ]]> https://biospectrumindia.com/news/109/28239/amgen-launches-first-scholars-programme-at-iiit-hyderabad.html https://biospectrumindia.com/news/109/28239/amgen-launches-first-scholars-programme-at-iiit-hyderabad.html Thu, 30 Jul 2026 21:05:18 +0530 Amgen has announced the launch of the first Amgen Scholars Programme in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), bringing the globally respected undergraduate summer research programme to India for the first time. Supported through a two-year commitment from Amgen through summer 2027, the programme reflects the company's long-standing commitment to advancing science education and inspiring future innovators. The inaugural cohort comprises 10 undergraduate scholars, including students from India, Vietnam, Qatar, and Dubai, creating opportunities for scientific collaboration and exchange across Asia. The students represent universities across Asia and are pursuing undergraduate programmes in science, engineering, and related disciplines, reflecting the program's regional diversity and academic excellence. As part of the intensive two-month residential research experience, students will explore artificial intelligence and machine learning applications in fundamental sciences, drug design and discovery, healthcare, cheminformatics, genomics and related areas alongside faculty mentors at IIIT Hyderabad. They will also have an opportunity to participate in seminars, networking events and a regional Amgen Scholars Symposium to be held in Tokyo in August 2026. At the conclusion of the programme, each scholar presents their research through a scientific poster presentation. The scholars were selected through a rigorous evaluation by an expert committee at IIIT Hyderabad based on academic excellence, research aptitude, motivation for doctoral studies, and demonstrated interest in applying AI and machine learning to drug discovery. Designed to inspire the scientists of tomorrow, the Amgen Scholars Programme is a long-standing, signature initiative of the Amgen Foundation, providing undergraduates the opportunity to engage in a compelling summer, scientific research experience at some of the world’s leading institutions. The Amgen Scholars Programme seeks to expand research, learning and networking opportunities for students committed to pursuing advanced degrees in STEM.  ]]> https://biospectrumindia.com/news/109/28218/prorithm-accelerates-expansion-across-southern-india-eyes-nationwide-presence-by-early-2027.html https://biospectrumindia.com/news/109/28218/prorithm-accelerates-expansion-across-southern-india-eyes-nationwide-presence-by-early-2027.html Mon, 27 Jul 2026 17:28:18 +0530 DeepFacts, a HealthTech startup behind proRITHM (an AI- and IoT-enabled Smart Remote Patient Monitoring platform), has announced its expansion roadmap, with plans to strengthen its presence across Andhra Pradesh, Karnataka, Tamil Nadu, and Odisha before expanding across India by early 2027. It already holds a strong ground in Telangana. The company is also preparing for its entry into the US market by late 2027 or early 2028 as it continues to scale its AI-enabled healthcare solutions. As part of its innovation journey, DeepFacts has secured three granted patents, reinforcing the company's focus on building proprietary healthcare technologies. With a growing portfolio of intellectual property, expanding healthcare collaborations, and a clear roadmap for domestic and international growth, DeepFacts aims to accelerate the adoption of proRITHM, its AI-powered remote patient monitoring platform, while contributing to improved healthcare accessibility and outcomes. Vamsi Karatam, Founder & CEO of DeepFacts said "The future of healthcare lies in continuous, intelligent monitoring that enables timely interventions rather than reactive treatment. Our focus is to make clinically reliable remote monitoring accessible to healthcare providers across India while building globally relevant technology. The next phase of our expansion is centred on strengthening our presence in key Indian markets, deepening collaborations with healthcare partners, and preparing for international expansion." ]]> https://biospectrumindia.com/news/109/28156/telangana-to-establish-indias-first-green-pharma-focused-applied-ai-centre-of-excellence.html https://biospectrumindia.com/news/109/28156/telangana-to-establish-indias-first-green-pharma-focused-applied-ai-centre-of-excellence.html Sun, 19 Jul 2026 15:41:37 +0530 The Government of Telangana, in collaboration with Microsoft India 1M1B (1 Million for 1 Billion) and MeitY Startup Hub, has announced the establishment of India's first Green Skills & Applied AI Centre of Excellence (CoE) dedicated to Green Pharma. The initiative marks a significant step towards strengthening Telangana's position as a global hub for sustainable life sciences manufacturing while building a future-ready talent ecosystem.Expected to become operational by August 2026, the Centre will focus on equipping youth with industry-relevant skills in Applied Artificial Intelligence (AI), sustainable manufacturing and emerging technologies. The initiative aligns with the Telangana Next-Generation Life Sciences Policy 2026–30, which places strong emphasis on sustainability, advanced technologies and workforce development to drive the next phase of growth in the state's life sciences sector.The roadmap for the Centre was presented to ITEC and Industries Minister Sridhar Babu Duddilla at Telangana State Secretariat. The meeting was attended by Microsoft India Development Centre President and Managing Director Rajiv Kumar, Microsoft Senior Director (Elevate-CSR) Manju D., 1M1B (1 Million for 1 Billion) Founder and CEO Manav Subodh, Director - Sustainability & Government Advocacy Deepika Venkatesh, IT Advisor Sai Krishna, Telangana Life Sciences CEO Sarvesh Singh, and other senior government officials.The Centre is expected to play a key role in supporting Telangana's goal of creating over five lakh jobs across the life sciences ecosystem by developing an AI-enabled workforce equipped to meet the evolving needs of the pharmaceutical and advanced manufacturing industries. ]]> https://biospectrumindia.com/news/109/28135/medtronic-and-apollo-hospitals-to-establish-state-of-the-art-advanced-icu-in-hyderabad.html https://biospectrumindia.com/news/109/28135/medtronic-and-apollo-hospitals-to-establish-state-of-the-art-advanced-icu-in-hyderabad.html Thu, 16 Jul 2026 16:53:07 +0530 Medtronic, a global leader in healthcare technology, and Apollo Hospitals have announced the inauguration of “ICU of the Future” an 11-bed, state-of-the-art Intensive Care Unit (ICU) at Apollo Hospitals, Jubilee Hills. The new facility will be fully integrated with Medtronic’s advanced Acute Care & Monitoring (ACM) technologies and solutions, marking a significant milestone in collaborative healthcare innovation. The MoU was officially signed by Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group; Manpreet Singh, Chief Executive Officer, Apollo HealthAxis and Mandeep Singh Kumar, Managing Director & Vice President – India Subcontinent Countries, Medtronic during a formal inauguration ceremony held at the Jubilee Hills campus. Developed in collaboration with Medtronic’s ACM team, the initiative represents a step forward in strengthening critical care infrastructure and advancing collaborative healthcare innovation. The integrated ICU is designed to support evolving clinical needs while fostering closer collaboration between clinicians and technology leaders. By bringing together clinical expertise and advanced technologies, the collaboration aims to help enable more informed care delivery and contribute to improved patient outcomes. Mandeep Singh Kumar, Vice President – India Subcontinent Countries, Medtronic said, “This advanced ICU at Apollo Hospitals reflects a shared commitment to patient care and clinical excellence. Through this collaboration, we aim to gain valuable insights from real-world clinical environment that can help inform the development of technologies designed to support clinicians and improve patient care in India and around the world.” Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group said, “Critical care is where every decision, every minute and every intervention can make the difference between life and loss. As medicine becomes increasingly data-driven, our responsibility is not only to bring the best technologies to India but to ensure they meaningfully improve clinical decisions and patient outcomes."   ]]> https://biospectrumindia.com/news/109/28120/leiutis-pharma-announces-cdsco-approval-for-global-first-synthetic-cbd-therapy-to-cure-mild-to-moderate-anxiety-disorders.html https://biospectrumindia.com/news/109/28120/leiutis-pharma-announces-cdsco-approval-for-global-first-synthetic-cbd-therapy-to-cure-mild-to-moderate-anxiety-disorders.html Tue, 14 Jul 2026 18:33:35 +0530 Hyderabad-based Leiutis Pharmaceuticals LLP, a speciality therapeutics company, has announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to collaboration partner Zenara Pharma to manufacture its proprietary Synthetic Cannabidiol Oral Solution 150 mg/mL for the management of mild to moderate anxiety disorders when used in conjunction with cognitive behavioural therapy (CBT).   The product is to be prescribed only by psychiatrists. The approval is based on a successful Phase III clinical trial conducted in India in accordance with CDSCO requirements and will be followed by a Phase IV study.   Leiutis said it marks the world's first regulatory approval of a fully synthetic cannabidiol oral solution for the management of mild to moderate anxiety disorders. The product was researched, developed, patented and clinically validated entirely in India.   The product combines a synthetic cannabidiol active pharmaceutical ingredient (API), developed by Biophore India Pharmaceuticals, with Leiutis' proprietary nanodispersible drug delivery platform, manufactured at Zenara's CDSCO-, FDA-, and EU-compliant facilities.   The company said the product represents end-to-end pharmaceutical innovation achieved in India, spanning API development, drug delivery, clinical development, and regulatory approval.   The approval comes at a time when anxiety disorders remain a significant public-health challenge in India. ]]> https://biospectrumindia.com/news/109/28121/cmc-vellore-iiit-h-develop-multilingual-ai-companion-for-cancer-patients.html https://biospectrumindia.com/news/109/28121/cmc-vellore-iiit-h-develop-multilingual-ai-companion-for-cancer-patients.html Tue, 14 Jul 2026 19:18:23 +0530 A multi-partner consortium led by Christian Medical College (CMC) Vellore, in collaboration with IIIT Hyderabad’s Language Technologies Research Centre (LTRC), is developing BandhuCare – a multilingual AI companion that answers patients’ queries in their own language, captures their symptoms through natural conversations, and helps clinicians understand what happens between hospital visits.  Unlike consumer AI assistants that answer virtually anything, BandhuCare emerged after years of working closely with oncology patients and understanding where healthcare delivery quietly breaks down, not during diagnosis or treatment, but between hospital visits. The consortium brings together clinical expertise from CMC Vellore, AI and language technologies from IIIT-H’s Language Technologies Research Centre, startup partner Revan AI, AIIMS Guwahati as an external clinical collaborator, and patient advocacy organisation, PatientsEngage that ensures patient voices remain central to development. The next phase, which is the pilot study on real cancer patients and specifically head and neck cancer patients, is perhaps the most important. At CMC Vellore, head and neck cancers constitute one of the largest cancer burdens, giving clinicians deep expertise and years of experience in understanding not just the disease, but the long-term challenges patients face after treatment. Supported by the National Cancer Grid and MeitY’s India AI initiative, BandhuCare has reached Technology Readiness Level 5, with ethics approvals in place for clinical pilot studies involving patients. ]]> https://biospectrumindia.com/news/109/28101/new-strategic-partnership-to-strengthen-telanganas-medtech-innovation-ecosystem.html https://biospectrumindia.com/news/109/28101/new-strategic-partnership-to-strengthen-telanganas-medtech-innovation-ecosystem.html Thu, 09 Jul 2026 22:29:52 +0530 A Memorandum of Understanding (MoU) has been signed between Research and Innovation Circle of Hyderabad (RICH) and the Medical Devices Park Industrial Welfare Association (MDPIWA), Telangana at T-Hub, for establishing a strategic partnership to further strengthen Telangana’s MedTech innovation ecosystem. This collaboration creates a structured framework for advancing key areas of ecosystem development, including international market access and strategic global partnerships, industry–research linkages, startup engagement and innovation support, joint MedTech conclaves and knowledge‑exchange platforms, and accelerated pathways for technology commercialisation. Through this MoU, RICH and MDPIWA will jointly enable deeper integration between the Medical Devices Park, home to more than 70 medical device companies, and the broader innovation landscape comprising researchers, clinicians, healthcare institutions, and international collaborators. The partnership aims to catalyse innovation, support the development of high‑impact medical technologies, and enhance the global competitiveness of Telangana’s MedTech sector. Together, RICH and MDPIWA look forward to building a stronger, innovation‑driven, and globally connected MedTech ecosystem, creating meaningful opportunities for collaboration, growth, and technological advancement in Telangana and beyond. ]]> https://biospectrumindia.com/news/109/28084/ciro-pharma-invests-rs-800-cr-to-open-indias-first-integrated-oncology-manufacturing-facility-in-hyderabad-.html https://biospectrumindia.com/news/109/28084/ciro-pharma-invests-rs-800-cr-to-open-indias-first-integrated-oncology-manufacturing-facility-in-hyderabad-.html Wed, 08 Jul 2026 21:40:32 +0530 Ciro Pharma has launched India's first integrated oncology manufacturing facility with an investment of Rs 800 crore at at Genome Valley - Hyderabad's Life Sciences District, Biotech Park Phase III.Inaugurated by IT and Industries Minister Sridhar Babu Duddilla, the state-of-the-art facility will produce oral oncology medicines, sterile injectables, lyophilised powder injections, and soft gel capsules using advanced containment technology for cancer care.The unit is set to generate 500 direct jobs initially, with employment expected to double in the coming years. The launch of this state-of-the-art facility marks another significant milestone in strengthening Telangana's position as a global life sciences and pharmaceutical manufacturing hub. ]]> https://biospectrumindia.com/news/109/28062/shantha-biologics-partners-with-denmarks-novo-nordisk-for-cartridge-fill-finish-in-diabetes-and-obesity-care.html https://biospectrumindia.com/news/109/28062/shantha-biologics-partners-with-denmarks-novo-nordisk-for-cartridge-fill-finish-in-diabetes-and-obesity-care.html Thu, 02 Jul 2026 17:17:40 +0530 Pharma major Shantha Biologics has signed an agreement with Novo Nordisk, the Danish pharmaceutical company, to manufacture cartridges for injectable medicines at its Hyderabad plant.   It means Shantha Biologics will fill the cartridges and prepare them for use, a final and highly sensitive step in producing drugs like insulin and other injectable therapies. The financial terms and production volumes remain undisclosed.   Cartridge fill-finish involves loading a drug into a slim, pre-filled cartridge that clicks into a pen injector, the format patients use to self-administer their own medication at home rather than in a hospital. The process demands sterile, contamination-free conditions and tight dosing accuracy, since the drug goes directly into the body. This manufacturing format is used across a range of chronic and long-term conditions, including diabetes, obesity, growth hormone deficiencies and certain autoimmune and oncology treatments delivered through biologic therapies.For Shantha Biologics, the deal is validation as much as it is business. The company's fill-finish lines are automated and approved by the US FDA, one of the toughest regulators in the world. Winning this CDMO (contract development and manufacturing organisation) mandate from Novo Nordisk, one of the largest insulin and diabetes care companies globally, signals that a plant in India can meet that bar.The timing works in Shantha Biologics' favour. CDMO partnerships for biologic drugs, medicines made from living cells rather than chemicals, are powering a fast-growing global market. It was valued at $25.32 billion in 2025 and is expected to grow to $38.29 billion by 2031, according to industry estimates. Shantha Biologics said it plans to expand further in vaccines, biologics and injectable manufacturing as that demand grows.The company expects its Hyderabad workforce to grow to around 500 employees in the near future. ]]> https://biospectrumindia.com/news/109/28052/roche-expands-footprint-in-hyderabad-with-new-digital-tech-hub.html https://biospectrumindia.com/news/109/28052/roche-expands-footprint-in-hyderabad-with-new-digital-tech-hub.html Wed, 01 Jul 2026 16:51:59 +0530 Swiss firm Roche has announced its second Digital Tech Hub in India, expanding its global Technology Hub network to Hyderabad alongside its existing site in Pune. The new Tech Hub will be going live in the first quarter of 2027 and plans to scale up over the next few years. “Hyderabad is a destination for an exceptional talent pool, especially for the Pharmaceutical and Life Sciences domain,” said Ramesh Durvasula,  Chief Data Officer and Chief AI Officer a.i.. “By tapping into India’s vibrant healthcare and technology  ecosystem, we are creating scalable data-driven innovations to advance our core purpose of improving patient care.’’ On the development, Raja Jamalamadaka, Vice-President & Site Head, Roche Pune & Hyderabad Sites, shared “Our investment in Hyderabad - a rapidly growing destination for research, technology and high-end innovations - reflects our long-term commitment to India and its ecosystem.” He further added: ”By scaling our footprint, we are enhancing our capability to orchestrate seamless, next-generation digital and technology solutions.” The two Digital Technology Hubs in India will house teams delivering IT services and digital applications in areas such as Biostatistics, ERP, and Medical Safety. Hyderabad adds depth and capacity to the Life Sciences domain knowledge specifically tailored to accelerating the development of our digital solutions.   ]]> https://biospectrumindia.com/news/109/28006/quantoom-and-nucelion-therapeutics-to-expand-rna-capacity-in-india.html https://biospectrumindia.com/news/109/28006/quantoom-and-nucelion-therapeutics-to-expand-rna-capacity-in-india.html Tue, 23 Jun 2026 16:24:00 +0530 Belgium-based Quantoom (operating as Phoenix Biosciences SA) and Hyderabad-based Nucelion Therapeutics have announced the signing of a Memorandum of Understanding (MoU) to explore a preferred RNA contract development and manufacturing (CDMO) partnership in India. Under the MoU, Nucelion would operate Quantoom’s N-Force platform technologies to provide both research-grade and GMP-grade RNA manufacturing services to clients across human therapeutics and animal health. The collaboration reflects a shared view of the significant and growing opportunity for RNA-based products in India and the broader Asia-Pacific region — spanning mRNA therapeutics, RNA-based vaccines, oligonucleotide therapies, and veterinary applications. Quantoom’s N-Force toolbox supports the rapid development of (sa)mRNA as a drug modality — from design through RNA production and encapsulation — via its Ntensify® equipment and consumables, reagent pre-mixes, and Ncapsulate® QCX delivery technology. Through the intended partnership, Nucelion aims to establish and scale RNA CDMO capability at its facilities in India, supported by Quantoom technology transfer and technical expertise. ]]> https://biospectrumindia.com/news/109/27982/axis-bank-partners-with-bits-pilani-to-establish-rs-100-cr-industry-research-technology-innovation-park-in-hyderabad.html https://biospectrumindia.com/news/109/27982/axis-bank-partners-with-bits-pilani-to-establish-rs-100-cr-industry-research-technology-innovation-park-in-hyderabad.html Wed, 17 Jun 2026 16:31:28 +0530 Axis Bank, one of the largest private sector banks in India, has signed a Memorandum of Understanding (MoU) with Birla Institute of Technology and Science (BITS) Pilani, to establish the Axis Bank–BITS Industry Research, Technology & Innovation Park at the BITS Pilani Hyderabad Campus.  This collaboration, with a Rs 100 crore CSR grant, marks a significant step towards strengthening India’s deep-tech and translational research ecosystem by creating an integrated launchpad for facilitating deeper industry-academia collaboration, driving innovation and entrepreneurship. With a focus on Life Sciences, Biopharma, healthcare and medical devices, the proposed Axis Bank–BITS Industry Research, Technology & Innovation Park at the Hyderabad campus is being developed as a dedicated platform to strengthen India’s innovation ecosystem, with a focus on enabling cost-effective healthcare solutions that benefit the public at large.  The Park's location in Hyderabad places it at the heart of Telangana's thriving life sciences corridor, anchored by Genome Valley. By embedding academia-led biopharma and deep-tech capabilities within this ecosystem, the partnership supports national priorities for affordable healthcare, translational research, and self-reliance in critical technologies under the Government of India’s ‘Atmanirbhar Bharat’ and ‘Make in India’ initiatives. Under the partnership, BITS Pilani shall guide the Research Park’s governance and research agenda, while Axis Bank shall support its infrastructure development. Spread across approximately 120,000 sq. ft., the Axis Bank–BITS Industry Research, Technology & Innovation Park shall house laboratories, incubation spaces, and diverse shared facilities under one roof, especially supporting innovators from academia, startups and MSME domains through structured partnerships, co-design and co-creation of projects. This will support technology transfer and IP management, and provide ready access to BITS Pilani’s academic expertise and talent. ]]> https://biospectrumindia.com/news/109/27979/neuland-to-open-20-m-dedicated-process-development-facility-with-integrated-kilo-labs-in-hyderabad-.html https://biospectrumindia.com/news/109/27979/neuland-to-open-20-m-dedicated-process-development-facility-with-integrated-kilo-labs-in-hyderabad-.html Tue, 16 Jun 2026 19:11:25 +0530 Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, will open a dedicated process development laboratory and integrated kilo lab at its Genome Valley campus in Hyderabad. The new 135,000 sq. ft. facility will see $20 million invested in a specialist fit-out and be operationalised in phases, with full completion expected by October 2026. Significantly, it has been designed as a purpose-built integrated scale-up laboratory dedicated exclusively to process development. Once completed, the site will take Neuland’s process development team to more than 500 scientists, making it one of the largest scale-up workforce in India. The centre will incorporate AI-driven route scouting, parallel synthesis, and Electronic Laboratory Notebooks (ELNs), enabling faster decision-making, reduced cycle times, and seamless data continuity. A centralised analytical wing will house a comprehensive suite of characterisation technologies, with the facility also including specialised zones for process engineering, polymorph studies, process safety, and advanced flow chemistry, alongside five peptide labs and three purification labs. The Kilo Lab will be equipped with 20–250 L all‑glass reactors, cryogenic capability, and multiple filtration systems. By bridging bench chemistry and plant operations, the Kilo Lab ensures processes are engineered with manufacturability in mind from the outset. ]]> https://biospectrumindia.com/news/109/27966/pulsus-group-targets-6000-jobs-at-ameenpur-ai-healthcare-hub.html https://biospectrumindia.com/news/109/27966/pulsus-group-targets-6000-jobs-at-ameenpur-ai-healthcare-hub.html Mon, 15 Jun 2026 16:15:10 +0530 PULSUS Group has announced plans to expand its Ameenpur AI Healthcare and Digital Innovation Hub, targeting a workforce of 6,000 direct and 30,000 indirect jobs as it scales operations at the 35-acre campus in Telangana. The move follows a Supreme Court ruling that upheld the project's IT/ITeS and SEZ status, clearing the way for accelerated development and fresh investment. PULSUS is backing its expansion plans with a proven employment record. Parliamentary records under the India BPO Promotion Scheme show that Omics International generated 2,836 direct jobs by March 2022 and is targeting around 6,000 jobs in Visakhapatnam, while supporting an estimated 30,000 indirect jobs. The records also recognise the company's Ameenpur operations, where employment has created about 1,500 of the 6,000 direct jobs. With the legal status recently received from the Supreme Court, PULSUS has fast-tracked plans to scale the Rs 500 crore Ameenpur campus into a major AI healthcare and digital services hub and increase its workforce to 6,000. For Telangana, the project represents another investment in sectors where the state has built a strong presence, particularly information technology, life sciences, healthcare innovation and Global Capability Centres (GCCs). The location near the Miyapur growth corridor is expected to strengthen the region's technology ecosystem while creating employment opportunities for graduates and skilled professionals. Beyond employment generation, PULSUS plans to collaborate with universities, research institutions, healthcare organisations, startups and technology companies to develop an ecosystem supporting innovation, research and global service delivery. The AI Healthcare hub is expected to drive demand for highly skilled professionals, including software engineers, AI specialists, healthcare data scientists, clinical research associates, bioinformatics experts and digital services professionals. ]]> https://biospectrumindia.com/news/109/27949/avio-smart-market-stack-strengthens-diagnostics-healthcare-vertical-in-discussion-with-mediciti-institute.html https://biospectrumindia.com/news/109/27949/avio-smart-market-stack-strengthens-diagnostics-healthcare-vertical-in-discussion-with-mediciti-institute.html Thu, 11 Jun 2026 19:48:44 +0530 As part of its strategy to build a scalable Diagnostics & Healthcare business, Avio Smart Market Stack (formerly Bartronics India) has initiated strategic discussions with Mediciti Institute of Medical Sciences (MIMS), Hyderabad, to explore opportunities for research collaboration, clinical validation, and adoption of advanced molecular diagnostic technologies. As part of the interaction, Huwel Lifesciences, ASMS' strategic molecular diagnostics partner, showcased its portfolio of indigenous diagnostic technologies and ongoing innovations in molecular diagnostics. The discussions brought together leadership teams, clinicians, researchers, and academic experts to examine how innovative molecular diagnostic solutions can strengthen disease detection, improve clinical decision-making, and enhance healthcare outcomes across India. During the discussions, Huwel Lifesciences showcased its comprehensive portfolio of indigenous molecular diagnostic technologies, including solutions for tuberculosis, multidrug-resistant tuberculosis (MDR-TB), sepsis, HPV screening, hepatitis, antimicrobial resistance (AMR) detection, respiratory diseases, and environmental surveillance. The discussions focused on collaborative research, clinical validation studies, real-world evidence generation, and opportunities for adoption and deployment of Huwel's diagnostic technologies within Mediciti's healthcare ecosystem. The organisations also explored the possibility of pilot programmes and product evaluations across selected departments to assess their impact on routine diagnostic workflows.     As part of its Diagnostics & Healthcare growth strategy, ASMS is actively building market access channels for advanced diagnostic technologies through partnerships with healthcare institutions, government programs, research organisations, and industry stakeholders. Through its partnership with Huwel Lifesciences, the company is working to accelerate validation, adoption, procurement, and large-scale deployment of indigenous diagnostic solutions across India and international markets. ]]> https://biospectrumindia.com/news/109/27937/oval-fertility-inks-mou-with-merck-to-strengthen-reproductive-care-standards-in-india.html https://biospectrumindia.com/news/109/27937/oval-fertility-inks-mou-with-merck-to-strengthen-reproductive-care-standards-in-india.html Wed, 10 Jun 2026 15:03:38 +0530 At a time when access to high-quality reproductive treatment remains limited, Oval Advanced Fertility Care and Merck Specialities, the Indian healthcare arm  of Merck KGaA, Darmstadt, Germany, and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MoU).  The collaboration aims to enhance access to advanced fertility care by strengthening clinical capabilities, improving transparency and patient experience, and driving more predictable, high-quality outcomes through integrated expertise, technology, and data-led approaches. India's IVF market, valued at approximately $2.35 billion in 2024, is projected to reach $5.03 billion by 2034, growing at a compound annual growth rate of 7.9 per cent. However, market growth alone does not ensure better outcomes for patients, and the collaboration aims to address the disconnect between rapid market expansion and consistent treatment standards. This collaboration seeks to address the gap between growth and consistent standards of care by combining scientific expertise, digital innovation, patient support frameworks, and clinical capability building to improve both access and treatment outcomes. Veena Reddy, Co-Founder & Director, Oval Fertility, said, "The partnership with Merck brings together shared values around transparency, clinical excellence, and putting the patient at the centre of every decision." Pratima Reddy, Managing Director, Merck Specialities Private Limited, said, “Fertility care in India is evolving rapidly, with patients seeking greater transparency, a more seamless experience, and stronger confidence in outcomes. As a leader in IVF, Merck is well positioned to partner with progressive care providers to address these expectations through an integrated approach, combining clinical expertise, advanced technologies, and data-driven insights." With a longstanding legacy in reproductive healthcare, Merck brings deep expertise across fertility treatments, IVF technologies, and clinical education, supporting healthcare professionals in delivering evidence-based fertility care.  Oval Advanced Fertility Care is backed by GVK, one of India's most established business conglomerates, and is led by an internationally acclaimed medical team. ]]> https://biospectrumindia.com/news/109/27927/merck-and-csir-iict-partner-to-strengthen-research-collaboration.html https://biospectrumindia.com/news/109/27927/merck-and-csir-iict-partner-to-strengthen-research-collaboration.html Tue, 09 Jun 2026 19:32:54 +0530 Merck Life Science India has signed a Memorandum of Understanding (MoU) with CSIR–Indian Institute of Chemical Technology (IICT), Hyderabad, to strengthen collaboration in scientific research, innovation, and academia-industry engagement. This partnership is aimed at fostering knowledge exchange, enhancing skill development, and driving collaborative initiatives that contribute to India’s research and innovation ecosystem. The MoU aims to strengthen industry-research collaboration by developing analytical methods and application notes for new products, molecules, and customer challenges, while fostering joint research initiatives, scientific knowledge exchange, and innovation.  The agreement was signed in the presence of Dhananjay Singh, Managing Director, Merck Life Science & Head, Discovery Solutions, India; Sakshi Yadav, Director and Head of Pharma Business (Large and Strategic Accounts), Discovery Solutions, along with Dr D. Srinivasa Reddy, Director, CSIR-IICT; Pravin Likhar, Chief Scientist and Chair, BDRM, Indian Institute of Chemical Technology; and Dr S. Rama Mohan, Chair, Knowledge and Information Management, CSIR-IICT, Hyderabad. ]]> https://biospectrumindia.com/news/109/27905/theranym-biologics-opens-rs-1200-cr-manufacturing-facility-in-telangana.html https://biospectrumindia.com/news/109/27905/theranym-biologics-opens-rs-1200-cr-manufacturing-facility-in-telangana.html Wed, 03 Jun 2026 19:15:50 +0530 TheraNym Biologics, a contract manufacturing organisation by Aurobindo Pharma, has inaugurated its state-of-the-art manufacturing facility at Borpatla village in Sangareddy district, Telangana. Established with an investment of Rs 1,200 crore, the facility marks a significant addition to the state’s rapidly expanding biotechnology and pharmaceutical ecosystem. MSD has joined as the anchor customer for this new facility. The facility will manufacture advanced biologics and critical medicines used in the treatment of cancer and other life-threatening diseases, with products catering to both domestic and international markets, including the United States. TheraNym is equipped with advanced infrastructure designed to meet international regulatory standards. The establishment of TheraNym marks Aurobindo Pharma's strategic entry into the biologics contract manufacturing segment. Beyond enhancing healthcare innovation, the project is expected to generate employment opportunities for more than 1,500 local youth, contributing to regional economic growth and skill development. ]]> https://biospectrumindia.com/news/109/27849/us-biotech-regeneron-to-launch-global-capability-centre-in-hyderabad.html https://biospectrumindia.com/news/109/27849/us-biotech-regeneron-to-launch-global-capability-centre-in-hyderabad.html Tue, 26 May 2026 12:38:26 +0530 Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance its mission of using the power of science to bring new medicines to patients in need. The Regeneron GCC is expected to grow to hundreds of jobs in the coming years as it expands capabilities across key global functions. Founded and led by physician-scientists, Regeneron is a global biotechnology leader headquartered in the United States (US) with 15 approved or authorised medicines and nearly 50 pipeline candidates spanning multiple therapeutic areas. The Regeneron GCC is expected to further strengthen Hyderabad’s position as a leading life sciences and GCC destination. With over 450 GCCs, Hyderabad offers access to a strong talent pool across biotechnology, life sciences, AI, digital technologies and analytics, supported by a mature innovation ecosystem, robust infrastructure and strong research capabilities. Expected to be operational in the second half of 2026, the site is planned to scale to hundreds of new roles in the coming years. Regeneron established its Bengaluru presence in 2022. The Regeneron GCC builds on that foundation by expanding the company’s global operations and reinforcing India’s role as a long-term strategic partner for its growth. ]]> https://biospectrumindia.com/news/109/27844/us-based-medtech-firm-align-technology-to-open-multi-million-dollar-manufacturing-facility-in-hyderabad.html https://biospectrumindia.com/news/109/27844/us-based-medtech-firm-align-technology-to-open-multi-million-dollar-manufacturing-facility-in-hyderabad.html Mon, 25 May 2026 13:51:26 +0530 US-based Align Technology, Inc, a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, has announced plans to open a new manufacturing facility in Hyderabad, in 2027, create more than 300 direct jobs, and spend approximately $200 million in both capital and operational expense over the next several years. This new facility reflects Align’s strategy to get closer to customers and scale its operations to support high-growth markets like India, while strengthening its supply chain resilience and operational efficiency to drive shareholder value. Align’s Hyderabad manufacturing facility will complement Align’s existing footprint in Hyderabad, which includes its Global Capability Centre, the Align Innovation Centre, further reinforcing the city’s strategic importance within Align’s global operations network. It would mark the company’s first manufacturing presence in India and its fourth globally. The proposed facility is expected to commence operations in 2027 and be margin accretive in the first year. ]]> https://biospectrumindia.com/news/109/27816/telangana-propels-to-become-145-b-life-sciences-ecosystem.html https://biospectrumindia.com/news/109/27816/telangana-propels-to-become-145-b-life-sciences-ecosystem.html Thu, 14 May 2026 19:26:04 +0530 Telangana’s life sciences ecosystem has achieved a landmark milestone, reaching an estimated valuation of $145 billion, fuelled by over Rs 84,000 crore in investments over the past two years—the fastest expansion in the state’s history. This transformative progress was highlighted during the 7th Board Meeting of the Telangana Life Sciences Foundation (TLSF), chaired by Industries & Commerce Minister D. Sridhar Babu. Shakthi M. Nagappan, CEO of TLSF, delivered a detailed presentation on the sector’s growth during his decade-long tenure, underscoring the last two years as a pivotal inflexion point under the dynamic leadership of Chief Minister A. Revanth Reddy and Minister (Industries and Commerce) D. Sridhar Babu. The life sciences sector has expanded nearly threefold since 2016, establishing Hyderabad as one of the world’s premier life sciences clusters across pharmaceuticals, biotechnology, medical technology, and health tech innovation. A standout achievement: Hyderabad now hosts technology and innovation centres from nine of the world’s top ten life sciences companies—the only region outside the United States with this distinction.  Key drivers include robust policy frameworks, strategic global partnerships, and targeted institution-building, cementing Telangana’s status as a highly integrated global ecosystem. The Board unanimously commended CEO Shakthi M. Nagappan for his leadership in shaping and scaling the ecosystem during this transformational phase. The Board further noted with appreciation that, in recognition of his contributions, the Government has appointed him as Advisor (Lifesciences), and that he will continue to serve on the Board of the Telangana Lifesciences Foundation. "Telangana’s life sciences sector has witnessed unprecedented growth over the past two years", the Minister stated. While the majority of the committed investments have been grounded, the Minister suggested that the investment MoUs executed for Green Pharma City, cumulatively amounting to about Rs 20,000 crore, should be grounded at the earliest. The meeting also introduced TLSF’s new CEO, Sarvesh Singh, who outlined the 2026-27 priorities. The Board emphasised the need to sustain the momentum of ecosystem growth and that accelerating the implementation of the Life Sciences Policy that has received overwhelming response, advancing initiatives such as the Telangana School of Life Sciences, etc. should be top priorities for the foundation.  ]]> https://biospectrumindia.com/news/109/27774/lakshmee-foundation-accelerates-healthcare-expansion-with-rs-90-cr-contribution-from-avantel-founder.html https://biospectrumindia.com/news/109/27774/lakshmee-foundation-accelerates-healthcare-expansion-with-rs-90-cr-contribution-from-avantel-founder.html Thu, 07 May 2026 22:22:10 +0530 The Founder, Chairman and Managing Director of Avantel Limited Dr Abburi Vidyasagar, has contributed 60 lakh equity shares of the company to Lakshmee Foundation, a philanthropic commitment currently valued at approximately Rs90 crore to strengthen healthcare infrastructure and expand access to affordable medical care in Andhra Pradesh and Telangana. The contribution will support the Foundation’s ongoing efforts to build a larger multi-specialty healthcare ecosystem in Vijayawada, bringing critical medical services closer to underserved communities. The planned expansion is expected to include advanced facilities across medicine, surgery, women and child healthcare, cardiac care, emergency medicine and intensive care, alongside integrated diagnostics and laboratory services. In 2024, he had donated 45 lakh shares of Avantel Limited, the realised value of which stood at approximately Rs 76.44 crore, helping support healthcare programmes, hospital operations and community outreach initiatives. The upcoming hospital expansion, envisaged as a 150+ bed multi-speciality facility, is expected to further strengthen healthcare infrastructure in the region by improving access to medical services across specialties under one roof. The initiative is also expected to help address the growing demand for healthcare services in Andhra Pradesh and Telangana, particularly for patients seeking access to diagnostics, emergency care, critical care, and long-term treatment facilities closer to their communities. ]]> https://biospectrumindia.com/news/109/27765/neuland-secures-development-collaboration-with-lir-life-sciences-for-transdermal-glp-1.html https://biospectrumindia.com/news/109/27765/neuland-secures-development-collaboration-with-lir-life-sciences-for-transdermal-glp-1.html Wed, 06 May 2026 22:05:49 +0530 Hyderabad-based Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada‑based biotechnology company focused on scalable and accessible obesity treatments, in advancing its cell‑penetrating peptide (CPP) platform. As part of this engagement, Neuland will develop, test, and manufacture CPPs to support pharmacokinetic (PK) and pharmacodynamic (PD) studies, as well as Phase I formulations for LIR Life’s transdermal GLP‑1/GIP programme.  LIR Life is developing a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity. Unlike traditional injectable formulations, the platform is designed to enable non-invasive administration, with the potential to improve patient adherence and broaden access. Currently, there are no approved transdermal GLP-1 therapies, positioning this approach as a potentially significant innovation in the treatment landscape. For Neuland, the partnership highlights its expanding capabilities in peptide development and manufacturing, particularly in complex and emerging modalities such as CPP-enabled delivery systems. The company supports peptide programs from early development through commercial scale, with integrated capabilities spanning process development, scale-up, and cGMP manufacturing. The collaboration builds on Neuland’s recent investments in peptide infrastructure, including a new $20 million process development laboratory and a multi-phase commercial peptide manufacturing facility at its Bonthapally campus in Hyderabad. Module one of the peptide facility, representing an investment of approximately $30 million and 6,370 litres of capacity, is expected to become operational by mid-2026.   ]]> https://biospectrumindia.com/news/109/27752/elite-expertise-expands-to-india-with-hyderabad-office-to-support-career-opportunities-for-pharmacists.html https://biospectrumindia.com/news/109/27752/elite-expertise-expands-to-india-with-hyderabad-office-to-support-career-opportunities-for-pharmacists.html Mon, 04 May 2026 00:00:00 +0530 Global EdTech platform Elite Expertise, known for its specialised training programmes for internationally trained pharmacists, has announced its expansion into India with the launch of its new office in Hyderabad aimed at supporting the growing number of Indian pharmacists aspiring to build careers abroad. The move marks a strategic step toward supporting Indian pharmacy graduates and professionals aiming to build careers abroad, particularly in countries like Australia, Canada, Ireland, New Zealand, and the Middle East. The Hyderabad office is expected to be the first of several initiatives aimed at strengthening Elite Expertise’s footprint in India, with plans for workshops, partnerships, and hybrid learning models in the near future. Elite Expertise offers Expert-led preparation for global licensing exams; Step-by-step guidance for registration pathways; Career mentoring and interview preparation; Real-world insights into global pharmacy systems; Courses Aligned with Global Licensing Standards Through its programmes, the platform provides training for major international key licensing exams, including OPRA (Australia & New Zealand); PEBC (Canada); PSI Equivalence (Ireland); Australian Intern Written & Oral Exams; DHA Exam (Dubai) These programmes are designed to help candidates navigate complex regulatory systems and improve success rates in competitive global exams. Hyderabad has emerged as a major hub for pharmaceutical education and talent in India, making it an ideal location for Elite Expertise’s expansion. The new office will serve and act as a regional support center, enabling: Direct student engagement Local mentorship and counselling Workshops and offline interactions Community-building initiatives Access to expert-led training programs aligned with global standards With its India presence, the company aims to: Expand access to high-quality training Build stronger India-to-global career pipelines Create a support ecosystem for aspiring pharmacists Following the success of Pharma Connect Melbourne 2026, which brought together over 200 pharmacists, interns, and international graduates, Elite Expertise has plans to host the next edition of Pharma Connect in India. The upcoming India edition of Pharma Connect is expected to further strengthen collaboration between education, industry, and global healthcare opportunities. The India edition is expected to replicate the community-first, practical learning format that made the Melbourne event highly impactful.   ]]> https://biospectrumindia.com/news/109/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html https://biospectrumindia.com/news/109/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html Tue, 07 Apr 2026 00:00:00 +0530 AstraZeneca Pharma India has signed a Memorandum of Understanding (MoU) with the Government of Telangana to introduce artificial intelligence (AI)-enabled lung cancer screening across public healthcare facilities in the state. The collaboration aims to strengthen early detection and improve outcomes for patients in both urban and rural areas. Lung cancer is among the most pressing public health challenges in India today. National incidence is projected to rise from approximately 63,700 cases in 2015 to over 81,200 by 2025, a 27% increase over the decade, driven by tobacco use, environmental pollution, and critically, the near absence of routine screening.  Telangana reflects these national pressures acutely. The state is projected to record 46,762 new cancer cases among adults in 2026, rising to 47,314 by 2030, an estimated 13% increase by 2027. Women bear a disproportionate share, with 25,510 new cases expected this year against 21,252 in men.  Under the MoU, AstraZeneca will facilitate the deployment of Qure.ai's AI-powered chest X-ray solution to be integrated into routine workflows at public health facilities across Telangana. The technology helps clinicians flag the high-risk pulmonary nodules, a predominant precursor of lung cancer along with 29 other lung conditions. The high-risk patients will be triaged for lung cancer confirmation or future follow up to ensure stage-shift of lung cancer at diagnosis. A similar model has already been adopted in Goa, Tamil Nadu, and Karnataka.  The initiative is expected to roll out across 20 public health facilities, covering urban and rural health systems. It includes training and upskilling of healthcare professionals to support effective and sustainable adoption, as well as infrastructure enhancements where needed to ensure seamless integration into the public health system. ]]> https://biospectrumindia.com/news/109/27588/hrv-pharma-and-shodhana-labs-forge-cdmo-alliance-to-fast-track-next-gen-api-development.html https://biospectrumindia.com/news/109/27588/hrv-pharma-and-shodhana-labs-forge-cdmo-alliance-to-fast-track-next-gen-api-development.html Mon, 30 Mar 2026 00:00:00 +0530 HRV Global Life Sciences (HRV Pharma), India's first integrated Virtual API and Pharmtech company, has announced a comprehensive, multi-year Contract Development & Manufacturing partnership with Shodhana Laboratories, a Hyderabad-based USFDA-aligned API manufacturer, to co-develop, manufacture and supply a curated pipeline of high-science APIs, including pharmaceutical-grade API’s primarily used in longevity biology, backed by a US Drug Master File (DMF).   This makes HRV the holder of the first and only active Indian DMF in this product as a pharmaceutical API. The collaboration brings together HRV's global market access across 50+ countries, AI-enabled Virtual API platform and regulatory DMF engine, with Shodhana's deep process chemistry, high-purity synthesis expertise and GMP infrastructure creating a seamless development-to-commercialisation pathway for molecules at the frontier of precision medicine.   The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework.   Under the multi-year agreement, both companies will jointly execute: Development and US DMF filing for pharmaceutical-grade API — a master coenzyme governing cellular energy, DNA repair and aging, now emerging as a regulated therapeutic API in oncology supportive care, neurodegeneration and longevity medicine. A pipeline of five high-science APIs spanning CNS, rare/orphan disease, and metabolic/neurological API’s — with partner anchor end-customers across the USA and EU End-to-end GMP manufacturing, CMC documentation, stability studies and validation aligned to USFDA, EMA, PMDA and ANVISA standards Global regulatory DMF filings across US, EU, LATAM, MENA & APAC with HRV managing all regulatory interactions and expenses A unified quality, compliance and audit-readiness framework for the highest tier of regulated market access ]]> https://biospectrumindia.com/news/109/27502/beable-health-jeevaniyam-iit-h-sign-mou-to-develop-ai-based-rehab-for-children.html https://biospectrumindia.com/news/109/27502/beable-health-jeevaniyam-iit-h-sign-mou-to-develop-ai-based-rehab-for-children.html Tue, 17 Mar 2026 00:00:00 +0530 BeAble Health, a Hyderabad-based healthtech startup developing artificial intelligence (AI)-enabled, game-based rehabilitation technologies, has signed a tripartite agreement with Jeevaniyam Research Center, and Centre for Healthcare Entrepreneurship (CfHE) at the Indian Institute of Technology (IIT) Hyderabad to develop, clinically validate, and scale affordable AI-led rehabilitation for children with neuro-developmental and neuro-muscular conditions such as Cerebral Palsy (CP), Autism Spectrum Disorder (ASD), and attention deficit hyperactivity disorder (ADHD). The partnership is aimed at bridging the technology gap, the clinical evidence gap, and the skill gap that currently prevent Indian children with disabilities from accessing modern, validated rehabilitation devices. By bringing together BeAble’s engineering expertise, Jeevaniyam’s clinical experience and paediatric patient access, and IIT Hyderabad’s innovation ecosystem and academic strength, the collaboration creates a platform to advance technology-driven rehabilitation. Jeevaniyam currently operates the Jeevaniyam Ayurveda Hospital and Research Centre in Kochi and is preparing to inaugurate its new flagship facility, Jeevaniyam Medipolis. The centre is envisioned as a Centre of Excellence for Child Care, Neuro Care, Mind Care, and Family Care. It blends the Ayurveda system of medicine with modern diagnostic tools, innovative research, and synergistic therapies to create a holistic and effective rehabilitation environment.  The collaboration will focus on advancing paediatric rehabilitation through technology development, clinical research, and workforce training. On the technology front, BeAble’s flagship device ArmAble, designed for motor rehabilitation in children with cerebral palsy (CP) and neuromuscular disorders, will undergo usability testing, clinical validation, and formal clinical trials at Jeevaniyam’s Cochin facility. Product improvements will be guided by real-world feedback from paediatric patients and therapists to ensure the device is safe, age-appropriate, and effective for Indian children. On the training and skills front, structured programmes will be delivered for paediatric therapists, clinicians, and students to build confidence in using rehabilitation technology in paediatric care. Student internships and academic projects at Jeevaniyam and IIT Hyderabad will help develop a skilled workforce at the intersection of clinical rehabilitation and biomedical engineering. ]]> https://biospectrumindia.com/news/109/27441/indias-first-translational-extracellular-vesicles-ecosystem-opens-at-apollo-hospitals-hyderabad.html https://biospectrumindia.com/news/109/27441/indias-first-translational-extracellular-vesicles-ecosystem-opens-at-apollo-hospitals-hyderabad.html Mon, 09 Mar 2026 00:00:00 +0530 The Apollo Hospitals Educational and Research Foundation (AHERF) successfully launched India’s first Translational EV Ecosystem at a landmark three-day event held March 5–7, 2026, at AIMSR Medical College Auditorium, Apollo Hospitals, Jubilee Hills, Hyderabad.   The ecosystem integrates three platforms — the EV Biofoundry (ExoWorks), EV-Connect Clinical Consortia, and EV-Qual Reference Standards (RUO) — into a deployment-ready national infrastructure for EV-based diagnostics and therapeutics.   ExoWorks EV Biofoundry: A national end-to-end platform for EV isolation, characterisation, functional cargo analysis, QC, and translational assay development for diagnostic and therapeutic applications. EV-Connect Clinical Consortia: Multi-institutional networks harmonising biospecimen protocols and enabling national-scale biomarker and therapeutic target validation across Ophthalmology (LVPEI), Neurology, and Oncology. EV-Qual Reference Standards (RUO): India’s first traceable exosome reference materials, enabling inter-laboratory reproducibility for diagnostic assay certification and therapeutic EV batch characterisation. The AHERF Translational EV Ecosystem is designed to close that gap — not for one institution, but nationally, and not for one stakeholder, but for all. For diagnostic and therapeutic companies: validated reference standards (EV-Qual), clinically annotated cohorts, and advanced characterisation platforms — NTA, nano-flow cytometry, digital PCR, and multi-omics — compress the timeline from biomarker discovery to LDT deployment and IVD regulatory filing. For therapeutic developers, GCP-aligned EV isolation, cargo loading, potency and stability assay workflows, and IND-enabling benchmarks mean faster, credible paths to clinical trials. For startups and early-stage innovators: EV-Connect’s shared clinical infrastructure eliminates the need to independently build multi-site trial networks, dramatically lowering the cost and time of clinical validation — the single largest barrier to product development for emerging companies. For academic researchers and students: harmonised, multi-site clinical data from EV-Connect enables sufficiently powered studies, strengthens grant applications, and generates IP in a domain where India can lead globally. The hands-on training delivered across the three-day workshop directly builds the next generation of translational EV scientists. For clinicians and hospitals: participation in EV-Connect consortia provides early access to next-generation diagnostic tools while contributing to national biomarker validation — a reciprocal model that improves patient care and clinical evidence simultaneously. For policymakers and funders: the ecosystem provides a replicable, standards-anchored national model directly aligned with Atmanirbhar Bharat, the BioE3 policy framework, and the National Biopharma Mission — demonstrating that India’s patient diversity can be a strategic asset, not just a resource, in generating globally credible diagnostics and therapeutics.   Translational Roadmap Diagnostics — Phase 1: LDT development: analytically validated EV biomarker assays deployable within AHERF and consortium hospitals. Phase 2: Certified IVD products integrating multimodal AI/ML models trained on harmonised EV multi-omics and clinical data from EV-Connect, enabling intelligent decision-support diagnostics at scale. Therapeutics — Phase 1: Lab-scale proof-of-concept EV production, cargo loading, encapsulation, and characterisation. Phase 2: GMP-grade manufacturing for IND-enabling studies, clinical trials, and commercial scale-up. EV-Qual underpins both pathways as the traceable batch release benchmark.   ]]> https://biospectrumindia.com/news/109/27456/neuland-to-open-commercial-peptide-facility-as-part-of-planned-phased-expansion.html https://biospectrumindia.com/news/109/27456/neuland-to-open-commercial-peptide-facility-as-part-of-planned-phased-expansion.html Mon, 09 Mar 2026 00:00:00 +0530 Neuland Laboratories  will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus in Telangana, with further capacity expansions planned as client demand increases.  The first of four planned modules is expected to be operational by the summer of this year, adding commercial-scale capabilities to Neuland’s existing clinical stage S-Block facilities. Module one has secured firm commitments of approximately $30 million.  Once open, Module One will provide 6,370 L of SPPS [solid phase peptide synthesis] and LPPS [liquid phase peptide synthesis] reactor capacity – for sizes of 250 L to 3000 L in LPPS, as well as SPPS reactors up to the 500 L scale.  Construction of the facility began last year and will enable client execution from small‑scale to multi‑ton commercial volumes, while also providing the flexibility needed for complex and long‑chain peptide programmes. With GLP-1 manufacturing consuming a growing share of global peptide capacity, Neuland is targeting innovator and emerging biotech programs facing tightening access to clinical and commercial manufacturing across a broad range of indications. R&D headcount is also expected to grow at a double‑digit rate this year, and the manufacturing team will more than double to support the ramp‑up. This complements Neuland’s existing 1,174,000 L of API manufacturing capacity across three US FDA–approved facilities, which are supported by a large, dedicated R&D Centre located in close proximity. This integrated setup enables seamless scale‑up, rapid tech transfer, and highly efficient development-to-commercial execution. The newly completed plants will feature advanced digital operation systems – controlled through DCS-based automation with eBMR integration – and scalable peptide technologies across synthesis, purification and drying. The facility includes expanded downstream capabilities: multi‑column prep‑HPLC systems, lyophilisers and dryers sized for commercial campaigns, enhanced solvent‑handling and tank‑farm infrastructure, dedicated warehouses, and upgraded waste‑management systems supporting high‑volume operations. The systems are designed to support data-rich process development, reduced batch variability and improved cycle times. ]]> https://biospectrumindia.com/news/109/27431/aig-hospitals-unveils-south-indias-first-zap-x-gyroscopic-neuro-radiosurgery-platform.html https://biospectrumindia.com/news/109/27431/aig-hospitals-unveils-south-indias-first-zap-x-gyroscopic-neuro-radiosurgery-platform.html Fri, 06 Mar 2026 00:00:00 +0530 Hyderabad-based AIG Hospitals has announced the launch of the ZAP-X® Gyroscopic Neuro-Radiosurgery® Platform, the first installation of its kind in South India and only the second in the country, marking a major advancement in the treatment of brain tumours and complex neurological disorders. Designed exclusively for intracranial radiosurgery, ZAP-X enables doctors to treat brain lesions with extreme precision that too without open surgery, without incisions, and as a day-care procedure. The system delivers highly focused radiation beams with sub-millimeter accuracy, targeting tumors and abnormal tissues while sparing healthy brain structures. For patients, this means a completely non-invasive treatment that is painless, requires no hospital stay, and allows them to return to normal life quickly. Stereotactic radiosurgery has emerged globally as a safer alternative for carefully selected cases, and the introduction of ZAP-X at AIG Hospitals brings one of the world’s most advanced neuro-radiosurgical technologies to patients across South India.  One of the areas where ZAP-X is expected to make a particularly significant impact is in the treatment of brain metastases, tumours that spread to the brain from cancers elsewhere in the body, most commonly from the lung, breast, or melanoma. Prof. John R. Adler, renowned neurosurgeon, inventor of CyberKnife® and ZAP-X®, and one of the world’s foremost pioneers in radiosurgery, emphasised the broader potential of the technology adding “Radiosurgery has evolved tremendously over the past three decades, and ZAP-X represents the next generation of this field. While brain tumors remain a primary indication, the precision of this technology also opens up exciting possibilities in the treatment of functional neurological conditions such as trigeminal neuralgia, movement disorders, and now we are seeing trials to treat depression as well. The goal has always been to treat disease with surgical accuracy but without the invasiveness of traditional surgery. It is gratifying to see institutions like AIG Hospitals bringing this level of innovation to patients in India.”   ]]> https://biospectrumindia.com/news/109/27433/lonza-selects-hyderabad-as-new-gcc-location.html https://biospectrumindia.com/news/109/27433/lonza-selects-hyderabad-as-new-gcc-location.html Fri, 06 Mar 2026 00:00:00 +0530 Lonza Group AG, a world-leading contract development and manufacturing organisation (CDMO), has announced its decision to establish a new Global Capability Centre (GCC) in Hyderabad. The development further strengthens Telangana’s growing prominence as a global life sciences hub. A delegation from the company met with Minister for Industries & Commerce, D. Sridhar Babu, and CEO of Telangana Lifesciences, Shakthi M. Nagappan, to formally convey the decision and share details of their proposed plans. Headquartered in Switzerland and founded in 1897, Lonza operates across more than 30 sites worldwide and employs close to 20,000 professionals. In 2025, the company reported sales of CHF 6.5 billion and a Core EBITDA of CHF 2.1 billion. The decision follows an extensive evaluation process from which Hyderabad was identified as a preferred destination based on its strong talent pool, quality infrastructure, and supportive industrial ecosystem. Over the past several months, senior representatives of Lonza have engaged with Telangana Lifesciences, the Industries & Commerce Department, and other stakeholders, which further reinforced the company’s confidence in Hyderabad as the right location for this investment. D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, said, “Lonza’s investment further strengthens Telangana’s position as a preferred destination for innovation-led growth in the global biopharmaceutical industry. I am delighted that the centre has the potential to create a substantial number of new jobs over the years. We remain committed to supporting such endeavours that promise job creation for our citizens.” Shakthi M. Nagappan, CEO, Telangana Lifesciences, said, “We are delighted that Lonza has chosen Hyderabad for this expansion. This decision marks another significant milestone in the continued expansion of Telangana’s life sciences ecosystem. We look forward to working closely with Lonza to ensure the successful execution of this project and to enable long-term value creation.” The new GCC is expected to contribute to the generation of high-value employment and further integrate Hyderabad into the global biopharmaceutical value chain.   ]]> https://biospectrumindia.com/features/109/27412/telangana-turns-catalyst-for-innovation.html https://biospectrumindia.com/features/109/27412/telangana-turns-catalyst-for-innovation.html Sun, 01 Mar 2026 00:00:00 +0530 The global life sciences industry is undergoing a structural transformation. Supply chain resilience, advanced therapeutics, precision medicine, and sustainable bio-manufacturing are no longer future priorities—they are immediate imperatives. Telangana’s Next-Gen Life Sciences Policy 2026–30, unveiled at the World Economic Forum Annual Meeting in Davos, represents a timely and strategic response to these shifts. With clear targets for investment, high-quality job creation, frontier R&D, clinical research, and talent development, the policy signals the State’s intent to move from being a leading manufacturing base to a fully integrated global life sciences innovation ecosystem. Strong investor momentum and Hyderabad’s rising global visibility make this the perfect moment to examine how policy, infrastructure, science, and industry are converging to shape Telangana’s next phase of growth.   From Manufacturing Leadership to Ecosystem Leadership For over two decades, Telangana—anchored by Hyderabad—has been a trusted pharmaceutical and vaccine manufacturing powerhouse. The State today accounts for nearly 40 per cent of India’s pharmaceutical production and contributes close to one-third of global vaccine output. With more than 269 US FDA-approved manufacturing facilities, Telangana has earned deep regulatory credibility across highly regulated global markets. However, as global industry dynamics evolve, leading life sciences hubs are increasingly defined not by volume alone, but by their ability to conceive, develop, clinically validate, and scale innovation. This inflection is articulated clearly by Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, who observes that the global life sciences industry is transitioning from “scale-led growth to an innovation-driven, value-centric model.” Telangana’s Next-Gen Life Sciences Policy directly aligns with this shift by prioritising frontier R&D, advanced manufacturing platforms, and precision medicine—areas that demand deep scientific capability, long-term capital, and ecosystem-level coordination. Over the next five years, this strategic repositioning will elevate Telangana from being a critical manufacturing node in global supply chains to a co-creator of next-generation therapies, platforms, and healthcare solutions.   Frontier R&D as a Core Growth Driver A defining feature of the policy is its strong emphasis on frontier R&D and advanced manufacturing. By actively promoting technologies such as biologics and biosimilars, cell and gene therapy, mRNA platforms, CRISPR technologies, antibody-drug conjugates, oligonucleotides, peptides, and precision fermentation, the policy signals a decisive move toward science-led growth. These platforms represent a step change from traditional small-molecule manufacturing. They are characterised by high entry barriers, complex regulatory pathways, and strong intellectual property creation—factors that favour ecosystems with deep scientific infrastructure and skilled talent. Over the next five years, this focus is expected to drive three structural shifts within Telangana’s life sciences ecosystem: Higher value creation per investment, as advanced therapies and platforms command premium global valuations. Tighter integration between research and manufacturing, enabling faster translation from lab to market. Stronger global innovation partnerships, particularly with multinational biopharma companies seeking end-to-end capabilities in regulated markets. This direction is reinforced by Krishna Kanumuri, Managing Director and Chief Executive Officer, Sai Life Sciences, who notes that the policy creates “a compelling platform for companies to continue partnering with global innovators and advancing high-quality R&D from India for the world.” Over the medium term, such innovation-led investments are likely to anchor long-term capabilities rather than short-cycle, capacity-driven expansions.   Genome Valley and  Cluster-Led Growth The expansion of Genome Valley and the planned establishment of a Bio-Innovation and Bio-Manufacturing Cluster in collaboration with the Government of India will be central to translating policy intent into on-ground outcomes. Genome Valley’s evolution—from India’s first organised life sciences park into a globally networked innovation cluster—illustrates Telangana’s ambition to compete with leading international hubs such as Boston-Cambridge, San Francisco Bay Area, and Greater Tokyo. Cluster-led development enables dense collaboration between startups, multinational companies, CROs, CDMOs, academia, and regulators. Over the next five years, this density is expected to significantly reduce time-to-market for complex therapies, lower entry barriers for startups through shared infrastructure, and encourage cross-pollination of talent and ideas. Satish Reddy, Chairman, Dr. Reddy’s Laboratories Limited, underscores the importance of such ecosystems, noting that strong research and industry integration is essential to “translate scientific advances into meaningful health and economic outcomes.” Telangana’s policy reflects this thinking by positioning infrastructure as a catalyst for innovation rather than merely a real estate intervention.   Clinical Research and Evidence-Driven Healthcare Another transformative pillar of the policy is its focus on strengthening the clinical research ecosystem. Globally, pharmaceutical and biotech companies are grappling with rising clinical trial costs, prolonged approval timelines, and patient recruitment challenges. Telangana’s proposed measures—faster approvals, disease-specific clinical registries, and the operationalisation of initiatives such as the Clinical Innovation Sandbox—directly address these constraints. Over the next five years, these interventions are likely to position Telangana as a preferred destination for clinical trials, real-world evidence generation, and precision medicine research, particularly for diseases with relevance to emerging markets. This aligns with the broader global perspective articulated by Shyam Bishen, Head of the Centre for Health & Healthcare and Member of the Executive Committee, World Economic Forum, who emphasises that the future of healthcare will be shaped by ecosystems that bring together science, technology, talent, and policy coherence. Telangana’s focus on privacy-compliant digital health records and clinical registries lays the foundation for population-scale, data-driven healthcare innovation.   Scaling the Pharma Services Opportunity The policy’s explicit focus on expanding the pharma services ecosystem—particularly Contract Research Organisations (CROs) and Contract Development and Manufacturing Organisations (CDMOs)—reflects a clear understanding of global outsourcing trends. As innovator companies seek flexibility, speed, and high-quality partners across the discovery-to-commercialisation continuum, service-led models are becoming central to global life sciences value chains. Telangana’s ambition to scale the pharma services sector from an estimated $2 billion to approximately $10 billion over the coming years represents a significant growth opportunity. Over the next five years, this expansion is expected to generate high-skill employment, strengthen global client linkages, and diversify the State’s life sciences revenue base beyond product manufacturing. This trajectory resonates with Madeleine Roach, Executive Vice President, Business Operations, Sanofi, who highlights the importance of advanced biomanufacturing, talent ecosystems, and regulatory excellence in redefining how global pharmaceutical companies serve patients worldwide.   MedTech, Diagnostics, and the Convergence of Biology and Engineering The policy’s focus on diagnostics, medical electronics, and MedTech reflects the growing convergence of biology, engineering, and data science in modern healthcare. As healthcare systems worldwide shift toward early diagnosis, minimally invasive interventions, and remote patient monitoring, MedTech innovation is becoming a critical pillar of healthcare delivery. The expansion of the Medical Devices Park and targeted support for diagnostics manufacturing are expected to strengthen Telangana’s MedTech ecosystem over the next five years—reducing import dependence while integrating domestic capabilities into global supply chains. Majid Kaddoumi, Executive Vice President, Eurasia, Medtronic, notes that forward-looking policy frameworks are essential for accelerating MedTech-led innovation. The presence of global engineering and innovation centres in Hyderabad underscores the State’s growing role in high-end medical technology development.   Talent as the Cornerstone of Long-Term Competitiveness Among the most enduring impacts of the Next-Gen Life Sciences Policy will be its emphasis on talent development. The proposed Telangana School of Life Sciences and associated skilling platforms reflect a recognition that sustainable competitiveness depends on a future-ready workforce. Over the next five years, industry-aligned curricula, structured internships, certification programmes, and lifelong learning pathways will help build talent pools in biologics, advanced analytics, artificial intelligence, regulatory sciences, and health economics. This focus on employability and inclusion ensures that sectoral growth translates into broad-based socio-economic impact. Dr Satyanarayana Chava, Executive Director and Chief Executive Officer, Laurus Labs, describes the policy as “unique and transformative,” noting that it lays out a clear roadmap for leadership in emerging areas of healthcare through innovation-driven growth.   Sustainability and Responsible Bio-Manufacturing Sustainability is increasingly becoming a decisive factor in global life sciences competitiveness. Telangana’s Green Pharma City—with its emphasis on zero liquid discharge, centralised waste management, energy efficiency, and net-zero practices—positions the State at the forefront of sustainable bio-manufacturing. Over the next five years, this focus will enhance Telangana’s attractiveness to global companies facing rising ESG expectations from regulators, investors, and customers, while also ensuring environmentally responsible industrial growth.   A Five-Year Outlook: From Participation to Global Leadership Taken together, Telangana’s Next-Gen Life Sciences Policy 2026–30 is poised to reshape the State’s life sciences industry in three fundamental ways over the next five years: Elevating Telangana’s role from a manufacturing hub to a global innovation partner. Deepening ecosystem integration, connecting science, industry, policy, and talent. Embedding sustainability, resilience, and long-term value creation into growth. As Shakthi M. Nagappan, Chief Executive Officer, Telangana Life Sciences, notes, the policy anticipated global shifts toward advanced manufacturing, deep innovation, and clinical research—trends now reinforced by national priorities and global industry movements. With strong leadership, disciplined execution, and global alignment, Telangana is positioning itself not merely to participate in the future of life sciences—but to help define it. The next five years will be critical in consolidating Hyderabad and the State at large as a globally integrated, innovation-led life sciences ecosystem that is competitive, sustainable, and future-ready.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/109/27399/cohere-health-announces-launch-of-global-capability-centre-in-hyderabad-.html https://biospectrumindia.com/news/109/27399/cohere-health-announces-launch-of-global-capability-centre-in-hyderabad-.html Thu, 26 Feb 2026 00:00:00 +0530 US-based startup Cohere Health®, a leader in clinical intelligence solutions for health plans, has announced the launch of its Global Capability Centre (GCC) in Hyderabad, India. As the company continues to expand its operational capabilities globally, this milestone reinforces its commitment to scaling innovation, technological excellence, and advancing its clinically trained AI platform.   As part of its long-term vision and investment in globally distributed teams, Cohere Health is scaling the GCC into a centre of excellence that fosters a culture of innovation and collaboration, deepens clinical intelligence, and improves outcomes for health plans, clinicians, and patients worldwide. India is a cornerstone of the company’s global operating model and a key driver of its mission to ensure patients everywhere receive the right care as quickly and safely as possible.   Tapping into India’s deep talent pool, the Hyderabad GCC brings together expert engineering, analytics, and clinical operations teams to strengthen Cohere Health’s global capabilities and accelerate product advancements. Working closely with US-based colleagues, the centre expands the company’s capacity to scale clinically trained AI and deliver more connected solutions that improve payer-provider collaboration.     Looking ahead, Cohere Health plans to continue expanding the Hyderabad GCC with strategic hiring across engineering, product, data science, and compliance, strengthening its global teams and capacity. This expansion positions Cohere Health to meet the increased demand for clinically trained AI solutions that streamline complex processes, improve health outcomes, and enhance payer-provider collaboration across the healthcare continuum–reinforcing its role as the leader in enterprise clinical intelligence for health plans.   ]]> https://biospectrumindia.com/news/109/27362/sai-life-sciences-to-recruit-700-professionals-in-fy27.html https://biospectrumindia.com/news/109/27362/sai-life-sciences-to-recruit-700-professionals-in-fy27.html Sat, 21 Feb 2026 00:00:00 +0530 Hyderabad-based Sai Life Sciences, one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), has announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services. The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others. A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies. The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up. As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth. ]]> https://biospectrumindia.com/news/109/27363/gvrp-and-yurogen-biosystems-partner-to-enhance-biologics-drug-discovery-in-india.html https://biospectrumindia.com/news/109/27363/gvrp-and-yurogen-biosystems-partner-to-enhance-biologics-drug-discovery-in-india.html Sat, 21 Feb 2026 00:00:00 +0530 Hyderabad-based GV Research Platform (GVRP) has announced a strategic distribution partnership with US-based Yurogen Biosystems, a global life sciences company specialising in custom biologics development. The collaboration is aimed at expanding access for Indian biotechnology and pharmaceutical companies, as well as academic research institutions, to advanced antibody discovery capabilities supporting early-stage drug discovery and translational research. Under this partnership, GVRP will serve as the commercial interface for Yurogen Biosystems in India, enabling streamlined market access, client engagement, and program coordination, while all scientific execution and service delivery will continue to be carried out by Yurogen Biosystems. The collaboration responds to the growing demand within India’s life sciences ecosystem for globally benchmarked antibody discovery services, particularly in areas requiring deep biological insight at early stages of research. By combining Yurogen’s scientific expertise with GVRP’s understanding of the Indian research ecosystem, the partnership enables smoother and more efficient engagement for domestic innovators. The partnership will provide access to Yurogen Biosystems’ proprietary SMab™ single B-cell technology, enabling rapid generation of high-affinity monoclonal antibodies to support early discovery and translational research programmes. ]]> https://biospectrumindia.com/news/109/27344/rx-propellant-injects-100-m-to-develop-integrated-large-format-life-sciences-campus-in-genome-valley-hyderabad.html https://biospectrumindia.com/news/109/27344/rx-propellant-injects-100-m-to-develop-integrated-large-format-life-sciences-campus-in-genome-valley-hyderabad.html Tue, 17 Feb 2026 00:00:00 +0530 Rx Propellant, India’s leading science and R&D  infrastructure platform established by Actis, has announced an investment of $100 million to develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India’s life sciences ecosystem. The project will comprise development of more than 1 million square feet of advanced laboratory infrastructure to be delivered in phases over the next six years.  Planned as a single, integrated campus with multiple blocks, the project will be the largest life sciences campus in Genome Valley designed for corporations looking to lease buildings with well-managed resilient support infrastructure. The campus will cater to Indian and global life sciences companies seeking scalable and quality infrastructure for R&D and allied operations, delivering institutional-grade laboratory spaces, bringing together fully compliant buildings and high-performance electromechanical services in a robust design.  Ashish Singh, CEO and Managing Director, Rx Propellant, said “India’s life sciences sector is entering a phase of decisive scale-up, and buildings and infrastructure solutions must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley, Hyderabad as a long-term anchor for global and domestic R&D. Rx Propellant already has an established track record in Genome Valley, with its 1GV and 3GV campuses already 100% leased, hosting a mix of marquee global and Indian life sciences companies. Sustained demand for high quality buildings in Genome Valley provides a strong foundation for our next phase of growth as we continue delivering high-quality infrastructure at scale, helping our customers expand with confidence and continuity.” Beyond Hyderabad, Rx Propellant is also developing Navi Mumbai Research District (NMRD) spread over a site of 16 acres, planned as Mumbai’s largest cohesive ecosystem for science and research. Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said “High-quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. With increasing global interest in research, development and manufacturing partnerships within India, this investment underscores our conviction in India and in Hyderabad’s role as a leading R&D hub." ]]> https://biospectrumindia.com/news/109/27253/india-leads-global-vision-for-patient-safety-at-apollo-hospitals-international-health-dialogue-2026.html https://biospectrumindia.com/news/109/27253/india-leads-global-vision-for-patient-safety-at-apollo-hospitals-international-health-dialogue-2026.html Fri, 30 Jan 2026 00:00:00 +0530 International Health Dialogue (IHD) 2026 opened on January 30th in Hyderabad, bringing together clinicians, patient safety leaders, accreditation experts, and health system policymakers from India and abroad. With the theme Global Voices- One Vision, Day 1 centred patient safety where it truly belongs, as a leadership and governance priority, shaped by equity and enabled by responsible digital transformation. The discussions reflected a clear direction across geographies: India’s lived experience of delivering care at scale, while steadily strengthening standards and accountability, is increasingly informing how the world thinks about patient safety and trust. Opening the conference, Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group, recalled the founding purpose of IHD as a platform built for sharing learning that should not remain confined to individual systems. “So much innovation is happening within our hospitals, within our systems. We are learning every day. But why is this knowledge staying within our own ecosystem? Why are we not sharing it more openly?” she said, adding that the intent has always been to “take what we have learned and make it useful for others”, she said. Reflecting the expanding global relevance of the platform, she noted that IHD 2026 received over 5,000 registrations, 300+ paper submissions, and 120+ award entries from 75+ institutions worldwide. Setting the tone for outcomes that work in real life, Dr Jayesh Ranjan, Special Chief Secretary for the Industries & Commerce (I&C) and Information Technology (IT) Departments, Government of Telangana, highlighted why equity must sit at the centre of patient safety design, “When we talk about sharing learning and improving systems, we have to start with the truth that patients are not homogeneous. Different patients live in different worlds, and safety means different things in each,” he said. “An equity lens forces a design lens. If we want patient safety to hold up in the real world, we must design for those who are most vulnerable, and we must plan for continuity, access, and how people actually behave,” he added. On digital inclusion, he observed, “The digital divide is not only infrastructure. Often, the mindset divide is bigger.” Across the day, speakers converged on one practical point: patient safety outcomes increasingly depend on how well the ecosystem works as a coordinated whole, across regulators, accreditors, providers, and technology partners. In the opening plenary, Dr Madhu Sasidhar, President and Chief Executive Officer, Hospitals Division, Apollo Hospitals Enterprise Limited, emphasised shared ownership and organisational accountability, “Patient safety cannot be solved by one stakeholder alone. It requires regulators, governments, accreditors, providers, and technology firms to work as one. Patient safety is not a departmental responsibility. It is in fact an organisational leadership responsibility.” A strong thread through multiple sessions was the need to move from reactive care to earlier, more preventive intervention. Speaking to the pressure health systems face globally, Dr Sangita Reddy noted, “Healthcare demand is rising. We cannot solve exponential problems with linear solutions.” The discussions linked this to sharper prevention strategies, clearer outcome measurement, and digital tools that are deployed with discipline and accountability. From a global quality and safety lens, Dr Carsten Engel, CEO, International Society for Quality in Health Care (ISQua), reflected on the gap between sustained attention and on-ground improvement, “Patient safety has been on the agenda for decades, but we still have to say we are not there yet,” he said. He cautioned against adding activity without impact, noting, “We risk creating safety clutter, procedures and activities done in the name of safety that do not improve safety.” He urged leaders to adopt a systems view of behaviour and context: “Don’t ask why people didn’t do what they should have done. Ask why it made sense for them to do what they did.” On standards and execution, Dr Atul Mohan Kochhar, CEO, National Accreditation Board for Hospitals & Healthcare Providers (NABH), underlined urgency with an implementation-first approach, “Patient safety is not only a technical issue. It is a moral, social, and economic imperative. Policies alone do not improve safety. Implementation efficiency does,” he said. Reinforcing ambition in measurable terms, he added, “We must be ambitious when it comes to patient safety. Zero harm is the only number that can be accepted for patient safety risk.” Building on this emphasis on implementation, accountability, and measurable safety outcomes, Apollo Hospitals also signed a Memorandum of Understanding with Roche Diagnostics India as part of Day 1 proceedings to explore the integration of advanced artificial intelligence into clinical decision-making. The collaboration will focus on translating AI-enabled insights into practical, clinician-friendly support across care pathways, strengthening consistency in clinical judgement, earlier risk identification, and safer, more standardised care delivery at scale. Apollo’s emphasis on culture-led transformation was articulated by Dr Rohini Sridhar, Chief of Medical Services, Apollo Hospitals, stressed that systems improve only when clinical teams move together with the organisation, “Unless clinicians walk with you, zero harm cannot be achieved. If one unit experiences harm, every unit must learn immediately. Technology accelerates learning, but culture determines action.” Later in the day, IHD 2026 hosted a dedicated spotlight session for the newly launched digital health startup community, with a curated set of startups pitching to investors. The session focused on solutions grounded in real clinical and operational gaps, including safer workflows, decision support, early risk identification, improved documentation, and scalable patient engagement. The segment reinforced IHD’s emphasis on translating innovation into validated, implementable tools that strengthen safety, outcomes, and trust. IHD 2026 continues on January 31 in Hyderabad with further sessions and showcases focused on patient safety, digital transformation, healthcare operations, and clinical learning.   ]]> https://biospectrumindia.com/news/109/27231/governor-of-telangana-inaugurates-lvpeis-lahoti-eye-centre-at-kondapur.html https://biospectrumindia.com/news/109/27231/governor-of-telangana-inaugurates-lvpeis-lahoti-eye-centre-at-kondapur.html Tue, 27 Jan 2026 00:00:00 +0530 L V Prasad Eye Institute (LVPEI) has announced the inauguration of its Lahoti Eye Centre at Pranava Vaishnaoi Business Park, Kondapur. The new facility, designed with patient experience and care at its core, was inaugurated by Jishnu Dev Varma, Governor of Telangana. Set in a bigger space, with enhanced facilities, the Lahoti Eye Centre delivers comprehensive eye care with the same level of excellence and trust, expected of L V Prasad Eye Institute. Key Highlights of the Lahoti Eye Centre, Pranava Vaishnaoi Business Park, Kondapur: Dedicated Outpatient Departments (OPDs) for Cataract, Cornea, Glaucoma, Oculoplasty & Cosmetic Eyelid Care (including Botox and fillers), Retina, Pediatric Eye Care, and Contact Lens Services Spacious layout optimised for improved patient flow Superior accessibility and ample parking Inclusive, safe, and patient-friendly premises Speaking at the inauguration, Jishnu Dev Varma, Honorable Governor of Telangana, said, "Telangana and Hyderabad are proud of L V Prasad Eye Institute for its groundbreaking research, outstanding eye care and for making eye health accessible to all, irrespective of the complexity of care needed or ability to pay.”   Dr G N Rao, Founder Chairman, LVPEI said, "Our objective is to take quality eye-care services to patients who need them the most. As the city continues to expand and distances grow, it is not feasible for everyone to travel to Banjara Hills. To address this challenge, we have established satellite centres to bring care closer to communities. This is our fourth satellite centre, and we will continue to identify and expand into areas where there is a genuine need. Currently, we provide services across Telangana, Andhra Pradesh, and Odisha, with a focused effort to reach even the remotest regions of these states." Dr Prashant Garg, Executive Chairman - LVPEI, added, "Currently, we operate four tertiary care centres located in Vijayawada, Visakhapatnam, Cuddapah, and Bhubaneswar. Annually, we serve close to 2.4 million outpatients and have patients coming from across the country. To extend our reach beyond Telangana, Andhra Pradesh, and Odisha, we have embraced technological innovation through tele-ophthalmology, branded as ConnectCare, developed in-house by our team."   ]]> https://biospectrumindia.com/news/109/27208/telangana-sets-global-ambition-with-life-sciences-policy-202630-targeting-25-b-investments.html https://biospectrumindia.com/news/109/27208/telangana-sets-global-ambition-with-life-sciences-policy-202630-targeting-25-b-investments.html Wed, 21 Jan 2026 00:00:00 +0530 The Government of Telangana unveiled its Next-Gen Life Sciences Policy 2026–30 at the World Economic Forum Annual Meeting in Davos, signalling the State’s intent to play a far more consequential role in shaping the future of global healthcare, advanced therapeutics, and sustainable bio-manufacturing. With a clear ambition to rank among the top five life sciences clusters worldwide by 2030, the policy targets $25 billion in investments, creation of 500,000 high-quality jobs, and deeper integration into global life sciences value chains. The policy was unveiled by Chief Minister A. Revanth Reddy in the presence of the Minister for IT & Industries, D. Sridhar Babu; Special Chief Secretary Sanjay Kumar IAS, and the CEO, Telangana Lifesciences, Shakthi M. Nagappan.   The policy implementation will be anchored by globally benchmarked infrastructure, including the Green Pharma City, ten Pharma Villages, expansion of Genome Valley, and further strengthening of the Medical Devices Park. Key Focus Areas of the Policy- Frontier R&D and Advanced Manufacturing: Promotion of next-generation technologies and platforms, including biologics and biosimilars, cell and gene therapy, mRNA platforms, CRISPR technologies, antibody-drug conjugates (ADCs), oligonucleotides, peptides, and precision fermentation, with a focus on value-added and technology-intensive manufacturing. Clinical Research: Strengthening the clinical trial ecosystem by enabling faster approvals, creation of disease-specific clinical registries, and operationalization of initiatives such as the Clinical Innovation Sandbox Pharma Services: Expansion of the pharma services ecosystem, including Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), to scale the sector from the current estimated size of USD 2 billion to approximately USD 10 billion. Diagnostics and Medical Electronics: Development of a robust hub for research, development, and manufacturing of diagnostics and medical electronics. Global Value Centres and Global Innovation Centres: Attracting Global Capability Centres (GCCs) and Global Innovation Centres focused on advanced analytics, artificial intelligence, engineering, digital health, and high-end R&D functions in the life sciences and healthcare domains. Precision Medicine and Personalized Therapies: Advancing precision medicine through the development of clinical registries and privacy-compliant digital health records to enable personalized therapies, data-driven healthcare interventions, and improved clinical outcomes.   Strategic Levers for Implementation: Infrastructure Development: The policy proposes the creation of world-class infrastructure to support the full life sciences value chain, including: ·       Establishment of the Green Pharma City, a sustainable and integrated industrial cluster incorporating zero liquid discharge (ZLD), centralized waste management, energy-efficient systems, and net-zero practices. ·       Development of ten (10) Pharma Villages, each spanning approximately 1,000 to 3,000 acres along the Outer Ring Road (ORR), to promote decentralized, balanced, and inclusive industrial growth across the State. ·       Expansion of Genome Valley and establishment of a Bio-Innovation and Bio-Manufacturing Cluster in collaboration with Government of India, featuring multi-tenant laboratories and flatted factories to promote collaboration, innovation, and ease of entry for startups and MSMEs. ·       The Policy also envisages the expansion of the Medical Devices Park, with enhanced common infrastructure and plug-and-play facilities to support R&D and manufacturing in medical devices and diagnostics.   Talent Ecosystem: The policy emphasises the cultivation of a dynamic and future-ready workforce through initiatives such as the flagship Telangana School of Life Sciences and other skilling and capacity-building platforms. Key measures include industry-aligned curricula, structured internships, lifelong learning pathways, and certification programs across critical domains such as biologics, advanced analytics, artificial intelligence and bioinformatics, and Health Outcomes and Economic Research (HOER). Regulatory Streamlining and Ease of Doing Business: Implementation of TG-iPASS as a single-window system with time-bound approvals and deemed approvals in case of delays. The policy permits 24×7 operations in designated life sciences parks, subject to prescribed safety norms. A dedicated consultation committee (CDSCO, Telangana DCA, and TGPCB) to simplify state-level clearances and active advocacy with central regulators. Funding Ecosystem: Establishment of a dedicated Life Sciences Innovation Fund with an initial corpus of Rs 100 crore ($12 million), scalable to Rs 1,000 crore ($111 million), structured through a public-private partnership model with co-investment alongside venture capital and private equity funds to support startups, scale-ups, and translational research initiatives.   Industry responds- "Telangana has been setting the direction for the next phase of life sciences growth well ahead of the curve. Guided by the Hon’ble Chief Minister Shri Revanth Reddy's long-term vision and Shri D. Sridhar Babu, Hon’ble Minister for Industries, Commerce and IT passionate leadership, our Life Sciences Policy 2026–30 anticipated this shift by prioritising advanced and complex manufacturing, deep innovation and R&D, and the creation of a strong, globally integrated clinical research and clinical trial network. The Union Budget’s focus on precisely these areas now amplifies this momentum, accelerating our goal of attracting $25 billion in investments and generating 500,000 jobs while reinforcing Hyderabad’s position as a global life sciences innovation hub.” Shakthi M. Nagappan, CEO, Telangana Life Sciences   “Telangana’s Next-Gen Life Sciences Policy 2025–30 is a timely and thoughtful step that reinforces the state’s ambition to be among the world’s leading life sciences hubs. By focusing on innovation-led growth, advanced manufacturing, and a strong science and talent ecosystem, the policy creates a compelling platform for companies like Sai Life Sciences to continue partnering with global innovators and advancing high-quality R&D from India for the world.” Krishna Kanumuri, MD & CEO, Sai Life Sciences   “The life sciences sector in Telangana has emerged as a significant contributor to innovation, healthcare advancement, and economic growth, supported by a strong research base, growing industry presence, and a vibrant startup ecosystem. Building on this momentum, this Policy reflects a clear and timely vision to strengthen research capabilities, accelerate innovation, and translate scientific advances into meaningful health and economic outcomes. I am confident that the Telangana Next-Gen Life Sciences Policy will serve as a strong foundation for sustained growth and societal impact. I congratulate the Chief Minister and his entire team for taking this decisive step towards building a life sciences ecosystem that is resilient, inclusive and globally competitive." Satish Reddy, Chairman, Dr. Reddy's Labs   “The NextGen Telangana Life Sciences Policy signals a bold transition from scale-led growth to an innovation-driven, value-centric model that the global life sciences industry increasingly needs. With its strong manufacturing base, regulatory credibility, and forward-looking investments in precision medicine, data-driven discovery, and sustainable infrastructure, Telangana is creating an ecosystem that can effectively translate science into scalable global impact.  This policy has the potential to position the state among the world’s leading life sciences clusters and a credible global partner in shaping the future of healthcare.” Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited   “Telangana Next-Gen Life Sciences Policy 2026-30 is unique and transformative. It lays out a clear road map for being a dominant player in the emerging areas of healthcare, pivoting on innovation. This policy is a forward looking vision statement for the state which currently has a great life sciences ecosystem. Wishing all the success for this bold and ambitious vision.” Dr Satyanarayana Chava, Executive Director and Chief Executive Officer, Laurus Labs   "Telangana's Next-Gen Life Sciences Policy 2026–2030 represents a transformative vision that positions the State at the forefront of global life sciences innovation. With Hyderabad as a global hub at the centre of Sanofi’s operations, this policy's ambitious framework for advanced biomanufacturing, talent ecosystems, and regulatory excellence creates unprecedented opportunities to redefine how we serve patients globally. I commend the Hon'ble Chief Minister and the Hon'ble Minister of Industries for their bold leadership in shaping the future of life sciences.” Madeleine Roach, Executive Vice President, Business Operations, Sanofi   "At a moment when the global life sciences sector is undergoing profound transformation, Telangana’s Next-Generation Life Sciences Policy reflects a long-term vision that recognises the future of healthcare will be shaped not by isolated breakthroughs, but by strong ecosystems bringing together science, technology, talent, and policy coherence. By focusing on innovation, resilience, and global collaboration—and by anticipating the convergence of biology, data, and engineering—Telangana is positioning itself not just to participate in the future of life sciences, but to help shape it.” Shyam Bishen, Head of Centre for Health & Healthcare, Member of Executive Committee, World Economic Forum   "Telangana’s life sciences policy demonstrates a timely commitment to MedTech-led innovation. This kind of forward-looking policy framework is critical to accelerating innovation and building globally competitive MedTech hubs. Our Medtronic Engineering & Innovation Centre (MEIC) in Hyderabad is a testament to Medtronic’s investment and partnership with the state of Telangana and is focused on accelerating innovation and putting patients first. I congratulate the Telangana government for their leadership and vision in shaping a policy that meaningfully advances innovation in healthcare." Majid Kaddoumi, Executive Vice President, Eurasia   ]]> https://biospectrumindia.com/news/109/27169/suzen-medicare-invests-rs-180-cr-to-open-iv-fluid-manufacturing-facility-in-hyderabad.html https://biospectrumindia.com/news/109/27169/suzen-medicare-invests-rs-180-cr-to-open-iv-fluid-manufacturing-facility-in-hyderabad.html Mon, 12 Jan 2026 00:00:00 +0530 Chief Minister of Telangana Revanth Reddy inaugurated Suzen Medicare’s state-of-the-art IV fluid manufacturing facility at Maheshwaram (E-City), Hyderabad, marking another significant milestone in Telangana’s expanding pharmaceutical and life sciences ecosystem.Established with an investment of Rs 180 crore, the 1.60 lakh sq ft facility spread across four acres is production-ready and will manufacture IV fluids and antibiotics, catering to both domestic and global markets. The unit has entered into a technology tie-up with Germany’s Rommelag, a globally reputed leader in injectable packaging solutions—bringing advanced German manufacturing technology to Telangana.Addressing the occasion, the Chief Minister highlighted the critical role of private investments in driving employment, industrial growth, and economic resilience, noting that Hyderabad’s rise as a globally competitive city is the result of sustained effort over the past three decades.He underlined that Suzen Medicare’s investment aligns with the government’s “Telangana Rising 2047” Vision, which aims to transform the State into a $1 trillion economy by 2034 and a $3 trillion economy by 2047. Both the Core Urban Region Economy (CURE)—focused on high-value services, innovation and technology—and the Peri Urban Region Economy (PURE)—driving large-scale manufacturing and industrial infrastructure—will play a pivotal role in achieving this ambition.Reaffirming Telangana’s leadership in pharmaceuticals, the Chief Minister noted that nearly 40% of India’s bulk drug production originates from the State, with Hyderabad emerging as a global pharma and life sciences hub attracting international attention, talent, and investment.With a focus on advanced manufacturing, global technology partnerships, and encouragement for young entrepreneurs, Telangana continues to position itself as a preferred destination for next-generation pharma and healthcare investments. ]]> https://biospectrumindia.com/news/109/27153/23rd-edition-of-bioasia-to-take-place-on-17-18-feb-2026-in-hyderabad.html https://biospectrumindia.com/news/109/27153/23rd-edition-of-bioasia-to-take-place-on-17-18-feb-2026-in-hyderabad.html Thu, 08 Jan 2026 00:00:00 +0530 The official announcement for BioAsia 2026, the 23rd edition of Asia’s premier life sciences and health-tech forum, was released by Minister D. Sridhar Babu (Minister for IT, Electronics & Communications, and Industries & Commerce, Government of Telangana), in the presence of Sanjay Kumar, IAS (Special Chief Secretary, Industries & Commerce and ITE&C Departments, Government of Telangana), Shakthi M Nagappan (CEO, Telangana Life Sciences) and other dignitaries. The poster release marks the ceremonial commencement of preparations for the upcoming summit scheduled to be held from 16–18 February 2026 in Hyderabad. Over the past two decades, BioAsia has emerged as Asia’s foremost platform for life sciences, biopharma, health-tech, and medical innovation, consistently bringing together global leaders, investors, innovators, researchers, and policymakers. Each edition has showcased cutting-edge science while reinforcing Hyderabad and Telangana’s position as a global hub for biopharma, vaccines, medtech, and digital health innovation, supported by world-class infrastructure and a deep pool of scientific talent. The 23rd edition of BioAsia is themed ‘TechBio Unleashed: AI, Automation & the Biology Revolution.’ The theme reflects the pivotal convergence of biology, data, and deep technology that is reshaping drug discovery, diagnostics, manufacturing of therapies, and healthcare delivery globally. TechBio is transforming how diseases are understood, how therapies are designed, and how care is delivered—making healthcare more predictive, personalised, and accessible while strengthening a resilient and inclusive global health system. Speaking on the occasion, Minister for IT, Electronics & Communications, and Industries & Commerce, Government of Telangana, D. Sridhar Babu said, “As Telangana embarks its journey towards becoming a $3 Trillion Economy by 2047, Lifesciences sector will play a critical role in shaping the growth of the state. Marquee event like BioAsia showcases Telangana’s leadership in life sciences and healthcare innovation and acts as a pivotal platform to foster new partnerships and explore opportunities for growth in this segment. With the release of the BioAsia 2026 poster, we begin yet another exciting journey that will bring together the world’s brightest minds to advance the TechBio revolution and build a healthier future for all.” The summit is expected to deliver strategic value for startups, researchers, investors, policymakers, and global organizations. BioAsia 2026 will connect innovators with investors, act as a bridge between laboratory breakthroughs and market adoption, and provide a forum for policymakers to co-create regulatory frameworks that encourage innovation while safeguarding patient safety and public interest. ]]> https://biospectrumindia.com/news/109/27131/pinnacle-blooms-network-to-scale-ai-powered-child-development-operating-system-with-70-m-funding.html https://biospectrumindia.com/news/109/27131/pinnacle-blooms-network-to-scale-ai-powered-child-development-operating-system-with-70-m-funding.html Mon, 29 Dec 2025 00:00:00 +0530 A leading global healthcare investment fund has offered $70 million to Pinnacle Blooms Network, the flagship pediatric-therapy enterprise of Hyderabad-based startup Bharath Healthcare Laboratories. The proposed two-tranche Series A investment, advised by Yukon Capital, would represent one of the largest early-stage financings in child-development infrastructure anywhere in Asia. The offer comes as Pinnacle evaluates strong interest from multiple global institutional investors seeking exposure to the fast-emerging developmental health sector. Pinnacle operates more than 70 multi-disciplinary therapy centres across India - and has delivered over 20 million one-to-one therapy sessions to date. The company's proprietary Pinnacle Child Development Operating System (GPT-OS®) is a multi-patent-filed digital-therapeutic platform that measures, forecasts, and personalises every dimension of a child's developmental journey across speech, motor, cognitive, and behavioural domains. The GPT-OS® architecture integrates modules including Diagnosis, Prognosis, TherapeuticAI®, AbilityScore®, Seven Readiness Indexes®, and TherapySphere™—multi-sensory therapeutic environments designed to accelerate neurological development in children with autism, speech delays, ADHD, and related conditions. The proposed funding is structured in two phases. Phase 1 comprises $70 million for rapid domestic expansion and technology acceleration. Phase 2 envisions a follow-on tranche as Pinnacle expands into Southeast Asia and the GCC. Capital deployment would fund expansion from 70+ to 300 centres within 24 months, R&D acceleration for home-based TherapeuticAI® applications, large-scale manufacturing of TherapySphere™ sensory rooms, and regulatory submissions for international market access. Pinnacle is targeting expansion with projected annual revenue scaling from Rs 160+ crore to Rs 6,000 crore. On 23 September 2026, Pinnacle Blooms Network published a source ledger for six company measures on its Verify evidence hub. The ledger defines each measure, its 17 July 2026 cutoff, counting method and location in two accountant reports signed on 3 September 2026. Those reports have different scopes: an SRS 4400 factual-finding engagement and an SAE 3000 limited-assurance engagement. Their limits are stated beside the figures.One frequently cited figure is 31,052,382 services. In this ledger, “services” includes assessments, screenings and parent training as well as therapy-related services. It is not a count of 31 million one-to-one therapy sessions or unique children, and it does not establish clinical outcomes. The 16 patent entries are applications, not granted patents.A separate MD-5 source record identifies PinnacleAI GPT-OS version 1.0.0 as Class B, non-diagnostic developmental-support software for children aged 0–12. The record does not grant authority to diagnose autism or prove clinical effectiveness. Verify also separates research preprints, protocols and reports from any later peer-reviewed evidence, with author and version links where available.The public ledger and MD-5 record let readers inspect specific statements against dated sources. Neither registration nor company scale should be read as an endorsement or a guarantee of benefit for an individual child. Source ledger: https://www.pinnacleblooms.org/verify/evidence/claim-ledger.htmlMD-5 record: https://www.pinnacleblooms.org/verify/evidence/records/md5.html ]]> https://biospectrumindia.com/news/109/27051/telangana-receives-biospectrum-best-performing-state-of-the-year-2025-award-.html https://biospectrumindia.com/news/109/27051/telangana-receives-biospectrum-best-performing-state-of-the-year-2025-award-.html Wed, 10 Dec 2025 00:00:00 +0530 Telangana, the leading life sciences hub in Asia, and known as India's Pharma City and Vaccine Capital received the BioSpectrum Best Performing State of the Year 2025 Award. MMA Spectrum Foundation and BioSpectrum India, an integrated B2B media platform for the bioscience industry in India, presented the award at a glittering function held in New Delhi on December 5. BioSpectrum India, in consultation with a six-member jury panel chaired by Dr Renu Swarup, Former Secretary, Department of Biotechnology, Government of India, selected Telangana for this prestigious award for its overall contribution to Bioeconomy of the country. In his acceptance note, Shakthi M Nagappan, CEO, Telangana Lifesciences, Govt. of Telangana said “I would like to extend my sincere gratitude for recognizing Telangana as the Best Performing State of the Year at the BioSpectrum India Excellence Awards 2025. This honour is deeply appreciated and reflects our commitment to the life sciences sector.” In his remarks the Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh, who served as Chief Guest, acknowledged the significant contributions of state governments for establishing robust biotech ecosystems. The states have built sophisticated research hubs, incubation centres, and industrial networks that support innovation from concept to commercialisation. Dr Jitendra Singh congratulating BioSpectrum on completing 23 years, applauded its role in highlighting achievements across India’s biotech ecosystem. He expressed his appreciation for the BioSpectrum Awards, noting that such recognition plays an important role in celebrating the country’s scientific and technological progress. Earlier welcoming the august gathering including Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh, Ravindra Boratkar, Publisher & Managing Editor, BioSpectrum India and Managing Trustee, MMA Spectrum Foundation said, “Today, we come together to honour the pioneers, the visionaries, the risk-takers, and the path-breakers who are shaping the future of biotechnology, pharmaceuticals, medtech, diagnostics, digital health, and research. Your work not only strengthens India’s scientific capabilities but also touches millions of lives across the world. The Excellence Awards represent the highest recognition in this journey, celebrating commitment to innovation, ethical leadership, and societal impact.” Sharing her views as the chairperson of the Jury Panel, Dr Renu Swarup, Former Secretary, Department of Biotechnology, said “The entire selection process was extremely robust, with the BioSpectrum team conducting extensive research to identify nominees before presenting them to the jury. The most satisfying moment for the jury is when we receive strong, high-quality nominations — and this year, the nominations were exceptionally rich in contribution. All jury members would agree that it took considerable deliberation to finalise the awardees because the level of competition was so high. This reflects both the strength of the biotechnology sector and the diligence of the evaluation process. During our discussions, the jury also emphasized the importance of recognizing young talent in the future, as nurturing this pipeline is essential for sustaining leadership in the biotechnology ecosystem.” The esteemed Jury members include Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC); Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Dr Sanghamitra Pati, Additional Director General, Indian Council of Medical Research; Dr Shirshendu Mukherjee, Managing Director, Wadhwani Innovation Network; and Prof. Vijay Chandru, Founder and Chairperson, Strand Life Sciences. The MMA Spectrum Foundation, launched recently, is set to commence its activities with a mission to drive the overall development of the Bio & Health Sciences, Life Sciences, and Food & Agriculture sectors, along with all their associated sub-sectors. As part of its mandate, the foundation will establish specialised expert groups aimed at empowering young innovators to launch and scale startups. These groups will also provide structured guidance and mentorship to aspiring entrepreneurs, fostering a strong ecosystem for scientific and agritech-driven enterprise. ]]> https://biospectrumindia.com/news/109/26954/biological-es-pneubevax-14-vaccine-receives-whos-pre-qualification.html https://biospectrumindia.com/news/109/26954/biological-es-pneubevax-14-vaccine-receives-whos-pre-qualification.html Thu, 20 Nov 2025 00:00:00 +0530 Biological E. Limited (BE), a leading Hyderabad-based vaccine and pharmaceutical company, has announced that the World Health Organisation (WHO) has granted Pre-qualification (PQ) status to their 14-valent Pneumococcal Conjugate Vaccine (PCV), PNEUBEVAX 14® (BE-PCV-14). PNEUBEVAX 14® becomes BE’s 11th WHO pre-qualified vaccine. Developed specifically to prevent invasive pneumococcal diseases, PNEUBEVAX 14® protects against infections caused by 14 different Streptococcus pneumoniae serotypes, including serotypes 22F and 33F—two strains not covered by select other PCVs. Administered to infants from six weeks of age, PNEUBEVAX 14® is designed to guard against serious diseases such as pneumonia, meningitis, and sepsis as part of the primary vaccination schedule. Commenting on the WHO pre-qualification, Mahima Datla, Managing Director, Biological E. Limited, said, “This milestone enhances global access to high-quality pneumococcal vaccines and strengthens supply security, particularly for children who need them most. WHO PQ enables broader reach through global immunisation initiatives, and we remain committed to supporting public health partners in delivering affordable, reliable vaccines across India and around the world.” ]]> https://biospectrumindia.com/news/109/26866/bharat-biotech-launches-next-gen-cell-and-gene-therapy-crdmo-nucelion.html https://biospectrumindia.com/news/109/26866/bharat-biotech-launches-next-gen-cell-and-gene-therapy-crdmo-nucelion.html Mon, 03 Nov 2025 00:00:00 +0530 Nucelion Therapeutics, a newly established, Hyderabad-based Contract Research Development and Manufacturing Organisation (CRDMO) focused on cell and gene therapies, has announced its formal launch: Nucelion, a wholly owned subsidiary of Bharat Biotech International Ltd. The CRDMO aims to support global life science innovators with high-quality, scalable process development and manufacturing solutions for advanced therapies, indicated for cancers, autoimmune disorders, and rare genetic disorders. The future of pharmaceutical innovation will be biological, with new modalities expected to drive a large share of growth worldwide. Within this shift, cell therapies—autologous, allogeneic, and emerging in vivo approaches—are poised to move from niche programs to scalable platforms, expanding from rare diseases into broader oncology, immunology, and regenerative care as manufacturing, analytics, and delivery technologies mature. Spread across a 30,000 square foot purpose-built facility in Genome Valley, Nucelion has commissioned a GMP facility capable of developing and manufacturing plasmids, viral and non-viral vectors, cell therapies, and aseptic fill & finish, providing end-to-end services for clients. The company will offer end-to-end services, from early-stage clinical development to commercial-scale manufacturing, while adhering to international regulatory standards, including those of the FDA and EMA. Dr Krishna Ella, Non-Executive Director, Nucelion Therapeutics, said, “The future of pharmaceutical innovation will be biological; CGTs are a key vector. Our vision is to integrate advanced therapy platforms into India’s healthcare ecosystem, enabling equitable solutions for complex and rare diseases.” Dr Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics, said, “At Nucelion, we will provide end-to-end solutions from clinical to commercial scale, ensuring regulatory compliance with global standards (FDA, EMA). Nucelion offers services for the development and manufacturing of plasmid DNA, Viral Vectors, Autologous, and Allogeneic Cell Therapies. Nucelion will operate with independent leadership, governance, and information systems, and will engage all sponsors—including Bharat Biotech—on arm’s-length commercial terms.The company’s talent acquisition is underway to onboard scientific and operational talent with global experience in cell and gene therapy execution.   ]]> https://biospectrumindia.com/news/109/26828/telangana-targets-rs-1-lakh-crore-investments-in-life-sciences-by-2030.html https://biospectrumindia.com/news/109/26828/telangana-targets-rs-1-lakh-crore-investments-in-life-sciences-by-2030.html Thu, 23 Oct 2025 00:00:00 +0530 Telangana has set an ambitious target of attracting Rs 1 lakh crore in new investments in the Life Sciences sector by 2030, aiming to generate employment for five lakh people, said Minister for IT and Industries Duddilla Sridhar Babu. Delivering the keynote address at the AusBiotech International Conference 2025 in Melbourne (being held from 21 to 24 October 2025) — organised jointly by AusBiotech and the Government of Victoria - the Minister said the State government has drawn up a comprehensive “Roadmap 2030” to position Telangana as a Global Life Sciences Hub. “Telangana is preparing a Comprehensive Life Sciences Policy to accelerate innovation, infrastructure, and global partnerships,” Sridhar Babu said, outlining the State’s strategy for the next phase of bio-digital growth. The Minister said Telangana continues to outperform national averages in economic growth. Though the State ranks 11th in geographical area and 12th in population, it contributes over 5% to India’s GDP. Telangana’s GSDP growth rate in 2024–25 stood at 8.2%, compared with the national average of 7.6%, he noted. Over the past 20 months, the State has attracted Rs 3.2 lakh crore in new investments, with Rs 63,000 crore coming from the Life Sciences sector alone. Exports from the sector crossed Rs 26,000 crore between April and December 2024. The State aims to increase the value of the Life Sciences economy from $80 billion to $250 billion by 2030, the Minister said. Citing a report by global consultancy CBRE, Sridhar Babu said Hyderabad has been featured in the Global Life Sciences Atlas 2025 among the world’s leading Life Sciences clusters — alongside Boston, San Francisco, Cambridge, Beijing, and Tokyo. Hyderabad is the only Indian city to feature in this list, he added. Life Sciences office leasing in the city expanded from 0.6 million sq. ft. in 2022 to 2.4 million sq. ft. in 2024, reflecting the sector’s rapid growth and investor confidence.   Sridhar Babu invited Australian companies to explore investment opportunities in emerging and high-growth areas such as Cell and Gene Therapy, Biologics and Biosimilars, mRNA Vaccines, Contract Research, Development and Manufacturing (CRDM), Diagnostics, MedTech, and Digital Health. He also highlighted Telangana’s focus on AI-based Drug Discovery, Genomics, Green Biomanufacturing, Agri-Biotech, and Animal Health, saying these sectors offer immense potential for collaboration and value creation.  ]]> https://biospectrumindia.com/news/109/26812/indias-first-microrna-based-blood-test-for-breast-cancer-screening.html https://biospectrumindia.com/news/109/26812/indias-first-microrna-based-blood-test-for-breast-cancer-screening.html Fri, 17 Oct 2025 00:00:00 +0530 PrecisionRNA Biotech (Prerna), a healthcare startup from Hyderabad, has announced the launch of Cantel™, India’s first microRNA-based blood test for breast cancer screening. This groundbreaking test is set to transform early detection by offering a simple, convenient, and highly accurate alternative to traditional methods, addressing the critical screening gap that has led to late-stage diagnosis of breast cancer in India. In a country where less than 2% of women are screened for breast cancer, Cantel™ offers a scalable solution. Unlike mammography, which is often hindered by cost, accessibility issues, and social stigma, Cantel™ is a minimally invasive blood test that can be performed at home or at a local diagnostic center. No compression, no imaging, and no radiation. This convenience is designed to significantly increase screening adherence and improve survival rates, which are currently among the lowest globally. The test utilises the power of microRNAs (miRNAs), small molecules that act as dynamic biomarkers for disease. The 2024 Nobel Prize in Medicine recognized the discovery of microRNAs and their role in gene regulation, highlighting their significance in modern diagnostics. Cantel™ leverages proprietary miRNA signatures, validated through extensive clinical trials, to detect early molecular signals of breast cancer with high sensitivity and specificity. "For far too long, breast cancer detection in India has been reactive. With Cantel™, we’re making it proactive, accessible, and designed around women’s real lives, empowering them to take control of their health with confidence and ease,” said Siddharth Reddy, Co-founder of CANTEL™ and a serial healthcare entrepreneur. "This is not just a diagnostic innovation. This is a step toward building a national health habit around early detection."   ]]> https://biospectrumindia.com/news/109/26799/msn-laboratories-introduces-affordable-jak-inhibitors-in-india.html https://biospectrumindia.com/news/109/26799/msn-laboratories-introduces-affordable-jak-inhibitors-in-india.html Mon, 13 Oct 2025 00:00:00 +0530 Hyderabad-based MSN Laboratories has announced that it is the first to launch the revolutionary JAK inhibitor molecules Tofacitinib (Tofadoz) and Upadacitinib (Upadoz) in India. This launch significantly enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease, and Atopic Dermatitis. Both molecules are also approved by the US FDA. MSN Laboratories is committed to providing affordable medicines, having previously launched close to 50 first-time molecules in India. The company holds the leading position in Active Pharmaceutical Ingredient (API) US DMF filings. "The introduction of Upadoz reflects our commitment to bringing affordable bioequivalent medications to alleviate the suffering of Indian patients," said Dr M.S.N. Reddy, Founder and CMD, MSN Group. Bharat Reddy, Executive Director, MSN Group, added: "Autoimmune diseases are a growing public health issue, and the cost of treatment is substantial. This launch will make treatment more accessible to Indian patients." ]]> https://biospectrumindia.com/news/109/26778/world-health-organization-prequalifies-shanchol-oral-cholera-vaccine.html https://biospectrumindia.com/news/109/26778/world-health-organization-prequalifies-shanchol-oral-cholera-vaccine.html Tue, 07 Oct 2025 00:00:00 +0530 Shanchol®, the oral cholera vaccine originally developed by Hyderabad-based Shantha Biotechnics, has received prequalification from the World Health Organization (WHO). This milestone enables global procurement agencies such as UNICEF, Gavi, and PAHO to source Shanchol® for use in countries where cholera remains a major public health challenge. “Shanchol® was conceived as an affordable, accessible solution for countries facing repeated cholera outbreaks. The WHO prequalification of vaccine carries forward that founding mission,” said Dr K.I. Varaprasad Reddy, Founder of Shantha Biotechnics. Over the years, close to 40 million doses of Shanchol® have been supplied worldwide through UNICEF-led vaccination campaigns. After production was paused under its former ownership, GCBC Vaccines (formerly Shantha)- has resumed manufacturing, with WHO conducting an on-site inspection and transferring the prequalification. Shanchol® remains the only oral cholera vaccine manufactured in India with WHO prequalification, underscoring India’s critical role in ensuring continuity of global supply. “As part of the founding family of Gland Pharma, I have seen how world-class sterile manufacturing from India can transform global healthcare. By resuming production of Shanchol®, we are bringing the same rigor and reliability to ensure this life-saving vaccine remains available worldwide,” said Dr Ravi Penmetsa, Managing Director, GCBC Vaccines. Shanchol® is a bivalent killed whole-cell oral cholera vaccine, effective against Vibrio cholerae O1 and O139. It has been a cornerstone of UNICEF-coordinated outbreak responses and preventive immunization campaigns, protecting millions of people worldwide. With WHO PQ approval, Shanchol® will continue to be supplied at scale to international demand and to meet country-level immunisation needs.   ]]> https://biospectrumindia.com/news/109/26780/telangana-govt-launches-coffee-table-book-showcasing-indias-life-sciences-leadership-and-hyderabads-gcc-rise.html https://biospectrumindia.com/news/109/26780/telangana-govt-launches-coffee-table-book-showcasing-indias-life-sciences-leadership-and-hyderabads-gcc-rise.html Tue, 07 Oct 2025 00:00:00 +0530 The Government of Telangana, in collaboration with global healthcare and lifescience consulting firm Healthark, unveiled a first-of-its-kind coffee table book titled “India’s Life Sciences Renaissance: The Hyderabad GCC Opportunity.” This visually compelling book offers a sweeping chronicle of India’s journey in life sciences and healthcare, with a focused lens on how Hyderabad is evolving as a global hub for innovation-driven Global Capability Centers (GCCs). The book was officially launched by Anumula Revanth Reddy, Chief Minister, Government of Telangana and D. Sridhar Babu, Minister for IT, Electronics & Communications, Industries & Commerce, Government of Telangana.  The coffee table book traces the evolution of Life Sciences and Healthcare GCCs (LSHC GCCs) in India, beginning in the early 2000s with a focus on cost efficiency and back-office support, through their transformation into high-value strategic hubs that now anchor global R&D, digital innovation, and enterprise leadership.  Today, Hyderabad stands as a beacon of this transformation with over 2,000 life sciences companies, contributing to one-third of the world’s vaccine production, and housing 250+ USFDA-approved sites, the highest concentration globally. Conceptualised by the HealthArk in collaboration with the Government, the book features success stories, leadership insights, and sectoral contributions of over 10+ global organizations that have chosen Hyderabad as their strategic base. It captures how these centers have evolved from support arms to global innovation powerhouses, driving value across functions like AI, cybersecurity, digital health, fintech, ESG, and more. The launch also marks the beginning of a broader knowledge-sharing initiative by the Government of Telangana to further elevate Hyderabad’s positioning as the life sciences capital of India and a global hub for GCC excellence. ]]> https://biospectrumindia.com/news/109/26764/gene-solutions-and-ampath-launch-advanced-genomics-laboratory-in-hyderabad.html https://biospectrumindia.com/news/109/26764/gene-solutions-and-ampath-launch-advanced-genomics-laboratory-in-hyderabad.html Thu, 02 Oct 2025 00:00:00 +0530 Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad. This collaboration aims to bring high-value, next-generation sequencing (NGS) technologies closer to patients and healthcare providers across the country. By combining AMPATH's extensive diagnostic network with Gene Solutions' expertise in genomics, the partnership will enable more timely, accessible, and informative testing in key areas such as reproductive health, cancer screening, and personalised medicine. The newly established NGS laboratory in Hyderabad will offer: triSure NIPT – A comprehensive non-invasive prenatal screening solution that provides insights into chromosomal conditions, microdeletions, and select single-gene disorders, supporting expectant parents with safe, early options for fetal health assessment and maternal well-being. SPOT-MAS – An innovative, clinically validated early cancer screening solution, designed to detect signals from 75 cancer types and subtypes using a single blood sample—providing physicians with additional tools to support early intervention. K-TRACK, K-4CARE – World-class cancer monitoring & genomic profiling solutions powered by multi-omics, enabling physicians to personalize treatment and monitor recurrence with greater confidence. "This partnership reflects a shared vision—making high-quality, science-driven genetic testing more widely available," said Dr Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions. "We believe that technology should be inclusive. Working with AMPATH allows us to deliver advanced solutions through a familiar and trusted healthcare network." Dr Maneesh Bagai, COO of AMPATH shared, "We are thrilled to expand into next-generation sequencing through this strategic alliance. Together, we are redefining what's possible in diagnostics—whether it's in maternal health, early cancer detection, or personalized oncology with patient centric approach." ]]> https://biospectrumindia.com/news/109/26722/hca-healthcare-sets-up-global-capability-centre-in-hyderabad.html https://biospectrumindia.com/news/109/26722/hca-healthcare-sets-up-global-capability-centre-in-hyderabad.html Wed, 24 Sep 2025 00:00:00 +0530 HCA Healthcare, Inc., a Fortune 100 healthcare leader with a network of approximately 192 hospitals and 2,500 care sites across the United States and the United Kingdom, has inaugurated its Global Capability Centre (GCC) in India, selecting Hyderabad as its strategic hub. The centre will serve as a strategic hub and use advanced digital and technology capabilities to help drive innovation and operational excellence across HCA Healthcare’s operations. With a planned investment of approximately $75 million by the end of 2025, HCA Healthcare - India is set to expand its workforce to 3,000 colleagues by the end of 2026 with continued growth expected. HCA Healthcare - India is focused on recruiting and developing talent across multiple lines of business including IT, supply chain, procurement, human resources, finance and accounting. The Hyderabad centre is expected to play a significant role in supporting HCA Healthcare’s commitment to providing high-quality patient care in the United States and United Kingdom. Located in HITEC City, the center spans over 400,000 square feet across four floors within the LEED-certified campus of Sattva Knowledge Park. The facility was inaugurated by Duddilla Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Legislative Affairs, Government of Telangana; in the presence of Emily Duncan, Senior Vice President, Global Capability Network, HCA Healthcare; Atul Kapoor, Vice President and Hyderabad Center Head, HCA Healthcare - India; along with other distinguished dignitaries. Duddilla Sridhar Babu  said, "Hyderabad is the gateway to a complete global ecosystem of healthcare, pharmaceuticals, and life sciences. With world-class hospitals, over 800 pharma companies producing APIs, drugs, biologics, speciality medicines, and vaccines, and the presence of leading global life sciences GCCs driving R&D and innovation, Telangana has built one of the finest healthcare infrastructures in the world. What sets Hyderabad apart is its ability to deliver affordable healthcare while maintaining the highest standards of quality and trust. We are proud to welcome HCA Healthcare’s first Global Capability Centre in India, a strong endorsement of Hyderabad’s leadership and a milestone that will further accelerate our journey as a global hub for healthcare and innovation."  ]]> https://biospectrumindia.com/news/109/26661/botanic-healthcare-invests-over-rs-25-cr-in-liposomal-manufacturing-facility-in-hyderabad.html https://biospectrumindia.com/news/109/26661/botanic-healthcare-invests-over-rs-25-cr-in-liposomal-manufacturing-facility-in-hyderabad.html Wed, 10 Sep 2025 00:00:00 +0530 Botanic Healthcare, a global leader in natural ingredients and nutraceutical innovation, has launched its dedicated Liposomal Manufacturing Facility in Hyderabad with an investment of over Rs 25 crore.   This expansion marks a significant milestone in advancing delivery technologies designed to enhance bioavailability and effectiveness across various health and wellness categories.   With a raw material capacity of over 8,500 metric tonnes annually, the LipsoBio® facility will produce powdered liposomal vitamins and minerals, botanically enriched beadlets, and customized formulations.   The unit incorporates Botanic Healthcare’s patent-filed DFS™ (Dietary Fiber Stabilised) Technology, which enables superior stability and consistent performance in liposomal formats.   This combination of cutting-edge technology and strict quality protocols ensures the company’s liposomal products meet international regulatory standards and deliver consistent performance for nutraceutical, pharmaceutical, cosmeceutical, and functional food applications.   The new unit has already created over 50 high-value jobs across R&D, manufacturing, and quality operations, while also generating indirect opportunities for local suppliers and vendors. Leading companies worldwide are incorporating Botanic Healthcare’s LipsoBio® liposomal ingredients into their formulations and successfully launching products that are generating strong market returns. Our innovative portfolio including, LipoGlo™ (Liposomal Glutathione), LipoQ10™ (Liposomal CoQ10), and Lipomac™ (Liposomal Vitamin C) is creating measurable impact across markets. A leading Korean company has recently launched LipsoBio®. Strategically designed to serve both domestic and international markets, LipsoBio® strengthens Botanic Healthcare’s supply network across South Korea, Taiwan, North America, Europe, and Asia-Pacific.   With integrated R&D and pilot-scale facilities, the new unit also accelerates product development, enabling the company to bring innovative formulations to market more quickly and efficiently.   ]]> https://biospectrumindia.com/news/109/26562/care-hospitals-emoha-eldercare-to-build-holistic-care-ecosystem-for-seniors-in-hyderabad.html https://biospectrumindia.com/news/109/26562/care-hospitals-emoha-eldercare-to-build-holistic-care-ecosystem-for-seniors-in-hyderabad.html Thu, 21 Aug 2025 00:00:00 +0530 CARE Hospitals and Emoha, India’s leading senior care brand, have announced a landmark partnership to redefine elder care in Hyderabad. The alliance will create a holistic care ecosystem that supports seniors.   As part of the partnership, a state-of-the-art Geriatric Care Facility will be launched on October 1, 2025, at CARE Hospitals, Hyderabad. This will be the first-of-its-kind dedicated unit designed to provide specialised medical attention tailored to elders’ complex and chronic health needs, from comprehensive geriatric assessment to advanced clinical interventions.   This partnership also ensures that elders leaving the hospital continue to receive expert medical support and compassionate care at home, reducing the risk of relapse, readmission, and emotional distress. Once discharged, Emoha’s trained carers, nurses, and care team step in to provide continuous support, from administering medications and monitoring vitals to assisting with daily health needs, ensuring elders recover safely in the comfort of their homes.   Equally important is the emotional dimension of care. Through the Emoha App, elders will stay connected to a vibrant community of seniors from across the country, enjoying online shows, interactive sessions, and specially curated events that keep them engaged and joyful.               Emoha’s community-first approach and local presence across neighbourhoods further ensure that elders never feel alone, but instead remain active, connected, and valued within their families and communities.   ]]> https://biospectrumindia.com/news/109/26563/thermo-fisher-to-establish-two-state-of-the-art-facilities-in-genome-valley-by-2025-end.html https://biospectrumindia.com/news/109/26563/thermo-fisher-to-establish-two-state-of-the-art-facilities-in-genome-valley-by-2025-end.html Thu, 21 Aug 2025 00:00:00 +0530 Thermo Fisher Scientific has announced plans to make significant investments in India’s biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. The announcements came when senior executives addressed government, industry and academia at the Biopharma Conclave 2025, held in Hyderabad on 19 & 20 August. In 2024, India’s biopharmaceutical market was $8.1 billion in size, and is expected to almost double to $15.9 billion in 2030. Key drivers of this growth include increasing market maturity, forthcoming environment for regulatory approvals globally, and high-unmet clinical needs within India.  “India’s biopharma sector is poised for a giant leap, and we are deeply committed to enabling that outcome,” said Tony Acciarito, President, Asia Pacific & Middle East, Africa, Thermo Fisher Scientific. “Our integrated solutions, from research to manufacturing, will help our customers innovate faster, increase productivity and maintain the highest quality standards. India is one of our fastest-growing markets, and we are building capacity and capabilities here to match its immense potential.” Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, both set to open by year-end 2025. The Bioprocess Design Center (BDC), developed in partnership with the Telangana Government, will provide expertise in bioprocessing and process scale-up to accelerate development of life-changing therapies. Complementing the BDC, Thermo Fisher's Customer Experience Center (CEC) will showcase advanced instrumentation and workflow solutions across molecular biology, proteomics, clinical diagnostics, cell and gene therapy among others. Subject matter experts will support method development, technology adoption, and industry upskilling. "India's biopharma industry currently faces challenges which include access to cutting-edge technologies and technology experts. The BDC and CEC will help directly address them, enabling both start-ups and established companies to reduce time-to-market. Therapies will meet stringent international quality requirements through this collaborative ecosystem”, added Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific.   ]]> https://biospectrumindia.com/news/109/26519/zs-strengthens-india-operations-with-expansion-in-hyderabad.html https://biospectrumindia.com/news/109/26519/zs-strengthens-india-operations-with-expansion-in-hyderabad.html Tue, 12 Aug 2025 00:00:00 +0530 ZS, a global management consulting and technology firm, has announced the opening of its new Hyderabad office, an approximately 50,000 sq ft facility that will house 550-600 people. This move is part of ZS’s broader strategy and commitment to delivering greater capacity and end-to-end global capability center (GCC) offerings to clients. The centre will continue to offer a range of flexible engagement models, including packaged offerings built for GCCs, embedded functional expertise and fully managed GCC-as-a-service models. Hyderabad has solidified its position as one of India’s fastest-growing GCC hubs, especially in healthcare and life sciences. Its thriving talent base and technology ecosystem gives ZS access to quality talent highly specialized in business and tech operations, analytics and data engineering to support GCC operations and their evolving needs. This new location will better position ZS to deliver customised, differentiated, high-impact solutions for global GCC partners throughout their operations life cycle. Mohit Sood, regional managing principal, ZS said, “GCCs are evolving from execution hubs to innovation and tech centers, and ZS is well positioned to support this industrywide transformation. We partner with GCCs to establish a strong foundation, scaled operations and future-proofed capabilities for long-term, enterprise-wide impact. The new office is a testament to ZS’s unique value, innovation and end-to-end service offerings to GCC clients. All of these factors have led to our strategic expansion within a year of our presence in Hyderabad. This move underscores our growth and commitment to building strong and long-term client partnerships, tapping into local talent and contributing to the GCC ecosystem. With more than 40 years of deep industry experience and strong expertise in data and AI, ZS has a competitive edge in the healthcare and life sciences.  ]]> https://biospectrumindia.com/news/109/26522/asian-institute-of-nephrology-urology-invests-rs-150-cr-to-open-new-hospitals-in-hyderabad.html https://biospectrumindia.com/news/109/26522/asian-institute-of-nephrology-urology-invests-rs-150-cr-to-open-new-hospitals-in-hyderabad.html Tue, 12 Aug 2025 00:00:00 +0530 Asian Institute of Nephrology and Urology (AINU), India’s largest single-speciality chain focused on Uro-Nephro care, marks a new milestone with the expansion of its flagship hospital in Banjara Hills, Hyderabad. The flagship hospital has a combined capacity of 150 beds, 4 Operating Rooms, 34 dialysis beds, and new-generation robotic technology for complex Urology and Nephrology surgeries, making it the largest corporate hospital in this single speciality across India.  With an outlay of Rs 150 crore earmarked for growth-related capital expenditure this year, AINU is set to accelerate its expansion footprint, enhance operational capabilities, and reinforce the foundation for its next phase of growth. The burden of urological diseases is rising rapidly in developing nations, with India at the forefront due to increasing lifestyle disorders such as hypertension, obesity, and diabetes, along with higher life expectancy. Urological conditions - from bladder and kidney diseases to cancers - affect men, women, and children alike. In India, 50–60% of men over 60 have benign prostatic enlargement (BPH), while prostate cancer, now the country’s second most common cancer in men, is growing at 2.5% annually. Vishal Bali, Executive Chairman at Asia Healthcare Holdings, said, “The rising incidence of Urology & Nephrology issues in the Indian subcontinent requires a specialised approach to meet the growth opportunity in this speciality. Through the Asian Institute of Nephrology and Urology we are building India’s leading single-speciality hospital network in this speciality, backed by highly qualified clinicians and state-of-the-art technology. With an outlay of Rs 150 crore capital expenditure earmarked for growth in FY 26-27, AINU is set to open 3-4 new urology and nephrology hospitals across India. This strategic investment will accelerate the company’s national expansion, strengthen its current infrastructure, and reinforce its position as a leader in single-speciality healthcare.”   ]]> https://biospectrumindia.com/news/109/26479/lilly-expands-india-presence-with-inauguration-of-hyderabad-site-to-accelerate-global-digital-innovation.html https://biospectrumindia.com/news/109/26479/lilly-expands-india-presence-with-inauguration-of-hyderabad-site-to-accelerate-global-digital-innovation.html Mon, 04 Aug 2025 00:00:00 +0530 Eli Lilly and Company (India) has announced the opening of its new technology and innovation site in Hyderabad; a new strategic hub for advanced digital and technology capabilities that will improve efficiency across Lilly’s global operations. By focusing on areas such as artificial intelligence (AI), automation, cloud computing, and software product engineering, the site will contribute to solving some of the world’s most pressing health challenges while also creating growth opportunities for local talent. Located in Gachibowli, Lilly’s Hyderabad site spans approximately 220,000 square feet across four floors within the Phoenix Equinox building. Lilly has already onboarded 100 professionals at the Hyderabad facility and plans to expand the headcount to 1,500 over the next few years. The facility was officially inaugurated by Diogo Rau, Executive Vice President and Chief Information and Digital Officer of Eli Lilly and Company, alongside Chief Minister of Telangana, A. Revanth Reddy, and D. Sridhar Babu, Hon’ble Minister for IT, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana. Sanjay Kumar, IAS, Special Chief Secretary, Industries and Commerce Department, was also present at the event. A. Revanth Reddy, Hon’ble Chief Minister of Telangana, said, “We are delighted to welcome Lilly to Hyderabad’s growing life sciences ecosystem. The inauguration of this new site further reinforces the city’s position as a global hub for healthcare innovation, built on scientific excellence, skilled talent, and international collaboration. The Government of Telangana remains committed to fostering an environment where pioneering companies like Lilly can thrive and deliver meaningful impact both in India and globally.” Lilly’s Hyderabad site will integrate advanced technology capabilities across key functions, supporting accelerated innovation, enhanced efficiency, and improved health outcomes for patients globally. ]]> https://biospectrumindia.com/news/109/26472/agilent-inks-partnership-with-tata-institute-of-fundamental-research-in-hyderabad.html https://biospectrumindia.com/news/109/26472/agilent-inks-partnership-with-tata-institute-of-fundamental-research-in-hyderabad.html Sat, 02 Aug 2025 00:00:00 +0530 In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Ageing). This partnership brings together Agilent’s global expertise in analytical science with TIFR’s research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country. A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India’s most ambitious government-supported initiatives in human health. ARUMDA is focused on bridging fundamental biology with clinical insights to drive data-driven discovery and inform public health strategies. Agilent’s role centers on enabling this vision through high-performance analytical solutions that support impactful translational research. This collaboration reflects a shared commitment to advancing science that is rigorous, relevant, and aligned with national health priorities. It is designed to empower researchers with the tools and workflows needed to explore complex biological systems, generate population-specific insights, and translate them into meaningful interventions. The collaboration also supports the development of a new analytical facility in Hyderabad, established in partnership with the National Analytical Facility for Research in Nutrition and Metabolism, under the ARUMDA umbrella. Aligned with the National Nutrition Mission, the facility is expected to play a critical role in advancing India’s research capabilities in metabolic health and nutrition science. ]]> https://biospectrumindia.com/news/109/26459/agilent-opens-experience-centre-in-hyderabad-to-support-indias-global-biopharma-ambitions.html https://biospectrumindia.com/news/109/26459/agilent-opens-experience-centre-in-hyderabad-to-support-indias-global-biopharma-ambitions.html Tue, 29 Jul 2025 00:00:00 +0530 Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has announced the inauguration of its new Biopharma Experience Centre in Hyderabad, Telangana. The facility marks a significant investment in India’s rapidly growing life sciences ecosystem and reflects Agilent’s long-term commitment to advancing biopharmaceutical innovation both locally and globally. The centre was inaugurated by Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India’s pharmaceutical and biopharma sectors. The new Agilent Biopharma Experience Centre in Hyderabad presents a major opportunity to accelerate the city’s leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs. “India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,” said Padraig McDonnell, CEO, Agilent Technologies. “Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the ‘Make-in-India’ initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.” The centre is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine. Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, “Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India’s leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India’s pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Centre is a significant milestone in strengthening Telangana’s position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.”   ]]> https://biospectrumindia.com/news/109/26348/sai-parenterals-secures-rs-50-cr-equity-investment-from-marquee-investors.html https://biospectrumindia.com/news/109/26348/sai-parenterals-secures-rs-50-cr-equity-investment-from-marquee-investors.html Tue, 08 Jul 2025 00:00:00 +0530 Hyderabad-based Sai Parenterals has announced the successful completion of a Rs 50 crore equity investment round by a group of marquee investors. The capital will support the company’s growth plans for establishing its international footprint as it pursues its vision to become a global pharmaceutical company. Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital led the fundraising round.  Anil Karusala, Managing Director of Sai Parenterals, remarked, "We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. This equity infusion will allow us to acquire high-potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities. We are honoured by the confidence of such professional investors in our company’s strategy and future. Sandeep Shenoy, Managing Partner of Samarsh Capital, commented, "Our investment in Sai Parenterals reflects our confidence in its solid fundamentals, scalable model, and potential to achieve strong growth in the global pharmaceutical sector. Under the visionary leadership of Anil, we expect Sai Parenterals to emerge as a leader in its segment." With two strategic business verticals—Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services—Sai Parenterals focuses on delivering value-added drug formulations. The company has built a diverse portfolio across dosage forms, including injectables, oral solids and liquids, and topical preparations. The company operates five facilities in India, of which some are approved by TGA Australia, GCC, SAPRA and WHO GMP, supporting a growing presence in both domestic and key international markets.   ]]> https://biospectrumindia.com/news/109/26233/bharat-biotech-to-advance-gsks-shigella-vaccine-development-for-severe-bacterial-diarrhoea.html https://biospectrumindia.com/news/109/26233/bharat-biotech-to-advance-gsks-shigella-vaccine-development-for-severe-bacterial-diarrhoea.html Thu, 12 Jun 2025 00:00:00 +0530 Hyderabad-based Bharat Biotech International Limited (BBIL) has partnered with GSK plc for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3. The agreement marks a critical step in the advancement of this promising vaccine, targeting Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results. It has already demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of 9-month-old infants. Now entering Phase 3 trials under Bharat Biotech’s leadership, altSonflex1-2-3 is poised to become the first scalable, affordable, and globally accessible vaccine to combat this urgent public health threat. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the Access and Delivery Plans and commercialisation strategy. GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system. This novel approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations.   ]]> https://biospectrumindia.com/news/109/26203/ikp-knowledge-park-inks-mou-with-bits-pilani-hyderabad-to-support-startups-.html https://biospectrumindia.com/news/109/26203/ikp-knowledge-park-inks-mou-with-bits-pilani-hyderabad-to-support-startups-.html Wed, 04 Jun 2025 00:00:00 +0530 IKP Knowledge Park had announced the signing of a Memorandum of Understanding (MoU) with BITS Pilani Hyderabad Campus TBI Society (TBIS) — a strategic collaboration to strengthen the innovation and technology transfer ecosystem. Through this partnership, IKP PRIME, the Technology Transfer Office at IKP, will spearhead efforts in: IP Protection & Filing Support: Customised assistance for filing patents, trademarks, and designs. Technology Transfer & Licensing: Guidance for commercialisation and establishing market linkages. IP & Innovation Policy Guidance: Support for students to align with institutional entrepreneurship policies and frameworks. Startup–Faculty Collaboration: Facilitation of partnerships between startups and faculty. Industry Linkages: Enabling industry collaborations and networking opportunities. Capacity Building: Conducting workshops, mentorship programs, and expert-led training sessions. Together, both IKP and BITS Pilani aim to empower researchers, startups, and innovators with the tools and support needed to bring groundbreaking ideas to market. This MoU marks a significant step in their shared mission to foster a dynamic, collaborative, and sustainable innovation ecosystem. ]]> https://biospectrumindia.com/news/109/26180/mapmygenome-goes-global-with-acquisition-of-microbiome-insights-.html https://biospectrumindia.com/news/109/26180/mapmygenome-goes-global-with-acquisition-of-microbiome-insights-.html Thu, 29 May 2025 00:00:00 +0530 Hyderabad-based Mapmygenome, an artificial intelligence (AI)-driven leader in genomics and personalised health, has announced the strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition includes Microbiome Insights’ CAP-accredited Canadian laboratory and rich intellectual property, boosting Mapmygenome’s scientific prowess and enabling its global expansion. Having supported over 600 global clients with 1,000+ cutting-edge microbiome studies, Microbiome Insights is a leading partner for academic, clinical, and industry researchers. Microbiome Insights will maintain its role as a premier contract research organisation (CRO), empowering global research. Simultaneously, Mapmygenome will introduce its integrated genomics and microbiome testing services to North America, making holistic, data-driven health solutions more accessible. “The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors,” declared Anu Acharya, Founder and CEO of Mapmygenome. “This accelerates our North American footprint aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year” “The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients worldwide,” said Malcolm Kendall, CEO of Microbiome Insights. ]]> https://biospectrumindia.com/news/109/26133/bharat-biotechs-oral-cholera-vaccine-demonstrates-success-in-ph-iii-clinical-studies.html https://biospectrumindia.com/news/109/26133/bharat-biotechs-oral-cholera-vaccine-demonstrates-success-in-ph-iii-clinical-studies.html Wed, 21 May 2025 00:00:00 +0530 Hyderabad-based Bharat Biotech’s Oral Cholera Vaccine Hillchol® has demonstrated success against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective oral cholera vaccine (OCV). The study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol® in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India. In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomised in a 3:1 ratio to receive either Hillchol® or a comparator vaccine. The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety. Hillchol® demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines. Adverse events were mild and comparable between the two vaccines. Dr Krishna Ella, Executive Chairman of Bharat Biotech said, “Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol®, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.” Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol®. ]]> https://biospectrumindia.com/features/109/26111/biomatiq-inaugurates-state-of-the-art-fully-automated-production-line-for-ready-to-use-culture-media-in-hyderabad.html https://biospectrumindia.com/features/109/26111/biomatiq-inaugurates-state-of-the-art-fully-automated-production-line-for-ready-to-use-culture-media-in-hyderabad.html Thu, 15 May 2025 00:00:00 +0530 The grand ceremony featured a ribbon-cutting by K.V.G.K. Raju, an esteemed figure, known for his immense contributions to the scientific and industrial domains. The momentous ribbon-cutting was followed by the ceremonial lighting of the inauguration diya, signifying a bright and prosperous beginning for this new phase in BiomatiQ’s journey. The diya was lit by K.V.G.K. Raju, along with Pavan Kumar, Natarajan, Jean-Francois Jochim from Biokar Diagnostics, Rakesh Aggarwal and Omkaranath, symbolizing unity, collaboration, and enlightenment. The presence of respected dignitaries and industry leaders added gravitas to the event, highlighting the importance of this new facility not only for BiomatiQ but for the life sciences eco-system. A Facility Built on Quality and Compliance BiomatiQ's new greenfield facility has been meticulously designed with a strong foundation in Quality by Design (QbD) principles. The infrastructure supports unidirectional men and material flow, ensuring minimal risk of cross-contamination. At the heart of the facility lies a Grade A/B cleanroom, dedicated to the aseptic filling of RTU media. Every component and layout decision has been made to comply with cGMP and WHO standards. The seamless integration of design, compliance, and technology ensures not just regulatory adherence, but also operational excellence. BiomatiQ’s investment in this facility reflects its commitment to raising the bar for quality in the Indian manufacturing landscape. Automated Processes for Enhanced Quality The centrepiece of the facility is a fully automated, Grade A aseptic filling line, built to deliver high-precision, contamination-free RTU culture media. The production workflow includes fully automated plate loading, stacking, silica sachet application, gamma label application, triple wrapping, and packaging. All plates undergo gamma irradiation, followed by 100% batch incubation and visual inspection, ensuring only products that meet the highest quality standards are dispatched to customers. This rigorous and automated process reduces human intervention, thereby minimizing contamination risk and improving batch-to-batch consistency—a key requirement for customers in regulated industries like pharmaceuticals, biotechnology, and healthcare. Advanced Equipment for Smart Manufacturing The facility is equipped with cutting-edge equipment, including filling lines, media preparation and sterilization vessels, incubators, and autoclaves, all of which are 21 CFR Part 11 compliant. This ensures secure, electronic records and controlled access to critical systems. Each system is integrated with a centralized data acquisition setup for timely monitoring and analysis, allowing for proactive quality control, assurance and trending. The equipment is designed to support the company's commitment to quality, regulatory compliance and traceability. State-of-the-Art Contract Testing Laboratory In addition to the production line, BiomatiQ is also setting up a state-of-the-art contract testing laboratory for microbiology testing. The laboratory will cater to the testing requirements of the pharmaceutical, biopharma, and food industries, with services aligned to national and international standards. What sets this lab apart is its planned adoption of  Rapid Microbiological Methods (RMM), enabling faster turnaround times, enhanced traceability, and better compliance with regulatory expectations. The lab will also offer routine testing, environmental monitoring services, and validation studies for manufacturing clients. Bridging the Academia-Industry Gap Beyond its production and testing capabilities, BiomatiQ is committed to bridge the gap between academia and industry. BiomatiQ plans to offer training programs, imparting essential skills to industry entrants and aspiring students. By doing so, BiomatiQ aims to foster a new generation of professionals equipped with the knowledge and expertise required to excel in the life sciences industry. These training programs empower aspirants to meet and exceed expectations, transitioning seamlessly from classroom learning to cleanroom applications. Building a Complete Life Science Business Eco-System BiomatiQ is creating a comprehensive life science ecosystem. From product distribution and manufacturing to testing and training, the company provides a one-stop solution for researchers, manufacturers, students, and regulatory bodies. This integrated model is designed to bring synergies across the value chain, improving efficiency, reducing dependency on imports, and enabling innovation at every level. In doing so, BiomatiQ is opening infinite possibilities for collaboration, advancement, and sustainable growth. Strengthening India's Life Sciences Sector With this new facility and laboratory, BiomatiQ is poised to become a significant player in the life sciences industry. The company's aim is to produce high-quality products and services that meet international standards, with a strong focus on regulatory compliance and robust Quality Management Systems (QMS). Directors' Vision Omkaranath B., the founding director and Rakesh Aggarwal (director), bring extensive industry experience to BiomatiQ. With a strong background in microbiology and technical expertise, they have built a team with the technical know-how to handle daily operations efficiently. The company's focus on quality, compliance, and customer satisfaction is a reflection of its founding directors' vision. The inauguration of BiomatiQ's state-of-the-art facility marks a significant milestone in the company's journey. With its commitment to quality, compliance, and building a complete life science business eco-system, BiomatiQ is well-positioned to become a leading player in the global life sciences industry. Looking Ahead The inauguration of this state-of-the-art facility is more than a celebratory event—it is a powerful statement of intent. BiomatiQ is ready to lead the change in how life science products are manufactured, tested, and delivered. As the diya was lit and the facility officially came to life, it is the dawn of a new era for BiomatiQ. An era defined by automation, compliance, innovation, and above all, a commitment to quality.   For more details contact : Toll free : 1800 571 9696 Email : contact@biomatiq.com Website : www.biomatiq.com ]]> https://biospectrumindia.com/news/109/26113/enliva-announces-launch-of-accelerator-free-nitrile-gloves-for-safety-of-healthcare-workers.html https://biospectrumindia.com/news/109/26113/enliva-announces-launch-of-accelerator-free-nitrile-gloves-for-safety-of-healthcare-workers.html Thu, 15 May 2025 00:00:00 +0530 Hyderabad-based Wadi Surgicals, India’s foremost manufacturer of nitrile gloves, has announced a major innovation milestone with the launch of accelerator-free nitrile gloves under its flagship brand Enliva. Developed through intensive R&D and global collaboration, these gloves are India’s first accelerator-free nitrile gloves, representing a leap forward in skin-safe, allergy-free hand protection. This innovation eliminates the use of common chemical accelerators such as thiurams, carbamates, and MBTs compounds known to cause allergic contact dermatitis (Type IV hypersensitivity) among frequent glove users. The gloves are manufactured using alternative non-sensitizing crosslinking agents and have been rigorously tested for dermatological safety, mechanical strength, and chemical resistance. Speaking on the occasion, Anindith Reddy, Managing Director of Wadi Surgicals said “With this launch, we are proud to bring Indian glove manufacturing to the forefront of global innovation. Accelerator-free nitrile gloves are no longer a luxury reserved for global brands - we are making them accessible and affordable. This product not only addresses a critical health concern for healthcare workers and industrial users but also reinforces our commitment to safe, high-performance, and sustainable glove solutions.” The gloves are certified under EN 455, EN ISO 374, ISO 13485:2016, and REACH-compliance frameworks, and are suitable for use in hospitals, cleanrooms, biotech labs, food processing, and electronics manufacturing. The Enliva Accelerator-Free range will be available across multiple variants: Enliva Pro – BIS-Compliant Medical Gloves Enliva Premium Nitrile Gloves – ASTM Standard Examination Gloves Enliva QuickDraw – Multipurpose Disposable Gloves Enliva UrbanShield – Food-Grade Gloves  ]]> https://biospectrumindia.com/news/109/26121/hyderabad-emerges-as-one-of-the-top-global-centres-of-life-sciences-manufacturing-activity.html https://biospectrumindia.com/news/109/26121/hyderabad-emerges-as-one-of-the-top-global-centres-of-life-sciences-manufacturing-activity.html Thu, 15 May 2025 00:00:00 +0530 CBRE, world’s leading real estate consulting firm, has released its report, ‘Global Life Sciences Atlas,’ profiling some of the world’s most important life sciences hubs—traditional and emerging- and examining investment and construction trends impacting the life sciences industry.  The growing prominence of the life sciences industry has significantly impacted the growth of real estate development globally, with more than 35 million sq. ft. of lab/research and development (R&D) properties under construction last year. While US markets top the world’s largest life sciences R&D centres, other mainstays can be found in Asia-Pacific (Hyderabad, Beijing, Shanghai, Greater Tokyo), Canada (Toronto, Montreal) and Europe (Cambridge, U.K., Paris). As per the findings, Hyderabad emerged as a prominent global centre of life sciences manufacturing activity in India. In the APAC region life sciences landscape, India has a leading position, driven by the expansion of pharmaceutical, biotech and medical devices companies. The report points out that Hyderabad is the key contributor and largest life sciences manufacturing and R&D cluster, undertaking research, training, and manufacturing. The city accounts for nearly one-third of the country’s pharmaceutical production, one-fifth of its pharmaceutical exports, and one-third of global vaccine output. Gross office leasing space by life sciences firms in India increased by ~56% Y-o-Y to about 5.8 million sq. ft., witnessing the highest-ever leasing activity by the sector. This growth has been driven by several factors, including increased foreign direct investment (FDI), enhanced manufacturing capabilities, a cost-effective talent pool, greater emphasis on R&D, and demographic trends such as a rising population and increasing life expectancy.  This momentum is being further reinforced by the Government of Telangana through progressive governance and strategic public-private partnerships. The recently launched Life Sciences Policy 2023–2028 offers a range of fiscal incentives and ready-to-use infrastructure to attract investment. Mega projects such as Hyderabad Pharma City—envisioned as the world’s largest integrated pharma cluster—and the Medical Devices Park are further cementing the city’s leadership as a comprehensive, end-to-end life sciences powerhouse. As per the report, innovation, evolving healthcare needs, and demographic shifts are driving increased demand across the pharmaceutical, biotech, and med-tech industries. Globally, leading hubs such as Boston-Cambridge, the San Francisco Bay Area, Beijing, Shanghai, and Cambridge (UK) are shaping the next wave of life sciences growth. In the Asia-Pacific region, Beijing, Shanghai, Singapore, and Greater Tokyo have emerged as the largest markets for life sciences labs and R&D space.   Looking ahead, India’s life sciences sector is on a clear trajectory of accelerated growth, powered by a convergence of strategic policy frameworks, rising global demand, and innovation-led development. Hyderabad’s continued expansion of integrated life sciences infrastructure, coupled with India’s growing presence in the global supply chain, positions the country to play a defining role in shaping the next decade of healthcare and biotech innovation. As new clusters emerge and existing ecosystems mature, India is set to become a global benchmark for end-to-end life sciences excellence, from research to large-scale manufacturing. ]]> https://biospectrumindia.com/news/109/26099/redversity-and-aihsm-roll-out-healthcare-programmes-for-aspiring-professionals-in-hyderabad.html https://biospectrumindia.com/news/109/26099/redversity-and-aihsm-roll-out-healthcare-programmes-for-aspiring-professionals-in-hyderabad.html Fri, 09 May 2025 00:00:00 +0530 In a strategic move to equip students with job-relevant skills and close the critical talent gap, RedVersity, the academic and skilling arm of RED Health, has partnered with the Asian Institute of Health Sciences and Management to launch nine specialised programmes in Hyderabad. These programmes are designed to shape the next generation of healthcare professionals through a blend of academic rigor and real-world application. With a combined annual intake of more than 500 students, the offerings include B.Voc., M.Voc., Diploma, Advanced Diploma, Postgraduate in Management, Executive Postgraduate Program in Management, PG Diploma, and Physician Assistant programmes. Admissions have officially opened, and classes are scheduled to begin in mid-August at the Hyderabad campus. At the core of these programmes lies a curriculum aligned with real-time industry needs. Students can specialise in key disciplines such as Emergency Medicine, Cardiac Care Technology, Cardiovascular Technology, Respiratory Therapy, and several others that are essential to modern healthcare delivery. These high-demand focus areas reflect the commitment of both institutions to address the most pressing clinical skill gaps in India and abroad. The curriculum emphasises practical, hands-on learning with simulation-based training. This approach ensures that students develop the critical thinking and clinical skills required to perform effectively in high-stakes healthcare environments. Every enrolled student will benefit from guaranteed internships and assured placements, reflecting the deep industry alignment embedded in the programme design.   ]]> https://biospectrumindia.com/news/109/25990/collaborative-ai-research-labs-foundation-joins-hands-with-atal-incubation-centre-ccmb.html https://biospectrumindia.com/news/109/25990/collaborative-ai-research-labs-foundation-joins-hands-with-atal-incubation-centre-ccmb.html Tue, 15 Apr 2025 00:00:00 +0530 Collaborative AI Research Labs Foundation (CAiRL) has announced the signing of a Memorandum of Understanding (MoU) with Atal Incubation Centre - CCMB (Cellular and Molecular Biology), a Hyderabad-based incubation centre focused on deep tech and biotech innovation. The MoU was signed by Sarvesh Singh (Director General, CAiRL) and Dr N. Madhusudhan Rao (CEO, AIC-CCMB). This collaboration is a significant step toward building a thriving innovation ecosystem at the intersection of Artificial Intelligence and Life Sciences. Through this partnership, CAiRL and AIC-CCMB will co-develop programmes that enable AI-driven research, support startup incubation, and nurture cross-disciplinary innovation. The shared vision is to accelerate scientific discovery and translational research by enabling bio-entrepreneurs and researchers to access cutting-edge AI tools, mentorship, and global exposure. The key focus areas include AI for genomics, drug discovery, and diagnostics; Startup acceleration in biotech and healthtech domains; Joint workshops, fellowships, and research grants; Collaborative projects that integrate data science and molecular biology. ]]> https://biospectrumindia.com/news/109/25939/aic-t-hub-launches-5th-cohort-of-healthcare-programme-to-nurture-startups.html https://biospectrumindia.com/news/109/25939/aic-t-hub-launches-5th-cohort-of-healthcare-programme-to-nurture-startups.html Fri, 04 Apr 2025 00:00:00 +0530 Hyderabad-based T-Hub, one of the world’s leading startup incubators, in collaboration with Atal Innovation Mission (AIM) has announced the launch of the 5th cohort of AIC T-Hub Healthcare Programme. The programme has selected 20 promising startups from a competitive pool of over 209 applications. This three-month hybrid programme is designed to accelerate innovation in medtech, digital health, and healthcare accessibility by providing startups with mentorship, market access, investor engagement, and regulatory guidance. Among the selected startups are Artyem Care, Bioscafil, Chqup, Cloud Palliative Care, Dag2IL, Epirelief, Dr. DICOM (GLOCAL DIGITAL), Kashi Medicos, Nahush Pharma, Oui Medical, Planytics, Reyansh Technologies, Sigma Mozak, Signel Biomedical, Skinska, Tap Health, thebabyland, TurocratesAI, 365Veda, and Warkas. These startups were selected based on their proof-of-concept readiness, technological innovation, regulatory compliance preparedness, market potential, and the strength of their founding teams. Throughout the programme, they will benefit from one-on-one mentorship with industry veterans, strategic introductions to hospitals and corporates, and exclusive investor networking opportunities to help secure funding and business collaborations. Through this programme, startups will gain access to leading hospitals and healthcare institutions for real-world validation and pilot studies, ensuring their solutions are market-ready and clinically viable. They will also receive expert guidance on navigating domestic and international healthcare regulations, which is critical for scaling in a highly regulated industry. Additionally, by engaging with venture capitalists, healthcare firms, and policymakers, startups will have opportunities to forge strategic partnerships and secure funding. Market access will be a key focus, with curated introductions to hospitals, corporates, and healthcare organizations that can facilitate growth and adoption of innovative solutions. The programme also aims to onboard one or two international startups to introduce them to India’s healthcare ecosystem, fostering cross-border innovation. Additionally, AIC T-Hub is building a robust network of doctors, hospitals, and sector-focused investors to support startup success. The programme will conclude with a Demo Day & Investor Connect in June 2025, where participating startups will present their solutions to industry leaders and potential investors.   ]]> https://biospectrumindia.com/news/109/25916/care-hospitals-launches-ai-powered-non-invasive-therapy-in-telangana-andhra-pradesh.html https://biospectrumindia.com/news/109/25916/care-hospitals-launches-ai-powered-non-invasive-therapy-in-telangana-andhra-pradesh.html Tue, 01 Apr 2025 00:00:00 +0530 CARE Hospitals, a renowned healthcare provider, has announced the launch of an artificial intelligence (AI)-powered, non-invasive therapy programme in collaboration with JOGO Health. This pioneering initiative in Telangana and Andhra Pradesh, offering protocol-based, non-invasive treatment pathways for patients with complex neurological, urological, and gastroenterological conditions.   Developed in the US by a Johnson & Johnson JLABS-incubated company, JOGO Health integrates patented wearable EMG sensors, artificial intelligence, and real-time biofeedback to stimulate neuroplasticity and aid patients in regaining lost muscle function. Clinically validated through research collaborations with Harvard Medical School and the Mayo Clinic, this cutting-edge technology is already in use at top medical centers across the US, Canada, and Asia.   Dr Nikhil Mathur, Group Chief of Medical Services, CARE Hospitals, emphasised the significance of this initiative, stating, “This collaboration with JOGO Health marks a significant advancement in patient care. By leveraging AI-powered therapy, we are introducing a revolutionary treatment option that is non-invasive, effective, and accessible to patients with chronic neurological, urological, and gastroenterological conditions.”   Biju Nair, Zonal COO, CARE Hospitals, added, “At CARE Hospitals, we are committed to bringing the latest medical innovations to our patients. The integration of JOGO Health’s AI-driven therapy into our treatment protocols represents a paradigm shift in rehabilitation and recovery, reducing dependency on invasive procedures and improving overall patient outcomes.”   Siva Nadarajah, Co-founder and President of JOGO Health, shared his enthusiasm for the collaboration, saying, “JOGO Health is proud to partner with CARE Hospitals to introduce this groundbreaking AI-powered therapy in India. With our clinically validated technology, we are confident that this program will significantly enhance patient recovery and quality of life.”  ]]> https://biospectrumindia.com/news/109/25919/ankura-hospitals-secures-rs-165-cr-funding-from-asian-development-bank.html https://biospectrumindia.com/news/109/25919/ankura-hospitals-secures-rs-165-cr-funding-from-asian-development-bank.html Tue, 01 Apr 2025 00:00:00 +0530 Hyderabad-based Ankura Hospitals, a leading healthcare provider specialising in super-specialty tertiary and quaternary care services for women and children, has secured Rs 165 crore in funding from the Asian Development Bank (ADB). This strategic investment will support Ankura's ambitious expansion plans and is aligned with its long-term vision to strengthen its market presence and enhance healthcare accessibility across India.   As part of its expansion strategy, Ankura Hospitals is focused on establishing new state-of-the-art facilities in key cities across India. Ankura Hospitals specialises in providing world-class care in maternity and gynecology, offering services such as normal deliveries, cesarean sections, fertility treatments, high-risk obstetrics, and comprehensive prenatal and postnatal care. The hospital also features advanced surgical solutions in gynecology, including laparoscopic surgeries and treatment for various gynecological conditions. Also, Ankura Hospitals is providing world-class services, including advanced neonatal intensive care, all paediatric subspecialties, pediatric surgery, child development, and behavioral health for children. With the support from ADB, Ankura Hospitals is poised to enhance its facilities, broaden its impact, and continue delivering exceptional care across India.   ]]> https://biospectrumindia.com/views/109/25894/we-aim-to-position-india-as-a-leader-in-personalised-medicine-and-drive-future-innovations-.html https://biospectrumindia.com/views/109/25894/we-aim-to-position-india-as-a-leader-in-personalised-medicine-and-drive-future-innovations-.html Mon, 31 Mar 2025 00:00:00 +0530 Congratulations on the launch of the Miltenyi Innovation Technology Centre (MITC)! What inspired the creation of this facility at Genome Valley, Hyderabad? Thank you. Miltenyi Biotech has been pioneering CGT for over 35 years, starting with a small cell separator and growing into a leader in innovation. Recognising India's potential in advanced medical treatments, we saw the need to educate researchers and partners on specialised equipment and evolving therapies. This led to the establishment of a state-of-the-art training centre in Hyderabad, where scientists from India and beyond can gain hands-on experience. Our goal is to provide comprehensive training, enabling researchers to advance CGT. By offering access to cutting-edge equipment and expertise, we aim to position India as a leader in personalised medicine and drive future innovations in this field. What new technologies are you bringing to India? Could you elaborate on some of the key technologies that make your centre a leader in CGT?  Our centre is equipped with the newest and most advanced machines for CGT. One of our key pieces of equipment is the Prodigy. It's the size of a large microwave; and it’s a fully automated system that can take cells, process them, and create a new finished product or a new cell. Scientists can programme the machine with specific instructions and ingredients to make therapies like CAR T cells, T cells, or other cells that help patients fight cancer using this advanced technology. Right now, we're focused on cancers that affect the blood, like leukemia and lymphoma, but we're also exploring other possibilities. We also have other machines that help scientists with specific tasks. For example, the CliniMACS Prodigy is excellent for separating cells, which is a very technical process. Once a scientist isolates a cell, they need to figure out what type of cell it is and how many they have. Our machines help them do this accurately and precisely. We're also introducing new technologies like Taito and Blaze. Blaze is a revolutionary machine for spatial biology. Imagine being able to see inside a living organism, like a rat or mouse, as if you were walking through it. This machine allows scientists to see exactly how molecules work, which cells are affected, and what treatments might be effective. These machines will be available in India very soon, as we're committed to giving Indian scientists access to the latest global advancements. You mentioned presenting CAR T-cell therapy at a medical conference. Beyond that, what are the primary research areas you're focusing on in India? Currently, we haven't launched any CGTs for sale in India or anywhere else in the world. However, we are working on bringing CAR T-cell therapy to market, which we recently presented at a major medical conference. In India, we're working closely with universities and research institutions to help them develop cell therapies that are specifically designed to treat Indian patients. Our research mainly involves partnering with academic and private organisations that are interested in pushing the boundaries of CGT. We're providing training to researchers and scientists to help them understand and use our technologies effectively. We are focused on providing them with the tools and knowledge to advance their own research and develop new treatments. We are dedicated to supporting the development of innovative therapies that can improve the lives of patients in India and around the world. How do you foresee the future of CGT in India? The future of CGT in India looks very promising. This field is expanding rapidly worldwide, and India is catching up quickly. Experts predict the global market for CGT will surpass $100 billion within the next three to four years. In India, which is a relatively new player in this area, the market is expected to reach around $600 to $700 million during the same period. We're seeing a lot of interest from pharmaceutical companies and academic institutions in India, all of whom are starting to explore personalised medicine. Places like Genome Valley in Hyderabad are clear examples of this growing interest. The Indian government, both at the state and central levels, is also actively supporting this growth through new policies. The progress we've seen in the last five years has been remarkable, and we anticipate even greater advancements in the next five years. The cost of CGT is a concern. How is Miltenyi Biotech working to reduce costs and make it more accessible? It's important to consider the value that CGTs provide, rather than just focusing on the cost in isolation. These therapies are often used to treat patients with very difficult conditions, like relapsed or refractory cancers, and research is expanding to cover solid tumors and neurological disorders. Our primary goal is to save lives. To make these therapies more accessible, we are exploring partnerships to develop appropriate pricing models. While our costs in India are lower compared to places like the US, Japan, and Europe, it's important to understand that these therapies won't be as inexpensive as generic medications. We are working to find a balance between providing value and ensuring accessibility. CGT, as a new treatment segment, has regulatory challenges. How do you view these? The Indian government is being very proactive in creating regulations for CGT. Of course, there are challenges, as everyone is learning together, but we are seeing strong support from both state and central governments. We are confident that the regulatory framework will become more established and solidified soon. Boris Stoffel, Global CEO of Miltenyi Biotech, spoke about the "democratisation" of CGT. What does that mean? Democratisation, in this context means making CGT accessible to more people. Our presence in India is focused on ensuring that these therapies are available to those who need them. We are creating an outreach programme to reach patients where they are, and we are partnering with academic institutions and hospitals to provide access to every deserving patient, regardless of their ability to pay. What distinguishes Miltenyi Biotech India from other players in the CGT sector? What unique value does it bring to the Indian market? Miltenyi Biotech India's unique selling proposition (USP) is deeply rooted in the cultivation of local expertise and the fostering of a collaborative ecosystem within the Indian CGT landscape. We recognise a remarkable abundance of skill and an insatiable thirst for knowledge across India's private, public, and academic institutions. This forms the bedrock of our strategy. Essentially, we are positioning ourselves as the premier partner in developing a highly skilled workforce within this specialised field.    Amguth Raju ]]> https://biospectrumindia.com/news/109/25832/tenthpin-launches-ai-labs-tail-in-hyderabads-life-sciences-hub.html https://biospectrumindia.com/news/109/25832/tenthpin-launches-ai-labs-tail-in-hyderabads-life-sciences-hub.html Fri, 14 Mar 2025 00:00:00 +0530 Switzerland based Tenthpin Management Consultants, a global consulting leader in technology advisory for life sciences companies, has announced the launch of Tenthpin AI Labs (TAIL) in Hyderabad, establishing a Global Centre of Excellence dedicated to AI-driven transformation in Life Sciences. TAIL's mission is to help pharmaceutical, MedTech, biotech, and research organisations distinguish between AI hype and accomplishing real value. By leveraging India's tech talent and Hyderabad's position as a life sciences hub, Tenthpin aims to support companies in accelerating AI adoption across the drug life cycle, from R&D to better patient outcomes. The facility at HITEC City was inaugurated by Jayesh Ranjan, Special Chief Secretary, Information Technology, Electronics & Communications (ITE&C) and Industries & Commerce, Govt of Telangana in the presence of Bart Reijs, Director, Tenthpin; Thomas Weber, Partner & Chief Product Officer, Tenthpin and Raghuram Janapareddy Partner & Managing Director, Tenthpin India. Tenthpin Solutions, a group company of Tenthpin is also expanding its footprint in India. Speaking on this occasion, Thomas Weber, Partner & Chief Product Officer added "Tenthpin develops new solutions under co-innovation model, jointly with the industry. Adding local talent to our development teams, coupled with AI Labs, we are far more closure to the Indian Market to develop solutions tailored to local companies." TAIL will provide expertise in integrating AI with underlying ERP systems and numerous other solutions, enabling seamless data flow and enhanced insights for improved decision-making. The lab will also collaborate with local research institutions, universities, and industry partners to drive advancements in AI for Life Sciences in India. Eckhard Drager, Founder and Member of the Executive Board of Tenthpin, says “Unlike traditional software tools implementation, AI adoption throws new challenges. There will be a need for new methodologies, new data governance models, new change management approaches etc. Tenthpin already has a tailored methodology covering all these aspects.” ]]> https://biospectrumindia.com/news/109/25828/telangana-government-to-unveil-new-life-sciences-policy.html https://biospectrumindia.com/news/109/25828/telangana-government-to-unveil-new-life-sciences-policy.html Thu, 13 Mar 2025 00:00:00 +0530 Telangana is set to launch a dedicated Life Sciences policy in the coming weeks, marking a significant step towards strengthening the state’s leadership in the sector. The announcement was made by Jayesh Ranjan, Special Chief Secretary, Department of Industries, IT, Electronics, and Communications, during the launch of Tenthpin’s new Life Sciences facility in Hyderabad. Speaking at the event, Jayesh Ranjan stated that the upcoming policy will chart a bold new growth path for Telangana's Life Sciences industry. It will drive advancements in emerging domains such as cell and gene therapy, genomics, biologics, precision medicine, peptides, digital innovation, and advanced R&D. “Hyderabad has emerged as a global leader in Life Sciences and Pharmaceuticals, with over 1,800 pharma manufacturing units and the world’s largest vaccine manufacturing hub. The city is home to seven out of the top 10 global life sciences companies. The new policy will further position Telangana at the forefront of cutting-edge innovation,” he said. Highlighting the growing importance of Cell and Gene Therapy (CGT), Ranjan noted that this next-generation treatment has the potential to cure rare and severe diseases like cancer. Telangana's new Life Sciences Policy will offer strong support for this sector, encouraging research and investment. The government is also leveraging Hyderabad’s thriving innovation ecosystem, which includes 24 innovation spaces like T-Hub, to foster AI-driven advancements in Life Sciences.   Overall, with the upcoming Life Sciences policy, Telangana aims to further solidify its position as a global leader in biotechnology, pharmaceuticals, and AI-driven healthcare innovations. ]]> https://biospectrumindia.com/news/109/25818/red-health-opens-global-centre-of-excellence-in-allied-healthcare-education.html https://biospectrumindia.com/news/109/25818/red-health-opens-global-centre-of-excellence-in-allied-healthcare-education.html Tue, 11 Mar 2025 00:00:00 +0530 Marking a bold step toward reshaping allied healthcare education, Hyderabad-based startup RED Health, Asia’s only JCI-accredited and India’s largest emergency medical care company, has introduced its dedicated education and training arm, RedVersity. This initiative is set to redefine emergency medicine and pre-hospital care training by equipping professionals with advanced skills and industry-leading expertise, addressing critical gaps in the healthcare sector. As the demand for skilled healthcare professionals continues to rise, RedVersity aims to empower aspiring medical professionals, working clinicians, and corporate partners through a diverse range of globally accredited programmes. These programmes, delivered through the recently acquired RED TACT Academy for Clinical Training, will provide internationally recognized certifications such as Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and Pediatric Advanced Life Support (PALS) from the American Heart Association (AHA) as well as Advanced Trauma Life Support (ATLS) from the American College of Surgeons (ACS). In addition to short-duration certifications, RedVersity will offer medium-duration industry readiness programs, including EmergePro, a specialized finishing school designed to prepare undergraduate and postgraduate students for careers in emergency medical services and allied healthcare. The training portfolio will also include long-term academic collaborations with leading universities and institutions in India, integrating clinical exposure with academic excellence. Large-scale industrial safety programmes will further enhance workplace emergency preparedness, while a dedicated global workforce mobility initiative will open international career opportunities for healthcare professionals.   ]]> https://biospectrumindia.com/news/109/25756/bio-asia-2025-recognises-5-startups-for-groundbreaking-innovations-in-life-sciences-landscape.html https://biospectrumindia.com/news/109/25756/bio-asia-2025-recognises-5-startups-for-groundbreaking-innovations-in-life-sciences-landscape.html Thu, 27 Feb 2025 00:00:00 +0530 Out of 84 startups shortlisted for Bio Asia 2025, top 5 most innovative startups were recognised for their groundbreaking innovation in the life sciences landscape. The winners were selected by an esteemed panel of industry experts. The startups receiving the award were: 1.SemGenome (its flagship platform enables labs, hospitals, clinicians and pharma companies with precision variant analysis for clinical insights) 2.Genica Bioscience (Focused on developing research tools, diagnostics, and therapeutic proteins) 3.ProEnz Biosciences (Working in cancer diagnostics kits for PCR technique on breast, colon and lung cancers) 4.Boltzmann Labs (Revolutionising AI-driven drug discovery with advanced platforms for small molecules, protein engineering, and clinical trial optimisation) 5.Utopia Therapeutics (Utopia's vaccine is designed to provide help to several million patients with a first of it’s kind approach to disease management)   D. Sridhar Babu, Minister of Industries and Commerce, Government of Telangana said, “In Telangana we are committed to skilling and workforce development and will ensure that our talent pool is future-ready to lead the next wave of biotech and HealthTech innovation. We are proud to announce the successful completion of our synthetic organic chemistry batch, under the skilling initiative by C4IR Telangana. Some socio-economic statistics of our program -82% of the students are female with 60% of them have completed their schooling in tier 2 and 3 cities or villages.This programme provides them with a valuable opportunity to advance their careers and improve their socio-economic status. This was made possible with the support of 4 industry partners - Syngene, Aragen, Sai Lifesciences and Aurigene."   ]]> https://biospectrumindia.com/news/109/25743/telangana-government-signs-mous-with-11-companies-for-green-pharma-city-project.html https://biospectrumindia.com/news/109/25743/telangana-government-signs-mous-with-11-companies-for-green-pharma-city-project.html Wed, 26 Feb 2025 00:00:00 +0530 The 22nd edition of BioAsia 2025, Asia’s largest life sciences and healthcare conference, themed ‘Catalysts of Change – Expanding Global Healthcare Frontiers, Transforming Healthcare with Innovation, Collaboration and Progress’ was inaugurated by A Revanth Reddy, Chief Minister of Telangana; Dr Jeannette Young, Governor of Queensland, and D Sridhar Babu, Minister for Industries and Commerce, Government of Telangana along with other dignitaries, on 25th February. Pharma MoUs were signed for the Green Pharma City, a flagship initiative of the Government of Telangana during the event. Already 6 pharma companies have signed MoUs with the government of Telangana with 11 more companies joining the initiative, as MoUs were signed with Granules, Orbicular, Aizant, Biological E, Virchow, Virupaksha, Jubilant, Vimta, Aragen, Bharat Biotech and Sai Life Sciences, bringing an investment of Rs 5445 crore, and creating 9800 new jobs. With these commitments, the total investment in Green Pharma City now stands at Rs 11,100 crore, with employment opportunities exceeding 22,300. A Revanth Reddy, Chief Minister of Telangana said, “We will develop Hyderabad and Telangana into one of the largest ecosystems for biosciences, biotech and life sciences innovation, R&D, manufacturing, skill development, and investment. We already have 160 Km outer ring road (ORR) and we are building a Regional Ring Road (RRR) of 360 Km outside the core urban area along with a network of radial roads connecting the two ring roads with radial roads and creating manufacturing hubs for pharma, EV’s data centres, green energy, seed manufacturing, agri-processing and other sectors. We are developing 10 pharma Villages between ORR and RRR which will generate over 5 lakh jobs. The Green Pharma city is also a key initiative under the Future City Project and is progressing rapidly. We have already signed 6 MoUs and signing another 11 MoUs today creating more jobs for the youth. We are all set to launch a new Life Sciences Policy which will chart a bold new growth trajectory for the sector. With this we will enter new domains such as cell and gene therapy, genomics, biologics, precision medicine, peptides, digital innovation, advanced R&D and complex manufacturing.” Sridhar Babu, Minister for Industries and Commerce, Government of Telangana, said, “We have witnessed several global life sciences companies open operations in the city  and have created more than 51,000 direct jobs and 1,50,000 indirect jobs over here.  We have inaugurated the Amgen’s largest innovation centre yesterday along with Miltenyi, cutting edge cell and gene therapy centre yesterday.    As we look to the future, our focus remains steadfast on skilling and workforce development.  We have established a skills university Young India Skills University  which will focus covering this gap. A key pillar in this mission is to establish a life sciences university which is progressing rapidly to equip Hyderabad workforce with industry relevant expertise. By collaborating closely with GCC Hyderabad we are designing a specialised curriculum in science and technology ensuring our talent remains globally competitive and Future ready. I am delighted to share the first batch of the chemistry skill programme successfully concluded this month. We are determined to insert Telangana into the global Pharma supply chain as a key player in terms of Bulk drug and also in generic pharma and be a world leader in the life sciences space.” ]]> https://biospectrumindia.com/news/109/25745/global-companies-to-open-new-centres-in-hyderabad-across-life-sciences-and-tech-sectors.html https://biospectrumindia.com/news/109/25745/global-companies-to-open-new-centres-in-hyderabad-across-life-sciences-and-tech-sectors.html Wed, 26 Feb 2025 00:00:00 +0530 A series of announcements were made by global companies that took part in the 22nd edition of BioAsia 2025, Asia’s largest life sciences and healthcare conference, themed ‘Catalysts of Change – Expanding Global Healthcare Frontiers, Transforming Healthcare with Innovation, Collaboration and Progress’. While MSD from US has announced the opening of a global tech centre in Hyderabad; US-based Agilisium, a company revolutionising pharma sector by leveraging data-driven insights, has launched its new office at RMZ Spire, Hyderabad. The company has also established a Life Sciences and Innovation & Talent Development Lab. On the other hand, ALS, an Australia-based global leader in testing, inspection, certification, and verification solutions, is establishing a state-of-the-art Bio Pharma cGMP testing lab in Genome Valley; and Taiwan-based company Lotus is setting up its 2nd R&D centre in Hyderabad. For Lotus, the new R&D centre will be located in Genome Valley, covering 20,000 square feet and employing around 100 people. The project will be developed in two phases, with the first phase expected to be operational by Q2 2025 and the second phase completed by Q4 2025. To facilitate this expansion, the company has established a new subsidiary called Meishi Pharma Services Private Ltd with an investment of Rs 36 crore. ]]> https://biospectrumindia.com/news/109/25730/biological-e-inks-strategic-partnership-with-bavarian-nordic-to-expand-access-of-chikungunya-vaccine.html https://biospectrumindia.com/news/109/25730/biological-e-inks-strategic-partnership-with-bavarian-nordic-to-expand-access-of-chikungunya-vaccine.html Tue, 25 Feb 2025 00:00:00 +0530 Hyderabad-based Biological E. Limited (BE) has announced a strategic partnership with Bavarian Nordic A/S (OMX: BAVA) to expand access to Bavarian Nordic’s Chikungunya Vaccine in low- and middle-income countries (LMIC). This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. To that effect, the companies have reached an agreement to expand their capacity to provide future supplies to endemic low- and middle-income countries. The initial technology transfer would be followed by regulatory approval applications and commencement of commercial manufacturing thereafter. BE's existing facilities in Genome Valley, Hyderabad will be augmented to make the Chikungunya Vaccine. The manufacturing of Chikungunya Vaccine at BE is expected to generate up to 300 new jobs. This agreement has come about as Bavarian Nordic continues to explore opportunities in line with its strategy to provide global access to its Chikungunya Vaccine via partners for markets outside the US and Europe. In February 2025, the US Food and Drug Administration (FDA) approved VIMKUNYA (CHIKV VLP) as the first chikungunya vaccine for persons as young as 12 years. An EU approval is pending decision from the European Commission following a recommendation in January 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).   ]]> https://biospectrumindia.com/news/109/25735/eleven-crdmos-collaborate-to-form-dedicated-industry-body-ipso.html https://biospectrumindia.com/news/109/25735/eleven-crdmos-collaborate-to-form-dedicated-industry-body-ipso.html Tue, 25 Feb 2025 00:00:00 +0530 In a step toward advancing Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector, eleven of the country’s leading CRDMO companies have come together to launch a dedicated industry body called Innovative Pharmaceutical Services Organization (IPSO), bringing together diverse expertise in discovery, development, biomanufacturing, and other specialized areas. The eleven CRDMO companies include Syngene, Aragen, Anthem Biosciences, Aurigene, Laxai, Piramal Pharma, Neuland, Sai Life Sciences, TCG Lifesciences and O2H Discovery. This collective initiative aims to advance India’s CRDMO sector and is dedicated to fostering pharmaceutical and healthcare innovation in India, that supports research, policy advocacy and industry collaboration to drive the next wave of biotech and pharma growth. A new report, Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organization (IPSO) at the ongoing BioAsia 2025 event in Hyderabad, states that the Indian CRDMO sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035. The report also reveals that India’s CRDMO sector must overcome five key challenges to sustain growth. It needs a 6-7x talent expansion by 2035, faster regulatory approvals and a stronger tier 1 supplier base to reduce import reliance. Limited funding and high capital costs hinder the 4-5x investment needed, while ESG compliance still lags behind Western peers. Peter Bains, CEO Designate, Syngene International Ltd. said, "The Indian CRDMO sector is positioned for major transformation, with the potential to become a leader in serving the global biopharma and wider life sciences outsourcing market models. Realizing this opportunity will require change and collaboration among all stakeholders in the Indian CRDMO ecosystem. We will also need to work with and collaborate with the Government to foster a more competitive regulatory and financial ecosystem in India to compete with other geographies. We will need to work with India’s academic ecosystem to ensure a strong flow of highly talented scientists, engineers and technology leaders to ensure we are capability competitive. Only by working together, can we unlock new opportunities in drug discovery, process innovation, and advanced manufacturing, that can strengthen India’s position in the global pharmaceutical value chain." Manni Kantipudi, CEO and Whole time Director, Aragen Life Sciences Ltd., added, "The shift in global pharma outsourcing, the rapid rise of biologics, and India’s expertise in chemistry and process innovation create a once-in-a-generation opportunity. However, to compete at a global level, Indian CRDMOs must not only scale capabilities in new modalities like ADCs, cell & gene therapies, and RNA therapeutics but also work together to build a resilient supply chain and streamline regulatory pathways. IPSO is committed to driving this change by working closely with stakeholders to improve access to capital, accelerate talent development, and champion policy initiatives that make India an even more attractive destination for pharmaceutical R&D and manufacturing. As an industry, we must come together to shape the future of Indian life sciences and secure our place at the forefront of global innovation” ]]> https://biospectrumindia.com/news/109/25717/novartis-picks-next-gen-innovators-paving-way-for-healthcare-breakthroughs.html https://biospectrumindia.com/news/109/25717/novartis-picks-next-gen-innovators-paving-way-for-healthcare-breakthroughs.html Sun, 23 Feb 2025 00:00:00 +0530 Novartis India, a focused innovative medicines company, successfully concluded the grand finale of NEST (Nurturing Excellence, Strengthening Talent) – a first-of-its-kind, real-world case-based competition focused on healthcare innovation. After months of rigorous competition and mentorship, the best minds in data science, artificial intelligence and clinical development came together to present their breakthrough ideas, aimed at reimagining medicine and improving patient care.  Sadhna Joglekar, Head, Development Hub, India, Novartis, reflected on the journey, stating: “NEST reflects our belief that fresh ideas, coupled with cutting-edge technology, and enriched by mentorship, can create transformative solutions to reimagine medicine and improve patient care. These past few months have been exhilarating, experiencing first-hand the energy, passion and ideas that the young, bright minds in India have to offer. I am confident that our winners represent the next generation of entrepreneurs in healthcare innovation in India.” The four winning teams (Team Echelon, VIIT Pune; Team BITSoM, Mumbai; Team Moneeshb8 from IIM Calcutta; and Team BioLogits from IIT Kharagpur), recognised for their ingenuity, technical excellence, and real-world impact, were awarded from the Rs 8,00,000 prize pool and secured pre-placement interview opportunities with Novartis Development hub in India.     NEST is a dynamic platform designed to empower the next generation of innovators in healthcare by bridging the gap between academia, startups, and industry. By providing a real-world problem-solving experience, expert mentorship, and access to key industry stakeholders, NEST equipped students and young professionals with the skills, knowledge, and opportunities needed to drive impactful change. Through NEST, Novartis is nurturing a talent pipeline that can shape the future of medicine and improve healthcare outcomes on a global scale. ]]> https://biospectrumindia.com/news/109/25716/granules-india-enters-cdmo-business-by-acquiring-senn-chemicals-ag-for-rs-192-5-cr.html https://biospectrumindia.com/news/109/25716/granules-india-enters-cdmo-business-by-acquiring-senn-chemicals-ag-for-rs-192-5-cr.html Sat, 22 Feb 2025 00:00:00 +0530 Hyderabad-based Granules India has announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specialising in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition, at the cost of Rs 192.5 crore, is subject to certain conditions. The closing is expected to occur in the first half of 2025. The acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments. This enables Granules’ acquiring capabilities into high-growth peptide- based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities. The acquisition marks Granules foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint. ]]> https://biospectrumindia.com/news/109/25677/foxx-life-sciences-strengthens-presence-in-telangana-with-two-new-manufacturing-plants.html https://biospectrumindia.com/news/109/25677/foxx-life-sciences-strengthens-presence-in-telangana-with-two-new-manufacturing-plants.html Fri, 14 Feb 2025 00:00:00 +0530 Foxx Life Sciences is delighted to announce the successful completion of its Open House event, held at the company's facility in Hyderabad, India. The event was well attended by industry leaders, partners, and community members, marking a significant milestone in Foxx Life Sciences ongoing commitment to innovation and excellence in the life sciences sector. Foxx celebrated 5 years of Bioprocess manufacturing in India and the inauguration of 2 new manufacturing plants, including a new state of the art blow and injection molding facility which is spread across 40,000 sq ft. Guests had the chance to interact with the company's experts, explore the latest advancements in manufacturing, and discover Foxx Life Sciences' innovative solutions. "We are thrilled with the turnout and the positive feedback from our Open House event. This event underscores our dedication to fostering innovation and collaboration in India within the life sciences community” stated Thomas Taylor, Founder and CEO of Foxx Life Sciences Eknath Kulkarni, Co-Founder, Part-Owner, and President of Foxx Life Sciences APAC, said “We are excited to continue building strong relationships with our customers, suppliers, and employees with these new major Investments. From R&D, prototyping, machining, welding, injection molding, clean room assembly, and Asia logistics, Foxx is ready to support our global customers”. Rick Schwartz, President of Foxx Life Sciences, also attended the event and added, "The Open House was a fantastic opportunity to showcase our capabilities and share our vision for the future. We are committed to driving growth and excellence in the industry, and events like this help us connect with the community and highlight our contributions." The 2 new plants in Hyderabad further strengthens Foxx Life Sciences' global positioning and enhances its manufacturing redundancies, ensuring robust and reliable operations across multiple locations. Manufacturing redundancy is critical for Vaccine, Biotech, Pharma and Medical end users. With a focus on quality (ISO 13485 since 2010), seven certified ISO Class 7 clean rooms, 5 manufacturing plants, Foxx is the perfect partner for your next Life Science disposable product or Bioprocess single-use custom assembly.   ]]> https://biospectrumindia.com/news/109/25636/braintap-unveils-cutting-edge-brain-fitness-technology-in-india.html https://biospectrumindia.com/news/109/25636/braintap-unveils-cutting-edge-brain-fitness-technology-in-india.html Wed, 05 Feb 2025 00:00:00 +0530 BrainTap, a pioneering Brain Fitness company, recently unveiled its state-of-the-art innovation to boost mental clarity, alleviate stress, and elevate overall well-being in India, at T Hub, Hyderabad. The revolutionary device was officially launched by Chief Guests Dr Nawab Mir Nasir Ali Khan, Consulate of Republic of Kazakhstan; Dr Patrick Porter, Founder & Co-CEO, BrainTap USA; Cynthia Porter, Co-Founder, CMO, (Brain Tap) USA; Vishal Baijal, Board of Director, (Brain Tap) USA; Dr Francisco Cidral, Chief Science Officer, (Brain Tap) USA; Chhayal Baijal, COO, Nirvana Neuro (Brain Tap) India; Harshil Maun, Business Development Head, (Brain Tap) India. Attendees witnessed the technology in action through an immersive live demo. After years of research, BrainTap has crafted an innovative tool that helps the brain reorganise and build new neural pathways for a more balanced and empowered life. Backed by clinical studies and trusted by thousands of healthcare providers, BrainTap technology has demonstrated significant benefits. “BrainTap seamlessly integrates ancient Indian wellness practices with modern neuroscience. Inspired by Dhyana (meditation), Nada Yoga (sound healing), and Trataka (light therapy), BrainTap uses binaural beats, guided visualisation, and photonic stimulation to activate the brain’s natural healing states. Just as Ayurveda balances mind-body energy, BrainTap harmonises brainwave activity—bridging timeless Vedic wisdom with cutting-edge technology for holistic wellness”, said Vishal Baijal. Despite its importance, mental health remains one of the most neglected aspects of healthcare. BrainTap aims to change that by providing a science-backed, at-home solution to improve focus, enhance willpower, promote sound sleep, reduce stress and anxiety and prevent burnout.     ]]> https://biospectrumindia.com/news/109/25639/nsure-healthy-spine-partners-with-nordic-health-to-strengthen-sports-healthcare-in-india.html https://biospectrumindia.com/news/109/25639/nsure-healthy-spine-partners-with-nordic-health-to-strengthen-sports-healthcare-in-india.html Wed, 05 Feb 2025 00:00:00 +0530 nSure Healthy Spine has announced the adoption of an advanced data-driven Musculoskeletal Health Technology Platform in exclusive partnership with Nordic Health Finland. The state-of-the-art biomechanically optimised exercise therapy devices for Spine, Shoulder, Hip & Knee Health will be incorporated at upcoming India’s 1st Center for Spine and Sports Health (CSSH) located at Kotak Pullela Gopichand Badminton Academy, Hyderabad. As part of a strategic collaboration to introduce cutting-edge spine and sports health technology platform for the first time in India, nSure Healthy Spine has recently hosted Technology Inventors from Nordic Health, Finland – Arno Parviainen and Sirkka Parviainen at CSSH, Hyderabad. Their visit marks a significant milestone in integrating advanced assessments, targeted muscle-strengthening training programs for Injury prevention, and preventive musculoskeletal care solutions, aimed at enhancing the performance and well-being of athletes and individuals seeking proactive health management. With Finland being one of the top innovative health technology ecosystems, the expertise of Nordic Health leadership has become instrumental in training our team to leverage advanced technology effectively and deliver world-class care at CSSH, Hyderabad. During the visit, Arno and Sirkka conducted comprehensive training & educational programs for the nSure Healthy Spine team. The sessions focused on the clinical use of biomechanically optimized exercise therapy devices to ensure precise assessments and evidence-based exercise therapy programmes. Throughout the training sessions, they emphasised the latest techniques in movement health, rehabilitation, and performance enhancement, to make our team remain at the forefront of spine and sports health. ]]> https://biospectrumindia.com/news/109/25621/gv-research-platform-and-becytes-partner-to-advance-biopharma-research-in-india.html https://biospectrumindia.com/news/109/25621/gv-research-platform-and-becytes-partner-to-advance-biopharma-research-in-india.html Mon, 03 Feb 2025 00:00:00 +0530 Hyderabad-based GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with Spanish startup BeCytes Biotechnologies to expand access to high-quality human and animal-derived biological materials for drug discovery and toxicology research in India. This collaboration leverages BeCytes’ specialised expertise in tissue procurement, primary cell isolation, and in vitro models, enabling Indian researchers to utilise cutting-edge tools for more predictive and translational studies. As part of this partnership, GVRP will facilitate the availability of cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customised cell isolation services, critical resources for drug metabolism, safety assessment, and disease modeling. “As India’s biomedical research landscape continues to expand, access to high-quality biological models remains a key challenge,” said Kalyan Korisapati, Co-Founder & Group CEO of GVRP. “By partnering with BeCytes, we are closing this gap and ensuring that researchers in India have seamless access to best-in-class hepatic cell models, including disease models such as NASH and Liver 3D Spheroids functional models, to advance their discoveries.” BeCytes Biotechnologies has a proven track record of supplying primary human and animal-derived cells to researchers worldwide. Their expertise in cell characterisation and in vitro model development ensures consistency and reliability, addressing a critical need in preclinical drug screening and toxicology studies. ]]> https://biospectrumindia.com/views/109/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html https://biospectrumindia.com/views/109/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html Fri, 31 Jan 2025 00:00:00 +0530 The Indian government has launched several initiatives to support the expansion of GCCs in the life sciences sector. Programmes like the "Make in India" initiative encourage foreign investment in pharmaceutical manufacturing and R&D. The National Health Policy aims to boost healthcare solutions, with a focus on local innovation, driving life sciences companies to establish R&D-focused GCCs. In AI, the $1.25 billion IndiaAI Mission strengthens the country’s AI ecosystem, helping GCCs adopt AI for faster drug development and efficient clinical trials. The Ayushman Bharat Digital Mission connects 500 million people to digital healthcare services, enhancing India’s healthcare system. Additionally, Special Economic Zones (SEZs) and Biotechnology Parks provide critical infrastructure and tax incentives, facilitating the growth of life sciences GCCs aligning with India’s broader vision to lead in pharmaceutical R&D innovation. State-Level Leadership: Karnataka and Telangana Among Indian states, Karnataka and Telangana stand out as key locations for the development of life sciences GCCs. Both states have created strong ecosystems that attract global investment and skilled professionals, enhancing the growth of the sector. Karnataka, particularly the city of Bengaluru, accounts for nearly 32 per cent of all life sciences GCCs in India. Karnataka’s GCC Policy 2024-29 is a cornerstone of its strategy to attract and expand GCCs. The policy offers a variety of incentives and provisions like targeted financial incentives such as rent coverage, tax breaks and reimbursements. The state's vision is to double the number of GCC from 500 to 1000 by 2029. Bengaluru has become a favoured destination for companies setting up GCCs due to its vast talent pool in AI, data analytics, and bioinformatics. The state government has also established Centers of Excellence for research and development, offering crucial support for startups and larger firms alike. Telangana, with Hyderabad as its epicentre, has made significant strides in establishing itself as a global hub for life sciences. Genome Valley, located in Hyderabad, is India's largest biotech and pharmaceutical cluster, home to over 200 companies involved in R&D. In 2024 alone, Telangana attracted more than $850 million in investment to bolster its life sciences capabilities. A major recent development in Telangana is the creation of the Life Sciences GCC Consortium, which has been in the spotlight. This consortium brings together the Hyderabad-based life sciences GCCs. Its primary aim is to boost collaboration, share knowledge, and address challenges in drug development and digital transformation. The consortium is expected to strengthen Telangana’s reputation as a leader in life sciences by facilitating partnerships between GCCs, academic institutions, and the government. Telangana is home to leading R&D centres like Novartis Biome, Hyderabad's first innovation hub, which focuses on integrating AI into pharmaceutical research. It collaborates with startups, researchers, and academic institutions to drive advancements in drug discovery and clinical trials. Similarly, Bristol Myers Squibb has invested $100 million to establish a GCC in Hyderabad, employing 1,500 professionals and utilising AI to accelerate drug discovery. Driving AI Adoption Artificial intelligence (AI) is playing a vital role in streamlining operations in life sciences GCCs, particularly in drug discovery, clinical trials, and supply chain management. With the average cost of bringing a new drug to market exceeding $2 billion and development timelines stretching to 10-12 years, AI is addressing these challenges by reducing costs and accelerating the process. AI-driven solutions can cut drug development costs by up to 70 per cent and shorten timelines by 40 per cent, making it indispensable for the future of pharmaceutical research. For instance, AI has made a significant impact on protein modelling, where tools like AlphaFold can model proteins in hours instead of months. This allows companies like GSK and Sanofi to speed up R&D by 30-40 per cent, enabling faster identification of drug targets. Indian GCCs are increasingly adopting these AI technologies to improve early-stage drug discovery and contribute to global pharma innovation. In the realm of clinical trials, AI-powered platforms optimise trial protocols, improve patient recruitment, and predict trial outcomes with greater accuracy. Pfizer, for example, has used AI to streamline clinical trial design, reducing costs and improving timelines. Indian GCCs play a critical role in these efforts, using AI-driven platforms to manage clinical trials more efficiently. AI is also helping GCCs with regulatory compliance, where automation has reduced the time required for submissions by 30 per cent while increasing accuracy. Indian GCCs have implemented AI tools that make the regulatory process faster and more reliable, keeping up with global standards. Implementing AI at scale requires overcoming challenges like data fragmentation and aligning strategies with parent organisations. GCCs are excelling by overcoming data fragmentation through structured management frameworks, leveraging India’s AI expertise, and aligning with global compliance standards. By utilising effective data aggregation, cleansing, and integration methods, these centres enable seamless AI deployment and innovation. Future Prospects and AI Integration The future of life sciences GCCs in India looks promising, particularly with the growing integration of AI technologies. At its peak, AI is expected to save the global pharmaceutical industry around $26 billion annually, revolutionising how drugs are developed, trials are conducted, and patient care is managed. As more pharmaceutical companies recognise India’s strengths, the number of GCCs is expected to increase, with these centres becoming key players in advancing AI-driven healthcare innovation. India’s deep talent pool, including 3.3 million software engineers and 446,000 AI/ML specialists, is a major asset that positions the country as a leader in AI-driven life sciences R&D. With scalable infrastructure, lower operating costs, and strong government backing through programmes like the IndiaAI Mission, India is poised to continue its rise as a global hub for life sciences. As regulatory frameworks evolve to support AI technologies, India’s position in the global life sciences industry is expected to strengthen further. Collaboration between government initiatives and private sector innovation will be crucial to maintaining this momentum. Life sciences GCCs will continue to lead in addressing global healthcare challenges, using AI to deliver faster, more effective solutions.   Dr Purav Gandhi, CEO and Founder, Healthark Insights ]]> https://biospectrumindia.com/news/109/25580/iiit-hyderabad-and-nims-create-pathology-datasets-for-cancer-kidney-disease.html https://biospectrumindia.com/news/109/25580/iiit-hyderabad-and-nims-create-pathology-datasets-for-cancer-kidney-disease.html Thu, 23 Jan 2025 00:00:00 +0530 In a boost to India-centric clinical research and development, International Institute of Information Technology, Hyderabad (IIIT-H), in collaboration with Nizam’s Institute of Medical Sciences (NIMS), Hyderabad has unveiled publicly available datasets comprising digitised histopathological images of brain cancer and kidney disease (Lupus Nephritis). The India Pathology Dataset (IPD) project, is a multi-stakeholder joint venture between academia, hospitals, industry, and the government to digitise slide images of tissue biopsies for reaping benefits that range from reduced risk of damaging physical slides to improved clinical decision-making to improved turnaround time and bettering research opportunities with the help of artificial intelligence (AI). As part of the initiative supported by iHub-Data, IIIT-H installed a whole slide digital scanner at the premises of NIMS, Hyderabad. One of the first datasets that has been released is the IPD-Brain dataset in Nature Scientific Data – a prestigious, open-access, online-only journal for descriptions of scientifically valuable datasets. With its focus on Indian demographics, it comprises 547 high-resolution H&E (haematoxylin and eosin stain) slides from 367 patients making it one of the largest in Asia. While a beginning has been made by curating a dataset on brain tumours, efforts are underway to expand the dataset to include other cancers such as breast cancer, lung cancer, colorectal, oral and cervical cancers. NIMS is also contributing to curating the dataset on lung cancer. In addition to the cancer datasets, the project has also compiled another on lupus nephritis. Lupus is a kidney disease that occurs when the immune system attacks the kidneys.  While subtyping and grading of the cancers are routine and time-consuming tasks traditionally performed by histopathologists, tasks that cannot be performed by human observers are predicting molecular markers from H&E slide images. Molecular profile details are traditionally obtained from genetic labs where such testing is done or by performing immunohistochemistry (IHC). The group has instead attempted to predict molecular details with the help of tissue morphology itself using H&E slide images. One such effort involves predicting IDH mutations which plays a critical role in the diagnosis and prognosis of brain tumor patients.     ]]> https://biospectrumindia.com/news/109/25545/hyderabad-based-popvax-wins-2-m-to-accelerate-development-of-influenza-vaccine.html https://biospectrumindia.com/news/109/25545/hyderabad-based-popvax-wins-2-m-to-accelerate-development-of-influenza-vaccine.html Tue, 14 Jan 2025 00:00:00 +0530 PopVax, a Hyderabad-based biotechnology startup developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design, has been awarded $2 million by the United States Biomedical Advanced Research and Development Authority (BARDA) as one of the winners of the Concept Stage of BARDA’s Patch Forward Prize for its seasonal influenza vaccine built on a novel mRNA-encoded immunogen display architecture delivered via dissolvable microarray patch. PopVax is developing this vaccine in partnership with Germany’s LTS Lohmann Therapie-Systeme AG (LTS), a leading player in transdermal drug delivery. The Patch Forward Prize is a multi-stage $50 million competition launched by BARDA to accelerate the development of microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. PopVax intends to use the award it has received to accelerate the development of its influenza vaccine programmes, including its broadly-protective influenza vaccine intended to protect against all key seasonal and pandemic strains in a single shot, leveraging both the LTS microarray patch technology and other delivery modalities. PopVax & LTS Lohmann are now working to advance the self-administered patch-delivered seasonal influenza vaccine into preclinical studies this quarter. PopVax’s next-generation COVID-19 vaccine candidate has been selected for a Phase I trial conducted & sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), which is expected to begin in Q2 2025. The company has six novel vaccine candidates in its preclinical pipeline, and intends to initiate five clinical trials over the next two years.  ]]> https://biospectrumindia.com/news/109/25542/aragen-secures-100-m-investment-from-quadria-capital-.html https://biospectrumindia.com/news/109/25542/aragen-secures-100-m-investment-from-quadria-capital-.html Mon, 13 Jan 2025 00:00:00 +0530 Aragen, a globally renowned Contract Research, Development and Manufacturing Organisation (CRDMO), has secured a $100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of $1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors. This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen. This partnership further solidifies Aragen's reputation for delivering high-quality “concept to clinic” and “concept to commercial” services to its global customer base comprising all sectors of health – Human, Animal and Plant. The announcement comes ahead of JPM Week 2025, where Aragen is expected to secure additional outsourcing partnerships. Manni Kantipudi, CEO, Aragen Life Science said, “Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently.” ]]> https://biospectrumindia.com/news/109/25544/indian-immunologicals-ltd-hosts-scientific-conclave-on-pandemic-preparedness-in-hyderabad.html https://biospectrumindia.com/news/109/25544/indian-immunologicals-ltd-hosts-scientific-conclave-on-pandemic-preparedness-in-hyderabad.html Mon, 13 Jan 2025 00:00:00 +0530 Indian Immunologicals Limited in collaboration with Department of Animal Husbandry and Dairying, Government of India and National Dairy Development Board (NDDB) recently conducted a “Conclave on Pandemic Preparedness & Vaccine Innovation” in Hyderabad. This is a unique conclave having diverse topics for discussion such as Animal Health, Human Health, Regulatory, Resilient supply chain for pandemic preparedness, Innovation, Artificial Intelligence in Healthcare, Cell and Gene Therapy vaccines and Policy matters.  The objective of this conclave on “Pandemic preparedness and vaccine innovation” is to ideate, explore and collaborate on the learnings of the pandemic, and to build a more robust & resilient health care system.   Several speakers from the national level and international level including FAO and CEPI presented. IIL planted 141 trees to make the one-day Conclave carbon neutral, which speaks volumes of IIL’s commitment to sustainability and reducing carbon foot print.   Speaking on the occasion Dr V K Paul informed that “One Health” approach is paramount to disease control and hence preparedness for pandemics with 100 days’ timeline will be the right way to prepare and face future pandemics.  Alka Upadhyaya, Secretary to Government of India, Dept of Animal Husbandry and Dairying, Government of India, informed that government needs to spend more on animal health for better productivity and also better supply chain and cold chain systems to make the last mile delivery effective. Dr Abhijit Mitra, Animal Husbandry Commissioner stressed upon vaccine security and need for pre-qualifications for animal vaccines. Dr K Anand Kumar, Managing Director, IIL said that the company is the single largest contributor to the nation in achieving self-sufficiency in the field of vaccines. Many animal and human vaccines produced in millions by IIL have not only offered affordability but also have saved several million lives. He said that we as a society are at crossroads, faced with many issues and it is only collectively that the right path can be chosen. ]]> https://biospectrumindia.com/news/109/25541/aig-hospitals-set-to-invest-rs-800-cr-to-revolutionise-cancer-treatment.html https://biospectrumindia.com/news/109/25541/aig-hospitals-set-to-invest-rs-800-cr-to-revolutionise-cancer-treatment.html Sat, 11 Jan 2025 00:00:00 +0530 The Board of AIG Hospitals has approved the acquisition of Proton Beam Therapy system. Consequently, AIG Hospitals has entered into an agreement to acquire state-of-the-art Proteus ONE Proton Therapy System including DynamicARC from IBA, a Belgium-based supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. With this new delivery technique called DynamicARC proton therapy, the system will be the first-of-its-kind installation in South-East Asia. This strategic acquisition marks a significant milestone in AIG Hospitals' commitment to delivering the most advanced, effective, and accessible cancer care to patients in India. Proton Beam Therapy is a highly precise form of radiation therapy that targets tumours with exceptional accuracy, substantially minimising damage to surrounding healthy tissues. This technology is a gamechanger in treating complex cancers, particularly in children and adults with tumors located near critical organs. Dr D Nageshwar Reddy, Chairman of AIG Hospitals said that “The Proteus ONE Proton Therapy System will be part of our new 300-bedded dedicated Oncology Centre coming up within the existing Gachibowli campus, enabling comprehensive cancer care comparable to the best in the world.” AIG Hospitals will invest Rs 800 crore in this new Oncology Centre, making it only the Third Proton Therapy Centre in the country and the first one in twin Telugu states of Telangana and Andhra Pradesh.       ]]> https://biospectrumindia.com/interviews/109/25491/we-are-focusing-on-developing-10-pharma-villages-to-decentralise-pharma-production-taking-manufacturing-closer-to-rural-areas.html https://biospectrumindia.com/interviews/109/25491/we-are-focusing-on-developing-10-pharma-villages-to-decentralise-pharma-production-taking-manufacturing-closer-to-rural-areas.html Tue, 31 Dec 2024 00:00:00 +0530 What key initiatives and strategic changes is the Telangana government implementing to attract investments in the pharmaceutical and biotech sectors, and how do these differ from previous policies like TS-iPASS? Ever since the new government led by Chief Minister A Revanth Reddy took charge in November 2023, over the past year, the government has taken various measures to support the existing industries and at the same time attract new investments in pharma, life sciences and other allied industrial sectors. Telangana state has a well-established pharma and biotech base with supporting academic and research institutions under public and private sectors providing the necessary skilled manpower needed for the industries. This is the main advantage for us to pull in more domestic and global investors to the state. In the past year, we could successfully attract investments worth over Rs 36,000 crore in the life sciences sector. These investments span more than 140 projects and include contributions from both Indian companies and global organisations. This highlights Telangana's commitment to building a business-friendly and supportive environment for the life sciences industry. The government is now preparing to launch a new life sciences policy, which promises to streamline processes and simplify regulations for companies interested in starting or expanding their operations in the state. This upcoming policy will also offer special incentives to attract more investments, ensuring businesses can operate smoothly and efficiently. The new framework has been carefully designed to meet the changing needs of the life sciences industry. It builds on the successes of Telangana's earlier initiatives, such as TS-iPASS, but offers significant improvements to further boost growth. By addressing gaps and evolving alongside industry trends, Telangana aims to solidify its position as a leading hub for life sciences innovation and manufacturing.   What are your insights into the recent interest from pharmaceutical and biotech companies in Telangana?  Just a few days ago, leaders from India’s pharmaceutical industry expressed their strong interest in setting up new manufacturing units and research and development (R&D) laboratories in the government-proposed Greenfield Pharma clusters. These clusters are part of an initiative to boost pharmaceutical production and innovation in the state. Six leading pharmaceutical companies—MSN Laboratories, Dr. Reddy’s, Laurus Labs, Hetero, Aurobindo and Gland Pharma—have already signed a Memorandum of Understanding (MoU) with the government. These companies have committed to investing Rs 5,260 crore, a significant move that is expected to create 12,500 new jobs in the region. The state government’s key responsibility in this partnership is to provide suitable land equipped with the necessary infrastructure, such as roads, water supply, and power. Work is already underway to ensure these facilities are in place to accommodate the companies and help them begin operations quickly. Apart from this, other major investments are also contributing to the state’s progress as a pharmaceutical hub. A notable example is Rs 2,000 crore collaboration between KrKA and Laurus Labs to establish biopharmaceutical manufacturing units in Genome Valley; this partnership alone is projected to create around 2,800 jobs. Another remarkable project involves Japan’s Takeda Life Sciences, which has partnered with Biological E to produce 5 crore doses of dengue vaccines annually. This collaboration further emphasises the region’s focus on advanced pharmaceutical production and addressing global healthcare challenges. These developments highlight Telangana's strategic vision of becoming a global hub for pharmaceutical manufacturing and innovation. The state’s focus on building world-class infrastructure and fostering collaborations with leading domestic and international companies ensures a thriving ecosystem for the life sciences industry.   How do you assess the development of the pharmaceutical and biotech sectors in Telangana during the fiscal year 2024-25, including standout achievements and areas needing improvement? The fiscal year 2024-25 has seen remarkable growth in our pharmaceutical and biotech sectors, with significant achievements such as the establishment of state-of-the-art R&D facilities by companies like Laurus Labs. However, we also recognise areas needing improvement, particularly in enhancing infrastructure to support rapid industry expansion.  To improve the skills of the youth, the government is proposing to set up a skill development university in the state. Once this becomes operational, not just pharma, life sciences and other allied industries but also industries offering IT services, manufacturing services and other services can avail skilled and talented workforce at affordable cost. Telangana will witness a new boom in industrial expansion in the coming days, offering jobs and rapid development to the region.    What is the current status of key projects like Hyderabad Pharma City, including any alternative plans if it is being shelved, and how are infrastructure developments along the Outer Ring Road progressing? Though the Hyderabad Pharma City project is a cornerstone of our efforts to position Telangana as the global hub for pharmaceutical manufacturing and innovation, at present, we are focusing on developing 10 'Pharma Villages' across different districts in and beyond the Outer Ring Road (ORR) regions in Telangana. These Pharma Villages are designed to decentralise pharmaceutical production, taking manufacturing closer to rural areas and underdeveloped regions. This approach will not only improve access to healthcare services locally but will also create opportunities for balanced economic growth across the state. Combined, these initiatives have the potential to generate up to 5 lakh jobs, providing employment opportunities to a wide range of skilled and semi-skilled workers. More importantly, they will contribute significantly to regional economic development, empowering local communities and boosting the state's economy. By creating the right mix of advanced infrastructure, streamlined policies, and innovation-driven growth, we aim to set a new benchmark for pharmaceutical production in the country and attract global players to Telangana.   How is Telangana fostering public-private partnerships in the pharmaceutical sector, supporting startups through initiatives like T-Hub and We-Hub, and ensuring sustainable growth concerning talent development and environmental governance? We are strongly promoting public-private partnerships in both the biotech and pharmaceutical sectors to accelerate growth and innovation. These partnerships are essential for creating a supportive environment where industries, the government, and private players can collaborate effectively. Initiatives like T-Hub and We-Hub are playing a crucial role in supporting startups. T-Hub focuses on technology-driven startups, while We-Hub empowers women entrepreneurs. These platforms provide startups with access to vital resources such as funding, infrastructure, mentorship, and networking opportunities. By offering guidance and support, they help young companies scale up and thrive in competitive markets. To address the challenge of talent shortages in the biotech and pharma industries, we are also partnering with educational institutions like NIPER, HCU, IIT Hyderabad and others through programmes like TASK (Telangana Academy for Skill and Knowledge).  TASK is a unique initiative that bridges the gap between education and employment by equipping students with industry-relevant skills. This programme ensures that our workforce remains highly skilled, capable, and ready to meet the evolving demands of these fast-growing sectors. Together, these efforts aim to build a dynamic ecosystem where startups, industries, and skilled talent can work in harmony, driving innovation, creating employment opportunities, and strengthening Telangana’s leadership in the biotech and pharmaceutical sectors.   Amguth Raju hyderabad@mmactiv.com   ]]> https://biospectrumindia.com/features/109/25490/telanganas-bid-to-achieve-positive-investment-growth.html https://biospectrumindia.com/features/109/25490/telanganas-bid-to-achieve-positive-investment-growth.html Tue, 24 Dec 2024 00:00:00 +0530 Telangana state overcoming various hurdles and challenges is rapidly strengthening its position as a global leader in the life sciences and Active Pharmaceutical Ingredients (API) sectors. In the past year from November 2023 to December 2024, the state government succeeded in attracting investments worth Rs 36,000 crore and Rs 5,260 crore in life sciences and API sectors respectively.  With over 140 projects in the pipeline, these investments in the life sciences sector are set to generate 51,000 direct jobs and an additional 1,50,000 indirect jobs, showcasing the state’s exceptional growth trajectory in the coming days ahead. Speaking on this remarkable achievement, Telangana's Industries and Commerce Minister, Duddilla Sridhar Babu, emphasised the state’s proactive policies and strategic vision. "Telangana has emerged as the epicentre for global life sciences innovation. This momentum includes both significant investments from new entrants and additional investments by existing companies that recognise the value of expanding in Telangana. This is a testament to the business-friendly approach of our government and the strong ecosystem we have built over decades," Babu stated.   Genome Valley: At the Heart of Innovation The cornerstone of Telangana’s success in the life sciences sector lies in Genome Valley, India’s first and largest R&D cluster. This hub continues to attract global industry leaders, driving significant investments and expansions. Over the past year, Genome Valley has witnessed remarkable developments, solidifying its reputation as a global innovation centre for pharmaceuticals and biotechnology. Among the key investments, KrKA (Europe) and Laurus Labs jointly committed Rs 2,000 crore to establish state-of-the-art facilities for pharmaceutical finished products and biopharmaceutical manufacturing. In addition, Laurus Labs inaugurated a cutting-edge R&D centre with an investment of Rs 250 crore, creating employment opportunities for 2,800 people. In a noteworthy partnership, Takeda (Japan) collaborated with Biological E to manufacture 5 crore doses of the dengue vaccine annually. This initiative has further reinforced Hyderabad’s reputation as the Vaccine Capital of the World. Another milestone was achieved with Rx Propellant and Terminus Group announcing a Rs 2,000 crore investment to develop 20 lakh square feet of world-class laboratory space within Genome Valley, expected to generate 10,000 new jobs. Additionally, the Telangana government partnered with Thermo Fisher Scientific, which plans to establish the country’s first scale-up biological manufacturing facility and bioprocess design centre in Genome Valley, marking another significant breakthrough for the region. Adding to this momentum, Miltenyi Biotec from Germany is setting up a world-class Cell and Gene Therapy facility, enhancing Hyderabad’s global profile in advanced medical research. Meanwhile, Aragen, one of India’s leading Contract Research and Development/Manufacturing Organizations (CRO/CDMO), has announced a Rs 2,000 crore expansion plan in Nacharam, which will create 1,000 new jobs and further strengthen its presence in Telangana. Other notable investments include expansions by global players such as Switzerland-based Ferring Pharma, Germany-based DFE Pharma, and USA-based Vivint Pharma, all of which are bolstering their operations in Genome Valley. These investments collectively underline Telangana’s rising prominence as a global leader in life sciences and innovation.   Global Capability and Innovation Centers In addition to manufacturing facilities, Hyderabad is rapidly emerging as a preferred destination for Global Capability and Innovation Centers (GCICs), attracting leading companies from across the world. Over the past year, several prominent announcements have highlighted the city’s growing importance as a hub for innovation and technology. Amgen, a global biotechnology leader, is establishing one of its largest innovation centres worldwide in Hyderabad. This facility, designed to accommodate 3,000 employees, underscores the company’s ambitious expansion plans in the region. Similarly, Zoetis, the world’s largest animal health company, recently inaugurated a cutting-edge technology and innovation centre in the city, further enhancing Hyderabad’s reputation as a centre for excellence in research and innovation. Adding to the momentum, Olympus, a Japanese medical technology giant, is setting up an engineering and R&D centre in Hyderabad. This facility is expected to employ around 500 people, driving advanced medical technology solutions. Meanwhile, HCA Healthcare, America’s largest healthcare systems provider, is building a large campus in the city to bolster its operational capabilities. In another significant development, Cigna, a Fortune 16 health services provider, is expanding its presence in Hyderabad through its subsidiary, Evernorth Health Services. The company is setting up a massive campus in the city, reinforcing its commitment to innovation and customer-focused solutions. Hyderabad’s growing appeal has also drawn investments from companies such as ModMed from Canada and RxBenefits from the USA, among others. These developments further highlight the city’s transformation into a global hub for innovation, driven by world-class infrastructure and a thriving ecosystem for research and development. Telangana’s growth is not limited to new entrants. In the past year, existing industry giants like Medtronic, which established its first IT centre outside the USA in Hyderabad with a Rs 500 crore investment, continue to scale up their operations. Companies such as Sanofi, Bristol-Myers Squibb (BMS), and Providence are further expanding their already significant presence, demonstrating their confidence in Hyderabad’s business ecosystem. As Hyderabad continues to attract new investments and foster innovation, the city is poised to remain at the forefront of the global life sciences industry. From cutting-edge R&D facilities to large-scale manufacturing and innovation hubs, Hyderabad is setting benchmarks that underscore its status as a world-class destination for life sciences. Expressing satisfaction with the city’s ability to attract and retain major players in the life sciences sector, the Minister said, “We are proud to see Hyderabad emerging as a global hotspot for life sciences innovation. The continued investments and expansions by industry leaders reaffirm the trust in Telangana’s robust infrastructure and business-friendly policies.”    New Life Sciences Policy on the Horizon Telangana’s strategic focus extends to the intersection of life sciences and technology. Hyderabad, with its deep talent pool in pharmaceuticals, biotechnology, artificial intelligence, and digital health, has become a prime destination for Global Capability Centers (GCCs) in healthcare and life sciences. The state government has launched a Life Sciences GCC Consortium to power curriculums of science courses with technologies such as Artificial Intelligence (AI). At present, 40 life sciences companies are the members of the consortium. The course designed by the consortium will support science students to secure jobs at GCCs.  The Minister noted that the course will be introduced based on a hybrid model. Firstly, GCC companies like Dr. Reddy’s Laboratories will undertake training related to their vertical at the Young India Skills University, secondly, these GCCs will connect with the Skills University for training in new niche areas, and thirdly, a subject will be introduced in the curriculum of colleges. "Hyderabad has created a niche for itself as the hotspot for GCCs, attracting investments across the life sciences and healthcare value chain, including pharma, biotech, medtech, and health insurance," said Jayesh Ranjan, Principal Secretary, Industries, Government of Telangana.  The state is preparing to launch a dedicated life sciences policy, aimed at streamlining processes, fostering innovation, and driving sustainable growth in the sector. "This policy will further consolidate Telangana’s position as a vital node in the global life sciences value chain," added Ranjan, highlighting the government’s commitment to building a robust and inclusive ecosystem.   Strategic Initiatives and Investments   With Telangana already a strong base for bulk drugs and Active Pharmaceutical Ingredient industries, the state contributes more than 30 per cent of India’s total API exports. Telangana plays a crucial role in India's API manufacturing landscape, contributing significantly to both domestic production and exports. With its strategic initiatives and continued investment in infrastructure and talent development, the state is poised to enhance its position further in the global pharmaceutical supply chain.  While Telangana has witnessed massive investments in the life sciences segment, the chemical, API, and bulk drug industries have experienced a similar surge. In the past year, several API manufacturing companies in Hyderabad have expressed plans to set up new units and expand existing facilities.  In November 2024, representatives of top pharma companies who met Chief Minister Revanth Reddy, signed a Memorandum of Understanding (MoU) with the state government, pledging investments into new Greenfield industrial clusters to the tune of over Rs 5260 crore in the state. Top investors from the API industry include Dr. Reddy’s Labs, Laurus Labs, Gland Pharma, MSN Laboratories and Hetero Group. These companies, apart from expressing their intent to invest, have also promised to employ over 12,500 people in the state. Confirming this, Satish Reddy, Chairman of Dr. Reddy’s Laboratories, said, “Our recent meeting with the Chief Minister had been positive. The state government is eager to expand the pharmaceutical sector in the rural areas. Accordingly, an MoU has been signed with the government to set up new units and expand existing facilities in the proposed upcoming Greenfield industrial areas.”    Overcoming Challenges Earlier plans for the Integrated Hyderabad Pharma City faced delays due to legal disputes and protests over land acquisition. The new government’s decentralised strategy aims to balance regional development while mitigating challenges. IT and Industries Minister Sridhar Babu stated, “We are identifying land along the ORR with infrastructure for Greenfield Pharma clusters, ensuring balanced regional growth.” While the state is witnessing significant growth and new investments in the pharmaceutical sector on one hand, it is also grappling with challenges in land acquisition for setting up these projects. For instance, as part of the state government’s plan to establish a Pharma Industrial Cluster in the Kodangal region, it faced strong resistance from the local population. One notable incident occurred in Lagacherla village, where a public hearing organised to seek consent for acquiring 1300 acres of land from farmers turned violent. During the meeting, residents attacked the district collector and other officials, expressing their opposition to the proposed Pharma Industrial Corridor. As a result of this fierce backlash, the state government was forced to cancel the proposal for the Pharma corridor and instead proposed setting up an industrial cluster. Even though the pharma industry has witnessed ups and downs, over the past many years in Telangana, with proactive industry policies, initiatives and measures from the state government, Hyderabad remains a global hub for generic pharmaceuticals and vaccines. With India’s pharma market projected to reach $120–130 billion by 2030, Telangana plays a pivotal role in advancing global healthcare solutions.   Amguth Raju hyderabad@mmactiv.com ]]> https://biospectrumindia.com/news/109/25477/lspedia-expands-global-presence-with-new-office-in-hyderabad-to-serve-pharma-sector.html https://biospectrumindia.com/news/109/25477/lspedia-expands-global-presence-with-new-office-in-hyderabad-to-serve-pharma-sector.html Fri, 20 Dec 2024 00:00:00 +0530 US-based LSPedia has announced the opening of its new office in Hyderabad, from January 2025. This strategic expansion supports the company's mission to serve international markets, scale customer service capabilities, and strengthen its footprint in India's thriving pharmaceutical industry. The Hyderabad office will play a key role in LSPedia's global growth strategy, delivering service to customers in Bahrain, Bangladesh, Singapore, Switzerland, UK, and the balance of the EU. Providing around the clock support and maintaining its industry leading first-response times, the team will augment US-based support to ensure seamless customer service across all time zones. The Hyderabad office will enable LSPedia to provide localised service to Indian Marketing Authorization Holders (MAHs) and Contract Manufacturing Organizations (CMOs). By offering the same trusted OneScan software relied upon by pharmaceutical companies globally, LSPedia will help Indian businesses streamline operations, ensure compliance, and grow global markets. In addition to supporting Indian customers, the Hyderabad team will work closely with international clients offering implementation expertise, technical support, and accelerated resolution times. This expansion enhances LSPedia's ability to serve global customers with tailored solutions and consistent service quality. LSPedia's expansion highlights its commitment to improving pharmaceutical supply chain security and patient safety worldwide. The Hyderabad office reinforces its ability to partner with pharmaceutical companies across the globe, offering cutting-edge solutions and a local touch to tackle industry challenges with confidence.   ]]> https://biospectrumindia.com/news/109/25440/usibc-signs-mou-with-government-of-telangana-hosts-ai-and-gcc-industry-roundtable.html https://biospectrumindia.com/news/109/25440/usibc-signs-mou-with-government-of-telangana-hosts-ai-and-gcc-industry-roundtable.html Wed, 11 Dec 2024 00:00:00 +0530 The US Chamber of Commerce’ s US India Business Council Global Private Limited (USIBC GPL) and the Department of Information Technology, Electronics & Communications (IT E&C), Government of Telangana, have signed a Memorandum of Understanding (MoU) to bolster US-India collaboration and partnership in technological innovation. The MoU was signed in the presence of Chief Guest, Minister for Information Technology (IT), Electronics & Communications (E&C), Industries & Commerce (I&C), and Legislative Affairs, D Sridhar Babu and Special Chief Secretary to the Government of Telangana for IT E&C and I&C; Jayesh Ranjan, Guest of Honour, Jennifer Larson, US Consul General Hyderabad, and USIBC Managing Director Rahul Sharma. The MoU outlines cooperation in key focus sectors including IT, Artificial Intelligence (AI), electronics and Global Capability Centers (GCCs). The signing was followed by an industry roundtable on AI and GCCs, reinforcing Hyderabad and Telangana’s role as a global technology hub. The discussion highlighted Hyderabad’s thriving ecosystem of skilled professionals and its pivotal role in US-India collaborations. The participants explored AI-driven opportunities across sectors as well as the ways to optimally harness AI technological innovation for global good while at the same time prevent misuse via regulation, governance, ethical use, in a manner that does not stifle innovation. ]]> https://biospectrumindia.com/news/109/25413/dr-reddys-launches-toripalimab-in-india-for-treatment-of-nasopharyngeal-carcinoma.html https://biospectrumindia.com/news/109/25413/dr-reddys-launches-toripalimab-in-india-for-treatment-of-nasopharyngeal-carcinoma.html Fri, 29 Nov 2024 00:00:00 +0530 Dr. Reddy’s Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).  In 2023, Dr. Reddy’s entered into a license and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab. Under this agreement, Dr. Reddy’s obtained exclusive rights to develop and commercialise Toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America.  Additionally, the agreement allows Dr. Reddy’s to expand the scope of the license to cover Australia, New Zealand and nine other countries. With this launch by Dr. Reddy’s, India becomes the third country in the world after China and United States to receive access to this next generation PD-1 inhibitor. Dr. Reddy’s will market it under the brand name Zytorvi® in India. The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin. This combination has shown a 48% reduction in risk of progression or death. Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumour cells. NPC is a malignant tumour that arises from the epithelium of the nasopharynx. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. In India, there were 6,519 newly diagnosed cases of NPC in 2022. The highest age-adjusted rates for NPC were found in the north-eastern states in India, with Kohima in Nagaland having an incidence of 19.4/100,000 population. ]]> https://biospectrumindia.com/news/109/25388/mapmygenome-unveils-groundbreaking-study-on-genetic-variants-linked-to-longevity.html https://biospectrumindia.com/news/109/25388/mapmygenome-unveils-groundbreaking-study-on-genetic-variants-linked-to-longevity.html Mon, 25 Nov 2024 00:00:00 +0530 Hyderabad-based MapmyGenome, a leader in genetic testing and personalised health solutions, has announced the publication of its latest research in NPJ Aging (Nature.com). The study, titled 'Genetic Variants Associated with Longevity in Long-Living Indians,' explores the genetic factors contributing to healthy ageing and long life spans in the Indian population. In a pioneering effort, the study analysed data from GenomegaDB, the most extensive genetic database of Indians, focusing on individuals aged 85 years and older, referred to as Long Living Individuals (LLIs). By comparing LLIs with younger controls (18-49 years), researchers uncovered key genetic variants contributing to ageing and longevity, and resistance to various diseases. The study confirmed the significance of the FOXO3A gene, a well-known marker for longevity in Japanese, German, and French centenarians, in the Indian population as well. Variants linked to slower heart rate (MYH6), reduced risk of osteoporosis and shorter body height (ESR1), and decreased risks of schizophrenia (RIMS1-KCNQ5) and anxiety (HSPA5) were notably more frequent in LLIs. Conversely, variants associated with increased risk of atrial fibrillation (GORAB-PRRX1) and biliary disorders (ABCC2) were less frequent in this group. By identifying genetic variants unique to Indian LLIs, the study adds a critical dimension to global aging research. It emphasizes the diversity in genetic factors influencing longevity and underscores the importance of population-specific studies in understanding the broader genetic landscape. ]]> https://biospectrumindia.com/news/109/25381/monitra-health-gets-us-patent-for-advanced-wireless-cardiac-monitoring-technology.html https://biospectrumindia.com/news/109/25381/monitra-health-gets-us-patent-for-advanced-wireless-cardiac-monitoring-technology.html Sun, 24 Nov 2024 00:00:00 +0530 Hyderabad-based startup Monitra Healthcare, a pioneer in health monitoring technologies, has announced the grant of its US Patent No. 12,109,029 B2, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals. This patent, issued by the United States Patent and Trademark Office, marks a significant milestone in Monitra Health’s mission to revolutionise cardiac care through innovation. The patented technology introduces a wireless patch-based cardiac monitoring device designed to enhance patient compliance and diagnostic accuracy. Unlike current products, the patch automatically detects its orientation on the patient and optimally selects electrode pairs to ensure the highest quality signal transmission, eliminating errors from improper placement. The device processes bio-potential signals in real-time and wirelessly transmits physiological data to external systems for further analysis. The innovation features advanced orientation detection to reliably identify and adapt to the patch’s placement on the patient. Its dynamic electrode pairing optimizes performance by automatically selecting the most effective electrode pairs based on real-time orientation and signal quality. Seamless wireless connectivity enables efficient transmission of ECG and other physiological data to external devices for immediate processing and analysis. Additionally, the device's lightweight, wire-free design ensures superior patient comfort, making it ideal for prolonged use. Monitra Health's patented technology promises to redefine ambulatory ECG monitoring, particularly for conditions like atrial fibrillation and other cardiac arrhythmias and QT prolongation monitoring in cardiac safety studies in clinical trials.The company plans to commercialise this breakthrough technology, expanding its presence in key markets, including the U.S., U.K., and Australia, to further strengthen its leadership in the healthcare technology sector. ]]>